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Abstract 
Lentiviral vectors, such as those derived from Human Immunodeficiency Virus-1 (HIV-1) and 
Equine Infectious Anaemia Virus (EIAV), can be targeted to the neurons by replacing their 
natural envelope with rabies-G glycoprotein (RV-G), through a process known as 
pseudotyping.  They are retrogradedly transported to distal projecting neurons in vivo 
where transgene expression occurs, an approach with significant potential for gene therapy 
of motor neuron diseases. However, the molecular processes that underlie retrograde 
transduction are unchartered and barrier(s) which result in low transduction efficiencies are 
thus not defined. The project aimed to characterise the processes involved in the entry and 
endocytic trafficking of RV-G pseudotyped lentiviral vectors in a differentiated motor 
neuron cell line, NSC-34,  and primary rat motor neurons.  
For the first time, the project demonstrates the co-internalisation of RV-G pseudotyped 
lentiviral vectors with its 3 specific receptors, namely p75 neurotrophin receptor (p75NTR), 
neural cell adhesion molecule (NCAM) and nicotinic acetylcholine receptor (nAchR).  
Furthermore, internalised lentiviral vectors follow a sequential Rab5 to Rab7 endosomal 
maturation along the axonal endocytic pathway. 
Using the process of tetracysteine tagging, a small genetic tag was successfully introduced 
into the matrix of the vector capsid and labelling of the tag with the biarsenical dye FlAsH 
was optimised. Utilising these and other differently labelled vectors, we demonstrate 
through live cell imaging, that it is the RV-G pseudotype that confers on the vectors the 
ability to traffic retrogradedly. This trafficking pathway utilises non-acidic axonal carriers as 
previously demonstrated for the p75NTR and tetanus toxin trafficking in motor neurons.  
Additionally, the nAchR is also targeted to this retrograde trafficking pathway.  Furthermore 
retrograde transport was studied in compartmented microfluidic motor neuron cultures and 
this trafficking was found to be both rapid and efficient. This suggests that the barrier(s) to 
efficient transduction with these vectors is post axonal transport. 
Additionally, studies to isolate and characterise axonal retrograde endosomes in primary 
motor neurons based on a system of pull-down of magnetic nano particles (MNPs) bound to 
a streptavidin displaying lentiviral vector were performed. The project optimised 
streptavidin expressing vector production and shown their ability to bind biotin coated 
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magnetic nano particles (MNPs) and transduce motor neurons with increased efficiency. 
Magnetic pull-down of the vector containing endosomes and subsequent proteomics have 
revealed a number of potential trafficking partners of RV-G pseudotyped lentiviral vectors. 
Taken together, this thesis characterises the processes involved in the entry and endocytic 
trafficking of RV-G pseudotyped lentiviral vectors and identifies the barrier to efficient 
transduction of motor neurons as post axonal transport and thereby opening up avenues to 
improve gene therapy vectors. 
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1.1 Gene Therapy: A Historical Perspective 
Gene therapy may be broadly defined as the treatment of a disease or medical disorder by 
the introduction of a therapeutic gene into affected cells. Genes are the basic units of 
hereditary as  eluded to by the father of genetics, Gregor Mendel, in the 1850s and 1860s 
and later by the work of Ronald Fisher during the early 20th century. This work confirmed 
that organisms contain ‘encoded information’ in the form of some kind of biological 
material which was later termed ‘gene’ by William Johannsen in 1909. 
In the early twentieth century, the correction of diseases using gene therapy approaches 
was considered nearly an impossible medical challenge as genes could not be directly 
manipulated because of their unknown nature at that time. Then, with the progression of 
the 20th century, there was an unprecedented explosion in scientific breakthroughs in the 
fields of genetics, biochemistry and molecular biology. Suddenly, gene therapy changed 
from a concept to a real possibility. Firstly, deoxyribonucleic acid (DNA) and not protein was 
identified as the biological molecule encoding genetic information by Avery et al. in 1944 
(Avery et al, 1944). DNA could be isolated and studied. Shortly after that, its structure was 
deciphered by Watson and Crick (Watson & Crick, 1953a, 1953b). The anti-parallel double 
helix organisation of DNA maintained by binding of specific pairs of deoxinucleotides 
provided an explanation for the physical transmission of genetic information. Crucially, the 
isolation of the enzyme polynucleotide phosphorylase allowed the in vitro synthesis of RNA 
molecules of known nucleotide composition (Grunberg-Manago et al., 1955). This 
breakthrough permitted the deciphering of the genetic code i.e. the equivalence between 
nucleotide triads (codons) and specific amino acids in a polypeptide chain (Ochoa, 1963). 
Subsequently, gene cloning and gene delivery into mammalian cells was becoming routine 
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in the 1970s and thus gene isolation and manipulation became a reality (Escors & Breckpot, 
2010). 
The 70’s were a dynamic time for the field as the molecular and genetic basis of many 
genetic disorders were beginning to be well understood. The first human gene therapy trial 
was carried out in early 1970s when three hyperargininemic patients were intravenously 
inoculated with Shope papillomavirus so that the virus encoded arginase could correct the 
disease (reviewed in Escors & Breckpot, 2010). The 1980s saw the first viral system for gene 
transfer being developed whereby the human gene for hypoxanthine phoribosyltransferase 
(HPRT) was successfully transferred into HPRT deficient mouse and humans using a 
retrovirus ( Miller et al., 1983; Willis et al., 1984). This was followed in 1985 by the first in 
vivo expression of a transgene in an animal model whereby the retroviral expression vector 
N2 was used to transfer the gene coding for resistance to neomycin (NeoR) into 
hematopoietic progenitor cells isolated from the bone marrow of immune competent mice. 
This was followed by engraftment of transduced cells into lethally irradiated mice and 
vector DNA was detectable 10 days post injection (Eglitis et al., 1985). The first approved 
gene therapy clinical trial was initiated in 1990 by Anderson et al. by treating two children to 
correct adenosine deaminase deficiency (ADA)- severe combined immunodeficiency (SCID). 
The trial involved engineering the patient’s own T cells ex vivo with a retroviral vector 
carrying the normal adenosine deaminase gene (Anderson et al., 1990). Although the trial 
was partially successful due to only transient transgene expression, the study provided 
proof of principle regarding the potential of human gene therapy. 
In the following years, many gene therapy trials had limited success. This was mainly due to 
barriers such as inadequate gene delivery systems, poor transgene expression and toxicity 
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to vectors. In addition, there was an induction of immune response to both vectors and 
modified cells (Cao et al., 2011). Perhaps, the most unfortunate setback in the field was the 
death of an 18 year old patient, Jesse Gelsinger, in 1999 who suffered a massive 
immunological response (multiple organ dysfunction syndrome) after systemic delivery of 
untested, high doses of an adenoviral gene transfer vector whilst undergoing a gene therapy 
trial for ornithine transcarbamylase deficiency (Raper et al., 2003). 
However, despite early hype, failures and tragic events , we are now reliving a time of great 
progress. During the last decade or so, immense scientific advancements have been made in 
terms of vector design, targeting and a better understanding of their behaviour within cells. 
Currently, more than 1,800 approved gene therapy clinical trials worldwide have been 
conducted or are still ongoing. Adenoviral vectors, retroviral vectors and naked plasmid 
have been the most commonly used gene transfer vectors in clinical trials (Figure 1.1.A).  To 
date, cancer counts for about 65% of all clinical gene therapy trials worldwide, followed by 
monogenetic and cardiovascular diseases (Figure 1.1.B). Currently, the first gene therapy 
product have been approved in Europe – Glybera, an adeno-associated viral vector 
engineered to express lipoprotein lipase in the muscle tissue for the treatment of severe 
lipoprotein lipase deficiency. It is very likely that gene therapy will find its place in specific 
areas of clinical medicine where there is an unmet need. 
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Figure 1.1: Gene therapy facts. (A) Timeline highlighting some important milestones in the 
evolution of gene therapy as a field. (B) Different gene transfer vectors used in clinical 
settings. Adenoviral, retroviral and naked plasmid DNA have been the most commonly used 
gene transfer vectors. (B) Different indications that have been addressed by gene therapy 
trials. Cancer has now taken the lead after initial studies were on monogenetic diseases. 
Source:  The Journal of Gene Medicine, Wiley and Sons, (2012) 
(http://www.abedia.com/wiley/index.html). 
A
B
C
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1.2 Strategies for gene therapy 
There are essentially four different strategies that may be considered for the treatment of 
monogenic diseases. These include (1) addition of a normal copy of a mutated gene which is 
best suited to loss of function mutations and this approach is by far the most common 
strategy (O’Connor & Crystal, 2006), (2) messenger RNA modification to avoid the 
consequences of a mutation (Gorman et al., 1998), (3) inhibition of expression of a mutated 
gene which is used to prevent the expression of a protein in a gain of function mutation or 
to inhibit cryptic splice sites which lead to expression of an abnormally spliced protein. This 
approach utilizes small interfering RNAs (siRNAs) (Thompson & Patel, 2009), (4) repair of the 
mutated gene in the host DNA sequence and reversal of the disease. This approach uses a 
DNA sequence specific binding domain and an endonuclease capable of orchestrating site 
specific double strand breaks in DNA. At the same time, a template of the wild type 
sequence that corresponds to the mutated stretch of the DNA is introduced into the cell and 
acts as a substrate for repair. Zinc finger nucleases have been used in this approach (Rémy 
et al., 2010). 
There are two approaches for the delivery of genetic material; in vivo and ex vivo. In the first 
approach, the DNA is delivered directly to the cells of the target tissue. The ex vivo strategy 
involves the transfer of a therapeutic gene to cells in vitro followed by transplantation of 
these modified cells to the target tissue. In order to be effective, the in vivo strategy needs 
(1) the target cells to be accessible for infusion or injection by a vector, (2) the vector should 
have the ability to specifically infect the target cell, (3) transgene expression should occur in 
the target cell only and be long term (Selkirk, 2004).   
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A        B   
 
 
 
 
Figure 1.2: In vivo and ex vivo gene transfer: (A) In vivo gene transfer strategy is based on  
the production of replication deficient virus in vitro followed by direct injection (or infusion) 
of the virus into an organ system. The virus genetic material will incorporate into cells and 
therapeutic genes will be expressed. (B) The ex vivo strategy is based on the utilisation of a 
surrogate cell that is infected with virus in vitro. The surrogate cell is subsequently 
transferred to the target tissue and expresses the therapeutic gene. Figure adopted from 
(Selkirk, 2004) 
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1.3 Vectors for gene therapy 
There are two broad approaches being deployed in gene therapy which are based on 
vectors used for gene delivery. These are the use of recombinant viruses to deliver genes 
and the other is the use of non-viral vectors. So far, transfer of therapeutic is most efficient 
when delivered by viral vectors and this group comprises the majority of gene therapy 
clinical trials. The major groups of viral vectors developed for gene delivery include 
adenovirus (Ad), adeno-associated virus (AAV) and retrovirus (Table 1.1). Progress has also 
been made in vectors derived from other viruses, such as herpes simplex virus (Glorioso, 
Goins, Fink, & DeLuca, 1994) and Sendai virus (the murine parainfluenza type 1)(Ferrari et 
al., 2004, 2007). Among the non-viral vectors, only cationic liposomes have been extensively 
explored.  
The selection of which viral vector to use for a particular study depends mainly on the cell 
type to be targeted and duration of expression required as well being able to be purified to 
high titres (Gillet & Macadangdang, 2009). In addition the vector must mediate transgene 
delivery and expression to the target cell without substantial toxicity or inducing an immune 
response. Many different viral vectors are currently available for gene therapy (Pfeifer & 
Verma, 2001) and all of them present advantages and disadvantages with regard to their 
use in gene therapy treatments as outlined in  Table 1.1. 
Oncoretroviral vectors integrate into host genome and are not immunogenic, however 
random integration may induce oncogenesis and can infect dividing cells only as nuclear 
entry of the virus can only occur when the nuclear membrane is disassembled and is, 
therefore, mitosis dependent, rendering them ineffective for non-dividing cells.  
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Lentiviral vectors integrate into the host genome and promote long term gene expression 
without eliciting a host immune response. In addition, lentiviral vectors can transduce non-
dividing cells with high gene transfer efficiency because they can access the nucleus of these 
cells by import through the nuclear pore, and therefore not mitosis dependent (Pfeifer & 
Verma, 2001).  
Adenoviral vectors can transduce a large variety of cells and can be produced in high titres. 
However, they do not integrate into host genome and some viral proteins are expressed 
during transgene expression which may elicit an immune response.  
Adeno-associated viral vectors usually remain episomal in the nucleus, but may also 
integrate into the host genome allowing long term expression of the transgene without 
eliciting an immune response by the host. However, on the down side they have a small 
packaging capacity and there are some limitations with regards to their production and 
purification.  
Herpes simplex virus viral vectors have a large cloning capacity and are suitable for       
transduction of neuronal cells. However, they are cytotoxic and do not integrate into the 
host genome and therefore only transient transduction of cells. 
 
29 
 
 
Vectors Genetic 
Material 
Vector Yield 
(transducing 
units/ml 
Packaging 
Capacity 
Tropism Transduction 
of quiescent 
cells 
Vector 
genome 
forms 
Duration of 
transgene 
expression 
Inflammatory 
potential 
Genotoxicity 
Oncoretrovirus RNA 1x 10
10
 ~7kb Broad No Integrated Long term 
(years) 
Low Integration may 
induce 
oncogenesis 
Lentivirus RNA 1x 10
10
 ~8kb Broad Yes Integrated Long term 
(years) 
Low Integration may 
induce 
oncogenesis 
Herpes 
Simplex Virus-
1 
dsDNA 1x 10
12
 >30kb Broad 
(strong for 
neurons) 
Yes Episomal Transient High Low 
Adenovirus ssDNA 1x 10
12
 ~30kb Broad Yes Episomal Short-term 
(weeks) 
High Low 
Adeno 
Associated 
Virus 
ssDNA 1x 10
12
 ~5kb Broad 
excpt. HSCs 
Yes Episomal 
(90%), 
Integrated 
(10%) 
Medium to 
long-term 
(year) 
Low Needs further 
investigation 
Table 1.1: Viral vectors used in gene therapy and their main properties. Table adopted from  (Bouard, Alazard-Dany, & Cosset, 2009).
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 1.4  Retroviral vectors 
Retroviral vectors are based on retroviruses which comprise a large class of lipid enveloped 
viruses with two identical single-stranded RNAs (7-11kb) as the viral genome. The particle is 
approximately 100 nm in diameter and spherical in shape. The Retroviridae family consists 
of seven genera, namely: alpharetrovirus, betaretrovirus, gammaretrovirus, deltaretrovirus, 
epsilonretrovirus, lentivirus and spumavirus (Cao et al., 2011). Each genus is characterised 
by differences in genetic structure, genome complexity, site of particle assembly and virion 
morphology. The first five genera are known as oncoretroviruses and was the basis of the 
first retroviral vector, Molony murine leukemia virus (MoMLV), a gammaretrovirus. 
Retroviral vectors were also developed based on lentivirus (Cockrell & Kafri, 2007), although 
traditionally only oncoretrovirus based vectors are referred to as retroviral vectors.  
1.4.1 Retrovirus Biology 
The classic feature of retroviruses is their replicative strategy which involves reverse 
transcription of the viral RNA into linear DNA and the subsequent stable integration of this 
DNA into the host cell genome. This makes them suitable gene carriers to deliver genes into 
target cells, which is one of the basic requirements of a gene therapy vector. 
Retroviruses contain a diploid genome made of two identical molecules of single positive-
stranded RNA. The genome is contained within an internal core made of several structural 
and enzymatic proteins, namely: nuclecapsid (NC), capsid (CA), reverse transcriptase (RT), 
integrase (IN) and protease (PR) (see Figure 1.3). In addition, there is an outer protein layer 
composed of matrix protein (MA), which interacts with the internal core and with envelope 
glycoprotein (ENV) in the virion lipid envelope. The envelope binds to the cellular receptor 
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and facilitates fusion between the viral envelope and the membrane of the target cell. ENV 
is post translationally processed into two subunits, namely, a transmembrane subunit (TM ) 
which is anchored to the virion lipid envelope  and a globular subunit (SU) which binds to 
the cellular receptor. The SU remains non-covalently attached to the TM. 
Retroviruses can be classified into two main groups based on their genome organisation. 
They may be classified as simple or complex retroviruses, although, in either case their 
genome organisation is fairly similar in general. The criteria separating complex and simple 
retroviruses is the presence of a variable number of accessory and regulatory genes.  
The genome of the simple retroviruses is organised from the 5’ to 3’ end with Gag, Pol and 
Env genes.  The Gag gene encodes structural proteins (MA, CA and NC ) as a polyprotein. Pol 
encodes enzymatic proteins (RT, IN and PR) associated to the RNA genome within the virion. 
It is expressed as a Gag-Pol polyprotein , synthesised by ribosomal frame shifting during Gag 
mRNA translation (Jacks et al., 1988). RT synthesises a single cDNA copy from two strands of 
genomic RNA using a multi-step reverse transcription mechanism. This reaction takes place 
within the retrovirus core soon after its entry into the cell cytoplasm. IN facilitates the viral 
cDNA integration in the host cell chromosome (provirus DNA). PR has a function of cleaving 
Gag and Gag-Pol polyproteins within the released viral particle leading to fully infectious 
virions (virion maturation). Env encodes envelope, expressed as polyproteins which are 
processed into mature forms during assembly of the virion and maturation. 
The integrated provirus genome is flanked by two long terminal repeats (LTRs) which are 
subdivided into U3, R and U5 regions (Escors et al., 2012). U3 (unique in 3’) is approximately 
450 nucleotides in length in both murine leukaemia virus (MLV) and HIV-1 and acts as a 
promoter of viral transcripts and contains the transcriptional enhancers and TATA box. The 
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R (repeat) region marks the starting point of transcription and is approximately 100 
nucleotides in length in HIV-1. The region contains a polyadenylation signal, typically 
AAUAAA, which allows efficient processing of viral RNA. U5 (unique in 5‘) region consists of 
a GU rich stretch of around 80 nucleotides which is involved in reverse transcription and 
contains the tRNA primer-binding site (PBS). This site is complementary to an 18 bp region 
of a host-derived tRNA which unwinds and binds to this region to act as a primer for minus 
strand DNA synthesis during reverse transcription (Dahlberg et al., 1974; Verma et al., 
1971). Downstream of the PBS, is the encapsidation or packaging signal (Ψ, psi), which 
facilitates efficient, preferential packaging of viral genomic RNA into virions during assembly 
in the cell cytoplasm (Watanabe & Temin, 1982). Immediately upstream of the 3’ U3 is the 
polypurine tract (PPT) which acts as a primer for plus strand DNA synthesis during reverse 
transcription. Furthermore, lentiviruses such as HIV-1 also possess a second origin for plus 
strand DNA synthesis called the central polypurine tract (cPPT), which is located within the 
integrase component of pol gene (Charneau et al., 1994) (Figure 1.3).  
The complex retrovirus genome, such as that of the HIV and human T cell lymphotropic 
viruses, has the same basic organisation. On top of this, it contains an additional set of 
accessory genes involved in regulation of transcription, RNA transport, gene expression and 
assembly (Frankel & Young, 1998). Examples of these are HIV-1 tat, rev, vif, vpr, vpu and nef. 
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Figure 1.3: Retrovirus virion structure and genome organisation represented by HIV-1 
virion. (a) Viral proteins depicted include the internal core (conical gray structure) made of 
nucleocapsid (NC), capsid (CA), integrase (IN), reverse transcriptase (RT) and protease (PR). 
The internal core is contained within a layer of matrix protein (MA) within the virus 
envelope. The envelope glycoprotein (ENV, within a dotted section) is made of the spherical 
subunit (SU) which is attached to the transmembrane domain (TM ). TM is inserted in the 
virus envelope. (b) The HIV-1 provirus genome organisation is shown as a model for a 
complex retrovirus: gag encodes MA, CA and NC, env encodes SU and TM glycoproteins, pol 
and pro encode the enzymes (PR), RT and IN. HIV-1 also contains the regulator genes tat and 
rev and the accessory genes vif, vpr, vpu and nef; Primer binding site (PBS); packaging signal 
(Ψ); Polypurine tract (PPT); Central Polypurine tract (cPPT); Rev response element (RRE), 
spacer peptide (p6). Figure adopted from (Coffin, 1992; Escors et al., 2012; Sinn et al., 2005; 
Watts et al., 2009). 
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1.5 Lentiviral life cycle 
Lentiviruses include primate and non-primate retroviruses. Examples of the former are HIV 
and SIV (simian immunodeficiency virus) and of the latter FIV (feline immunodeficiency 
virus), BIV (bovine immunodeficiency virus), CAEV (caprine arthritis-encephalitis virus), EIAV 
(equine infectious anaemia virus), and visna virus. 
The lentiviral life cycle can broadly be divided into two distinct phases: one in which the viral 
genome is transferred into the host cells (infection) and one in which this genome is 
expressed (replication) and viral propagation assured (See Figure 1.4). Lentiviruses differ 
from other retroviruses in terms of having a long latent period during infection. So their life 
cycle is characterised by an early phase of gene expression of viral regulatory products 
involved in replication, followed by a late phase when structural genes are expressed, 
leading to the assembly of viral particles (Kay & Naldini, 2001). Over the years, numerous 
studies have been done to characterise various stages of the life cycle and most of this work 
has focused on HIV-1 which can be regarded as a paradigm for other lentiviruses. 
1.5.1 Entry and uncoating 
The first step in the virus life cycle is the entry of the particle into its target cell. This is 
facilitated by recognition of a host cell surface receptor by the viral envelope component SU 
and this determines the virus cell and tissue tropism. To date, many lentiviral cellular 
receptors have been characterised. These include CD4 as the primary receptor for HIV-1 
(Dalgleish et al., 1984). In addition, the chemokine receptors CCR5 (Feng, Broder, Kennedy, 
& Berger, 1996) and CXCR4 (Deng et al., 1996) have been demonstrated as co-receptors for 
HIV-1. SU and CD4 binding induces a conformational change in SU revealing a conserved, 
high affinity, co-receptor binding domain. The binding of co-receptor leads to the exposure 
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of the TM fusion peptide, a hydrophobic region which interacts with the cell membrane, 
facilitating  fusion of the cell and viral membranes and internalisation of the capsid (Bosch et 
al., 1989). The fusion of the viral and cellular membrane delivers the viral core into the 
cytoplasm of the cell. Once inside, the protein composition of the HIV-1 core changes in a 
process known as uncoating. It has been demonstrated that a host protein, Cyclophillin A, is 
involved in the entry or uncoating process of HIV. The protein binds to CA (Luban et al., 
1993) and the inhibition of this interaction reduces virion infectivity in a step after receptor 
binding and membrane fusion (Braaten, Franke, & Luban, 1996). 
A point to note is that although the HIV core enters the cytoplasm by direct fusion between 
cell and viral envelope, other lentiviruses use a pathway of entering the cell by endocytosis 
followed by membrane fusion. Either way, the retroviral core is released into the cytoplasm. 
1.5.2 Reverse transcription 
During uncoating, the capsid protein dissociates and the core forms the reverse 
transcription complex (RTC) containing the proteins RT, IN, NC, phosphorylated MA and Vpr 
(M. I. Bukrinsky et al., 1993). The RNA genome is reverse transcribed within the RTC and 
from two RNA genome molecules,  one double stranded cDNA is produced. While this 
activity is taking place, the RTC traffics to the nucleus by binding to dynein motors and 
transporting along microtubules. During trafficking, the capsid is shed as reverse 
transcription proceeds. Cellular factors, like proteins aiding import and integration, are 
recruited to the RTC as it evolves into a preintegration complex (PIC) (Anderson & Hope, 
2005). Once at the nuclear envelop, translocation occurs through the nuclear pore. It is 
likely that when the RTC reaches the nucleus, reverse transcription has ended and RT 
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dissociates from the complex, thereby reducing its size, allowing translocation through the 
nuclear pore (M. Bukrinsky, 2004). 
In lentiviruses, it is probable that nuclear import requires the use of the nuclear pore 
complex. Cargo proteins bound for the nucleus contain a nuclear localisation signal (NLS). 
MA, IN and Vpr are associated within the viral DNA in the PIC and are candidates for nuclear 
import as they have putative NLS. It has been demonstrated that mutations in the putative 
NLS results in reduced nuclear import of viral DNA. Although replication was not impaired 
(Yamashita & Emerman, 2005). 
Other retroviruses are unable to cross the nuclear envelope and therefore they are only 
able to integrate their genome when the envelope breaks down during mitosis. Lentiviruses 
and vectors based on them have the unique ability of crossing the nuclear envelope and 
integrate into non-dividing cells which makes them ideal vectors for targeting non-dividing 
cells such as neurons. 
1.5.3 Integration 
Once in the nucleus, the viral cDNA integrates into the host cell DNA through the enzymatic 
activities of IN. Integration ensures that provirus (integrated retrovirus) DNA is replicated 
along with the host DNA and transmitted to the progeny as an element of host 
chromosomes (Hughes et al., 1978). 
Integration occurs in two catalytic stages. In the first stage, known as 3’ processing occurring 
in the cytoplasm within the preintegration complex (PIC), whereby IN cleaves and removes a 
dinucleotide from both ends of viral DNA (Katzman et al., 1989). The second stage occurs in 
the nucleus and is called strand transfer. In this stage, IN mediates a nucleophillic attack by 
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the 3’- hydroxyl residues of the viral DNA on phosphodiester bonds on opposite strands of 
the host target DNA. In the course of this step, the energy of the broken phosphodiester 
bonds in the chromosome is used for the formation of new bonds joining the viral 3’ ends to 
the target DNA (Miller, Farnet, & Bushman, 1997). In the final step of integration, the 
unpaired dinucleotides from the 5’ ends of viral DNA are removed and the single stranded 
gaps created between the viral 5’ end and target DNA are filled and this process is likely to 
be mediated by cellular enzymes. DNA episomes are also generated as by products of 
integration. Non-integrated viral DNA can support transcription (Y. Wu & Marsh, 2003) and 
is the basis of gene expression by integration defective lentiviral vectors. 
1.5.4 Transcription and Translation 
With its integration in the host cell genome, the provirus behaves like a normal host gene 
and therefore reliant on the cell machinery for transcription and translation of viral genes. 
The viral LTR contains all the cis-acting elements which are necessary for interaction with 
the host machinery. 
The host RNA polymerase II facilitates the transcription of viral RNA molecules. The HIV-1 
promoter does not assemble a particularly efficient RNA polymerase complex as the 
initiation rate is slow and the elongation rate is poor. Tat, which is a transcriptional activator 
protein, binds a stem loop structure (TAR). Rev then binds to unspliced mRNA at a Rev 
response element (RRE)  and this complex is exported from the nucleus to the cytoplasm 
where Rev stabilises viral transcripts (Pollard & Malim, 1998). 
The transcribed full-length genomic viral RNA and mRNAs encoding all the viral proteins are 
transported to the cell cytoplasm where they are translated. The Gag and Gag-pol 
polyproteins are translated from unspliced mRNA in a ratio of 20:1. The env gene is 
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transcribed as a full mRNA and translated to produce a precursor protein to the viral 
glycoproteins  gp120 and gp41. 
1.5.5 Virion assembly and budding 
Gag and Gag-Pol-Pro polyproteins associate with the inner surface of the cellular membrane 
where Gag multimerisation occurs and the viral genome is bound by a NC through a 
packaging signal (Ψ). The polyproteins assemble into virus like particles and are packaged 
with a number of host proteins. Virion budding then takes place at the cell membrane 
where the particle incorporates its lipid envelope containing ENV. Finally, virion maturation 
occurs after budding from the cell by the activity of viral protease, which proteolyses Gag 
and Gag-Pol polyproteins  leading to MA, CA, NC and enzymatic (RT and IN) proteins (Escors 
& Breckpot, 2010). 
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Figure 1.4: The HIV-1 life cycle. A schematic representation of the major steps (1) 
attachment, (2) entry (3) reverse transcription (4) transcription (5) translation (6) genome 
replication (7) assembly (8) exit. Adopted from (Carter, J., Saunders V., 2007) 
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1.6 Development of lentiviral vectors from lentiviruses 
It was recognised a while ago that lentiviruses were an ideal tool, having many of the 
characteristics of a gene delivery vehicle. First of all, lentiviruses such as HIV-1 have the 
ability to integrate their genomes into the chromosomal DNA of non-dividing infected cells. 
This is because their so-called pre-integration complex, a macromolecular structure 
comprising the viral genome, a few structural proteins and the enzymes responsible for 
reverse transcription and integration, hijacks the cell nuclear import machinery (Lewis, 
Hensel, & Emerman, 1992). This property is the main rationale for developing lentiviruses 
for gene therapy applications  (Naldini & Verma, 2000) and is a likely prerequisite for long 
term expression. Other important characteristics which make them suitable for 
development into gene delivery systems include: (i) their large cloning capacity, close to 10 
kb, (ii) they do not transfer virus-derived coding sequence, avoiding the recognition and 
destruction of transduced cells by vector specific cytotoxic T-lymphocytes. 
 At present vector systems have been derived from a range of lentiviruses, including Human 
Immunodeficiency Virus 1 (HIV-1), HIV-2, Equine Infectious Anaemia Virus (EIAV), Simian 
Immunodeficiency Virus (SIV), Feline Immunodeficiency Virus (FIV), Caprine Arthritis 
Encephalitis Virus (CAEV), Jembrana disease virus (JDV) and Visna virus (Olsen, 2001). As a 
group these viruses have a number of properties in common, however, there are enough 
differences between individual lentiviruses that make it worthwhile to explore whether 
these differences translate into useful gene transfer systems. However, among this group, 
HIV-1 based systems have been explored the furthest followed by EIAV. 
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 A major effort has been placed into the progressive removal of all the non-essential HIV-1 
sequences for viral replication from both transfer vectors and packaging constructs. 
Lentiviral replication is mediated by cis-acting sequences that do not encode any proteins. 
The trans-acting sequences encode the structural, regulatory and accessory proteins and 
these proteins are provided by the packaging plasmids. In other words, this means that viral 
proteins are transcribed in producing cells and only genetic material incorporated into the 
vector is the transgene cassette with non-coding viral elements (at the minimum LTRs, 
packaging signal, Rev responsible element (RRE)) (Figure 1.5). Since the lentivirus is a 
complex virus, the vectors and packaging systems have been difficult to develop and often 
lead to low titres (Delenda, 2004). 
In the first generation lentiviral vectors, viral elements were split into three separate 
constructs. These included the packaging construct (after major deletions of the packaging 
signal), the env gene (a heterologous envelope plasmid for pseudotyping) and the transfer 
vector RNA without any viral genes (Naldini et al., 1996). The redundant genes for gene 
transfer (Vif, Vpr, Vpu and Nef) were deleted from the packaging construct resulting in the 
second generation of lentiviral vectors (Figure 1.5), (Zufferey et al., 1997). The most 
commonly used envelope plasmid for lentivirus pseudotyping has been the vesicular 
stomatitis virus glycoprotein G (VSV-G) (Burns et al., 1993). Pseudotyping has broadened the 
transduction range and strengthened the otherwise fragile lentivirus.  
The bio safety of third generation lentiviruses has been further increased by substituting 
Tat-dependent transcription with an alternative heterologous promoter (Kim et al., 1998; 
Miyoshi et al., 1998) and splitting the original viral genome so that rev is expressed from a 
separate construct (Gasmi et al., 1999). After the integration, viral 3´LTR can have an effect 
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on genes near the integration site because of promoter activity or through an enhancer 
effect. The development of the self-inactivating (SIN) vector was achieved by creating 
deletions in the 3´LTR. This abolished the transcriptional activity of the LTR, thus minimizing 
the risk to form RCL and reduced the risk to interfere with endogenous genes  (Miyoshi et 
al., 1998; Zufferey et al., 1997). 
One approach towards safer lentivirus production has been to develop codon-optimized 
systems to reduce the risk of recombination. These are based on the synthesized complete 
codon-optimized HIV-1 gag-pol gene the expression of which is not rev dependent  (Koldej 
et al., 2005). Another alternative has been to split the gag/gag-pol gene into several parts (X 
Wu et al., 2000). 
 
A minimal transgene expression cassette contains the transgene, a heterologous promoter, 
a packaging signal and LTRs (Figure 1.5). The central polypurine tract (cPPT) has been shown 
to increase the nuclear localization and the total amount of genome integrated into the DNA 
of the target cells (Follenzi et al., 2000). In addition, incorporation of the post-transcriptional 
regulatory element from woodchuck hepatitis virus (WPRE) into the 3´end of the transfer 
vector has been shown to increase the total amount of mRNA and improve transgene 
expression (Zufferey et al., 1999). Some gene therapy applications may need expression of 
more than one gene. This has been achieved using bicistronic expression cassettes 
containing an internal ribosome entry site (IRES)  or a self-cleaving peptide 2A (Szymczak et 
al., 2004). Then two genes are transcribed as a single mRNA and the separation of two 
proteins occurs during the translation. To avoid transcriptional silencing of the viral vector in 
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vivo by adjacent host genetic elements, the use of heterologous cis-elements, such as 
insulators has shown promising results (Ramezani, Hawley, & Hawley, 2003). 
One safety concern of using an integrating gene therapy vector is its capacity for insertional 
mutagenesis. Insertional mutagenesis is more risky when integration occurs near the 
regulatory area of genes. In contrast to MLV retroviruses, lentiviruses do not show any 
preference for integration near transcriptional start sites (Liu et al., 2006) or CpG islands 
(Xiaolin et al., 2003). However, the integration profile may be cell type specific and can be 
different in dividing and non-dividing cells.  
The ability of the lentivirus to transduce non-dividing cells has also led to the development 
of integrase-defective lentiviral vectors. Expression of these vectors is transient because the 
viral genome is lost during the subsequent cell divisions. Nonetheless, long-term expression 
was achieved in non-dividing cells in vivo (Philippe et al., 2006). Other safety modifications 
include the use of tissue-specific promoters to target transgene expression to a selected 
tissue, or to use regulated expression systems to control the transgene expression. 
Currently, the tetracycline-based regulatory systems are the most widely used and both Tet-
ON- and Tet-OFF-based tetracycline-dependent systems have been used to attain inducible 
lentivirus expression (Goverdhana et al., 2005). 
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Figure 1.5: Schematic representation of various generations of HIV vectors. (A) In the first 
generation of HIV vectors, all the viral proteins except Env were in packaging plasmid. The 
Env (VSV-G) is provided by a different plasmid. HIV vector plasmid contains LTRs and the 
transgene is expressed under a strong viral promoter such as CMV. (B) In the second 
generation of HIV vectors, all  the accessory proteins are excluded from the packaging 
plasmid. Similar to first generation, expression of glycoprotein and transgene are provided 
by different plasmids. (C) The third generation of HIV vectors evolved to require four 
different plasmids. In addition to the three plasmids (i.e. a packaging plasmid, an Env-
encoding plasmid and a vector plasmid), Rev protein is provided by a different plasmid. The 
vector plasmid is also modified by deleting the U3 region from the 5’ LTR and partially 
deleting 3’ LTR to reduce the chance of production of replication competent viruses, and a 
strong viral promoter such as CMV is inserted for expression of vector. Adopted from 
(Sakuma, Barry, & Ikeda, 2012). 
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1.7 Pseudotyping 
The entry of an enveloped virus into a host cell is determined by the characteristics of the 
virus envelope glycoprotein and the interaction with its specific receptor and is termed 
tropism. The host cell tropism of a viral vector can be expanded or altered through a process 
known as pseudotyping. This involves changing the viral envelope glycoprotein (GP) with a 
heterologous envelope glycoprotein from another virus (Cronin et al., 2005). Such particles 
possess the tropism of the virus from which the GP was derived. 
The phenomenon of pseudotyping was first described over half a century ago, after the 
observation that cells infected with two different viruses, can give rise to phenotypically 
mixed particles (Granoff & Hirst, 1954). Surface glycoproteins from different families of 
viruses can be exchanged or mixed indicating some degree similarity between these 
molecules or the mechanisms by which they are incorporated into virions. As a result of this 
compatibility, a limited set of modifications can be introduced to retroviral particles by 
displaying surface molecules of other viral species. Since the primary function of viral 
surface glycoproteins is to mediate binding and entry to host cells, the replacement of 
retroviral envelope molecule in most cases changes the tropism and infectivity of the vector, 
because different receptors are involved. 
This phenomenon can be exploited for gene therapy approaches as it allows the broadening 
of virus host range. For example Ross River virus pseudotypes are more efficiently on glial 
cells than neurons (Kang et al., 2002); lymphocytic choriomeningitis virus (LCMV) 
pseudotypes preferentially transduce murine neural stem cells and human glioma cell lines 
(Steffens et al., 2004; Stein et al, 2005); foamy virus, rabies virus, mokola virus, and 
amphotropic murine leukemia virus pseudotypes are enhanced on human neuroblastoma 
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cell lines (Steffens et al., 2004); and rabies-G pseudotypes are useful for distal targeting of 
neurons in vivo because they are retrogradely transported (Mazarakis et al., 2001). 
Vesicular stomatitis virus glycoprotein (VSV-G) is among the first and the most commonly 
used viral envelope protein used for lentivirus vector pseudotyping. The widespread use of 
VSV-G to pseudotype lentiviral vectors has made this glycoprotein the standard against 
which the usefulness of other viral glycoproteins used to form pseudotypes are compared 
(Cronin et al., 2005). Pseudotyping HIV-1 vectors with VSV-G, for example, obviate safety 
concerns associated with the use of HIV-1 gp120, which has known pathogenic 
consequences. In addition, this natural envelope protein restricts  transduction of HIV-1 
vectors to CD4+ cells that limit its usefulness for gene therapy applications to CD4+ cells like 
T cells or macrophages. In contrast pseudotyping with VSV-G generates a vector with more 
diverse tropism and allow gene transfer into a broad variety of cells in vitro (e.g, CD34+ 
stem cells) and in vivo (e.g., brain, muscle and liver). In addition to changing tropism, VSV-G 
also enhances vector stability (Burns et al., 1993). However VSV-G has a number of 
limitations. Most importantly, it is toxic to cells if expressed constitutively making it 
challenging to generate stable packaging cell line. However, this barrier has been overcome 
to some extent by the use of tetracycline regulated promoter (Ory, Neugeboren, & 
Mulligan, 1996). In addition, VSV-G pseudotypes are inactivated by human serum and VSV-G 
vector preparations may harbour tubolovesicular structures which can stimulate the host 
antiviral immune system (Pichlmair et al., 2007).  
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Figure 1.6: Pseudotyping of lentiviral vectors. A lentiviral vector is pseudotyped with an 
envelope protein (Env) from a different virus. The vector binds specifically to cell surface 
receptors on the target cells, known as tropism. Pseudotyping is a process by which the 
tropism of the vector is altered by replacing the viral attachment glycoprotein with that of a 
different virus and thus is a way of targeting the vector. SU: surface subunit; TM: 
transmembrane subunit; Env: envelope glycoprotein. Modified from (Waehler, Russell, & 
Curiel, 2007). 
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1.7.1 Mechanism of pseudotyping 
The molecular events occurring during pseudotying of lentiviral vectors are still not fully 
understood. However, it is believed that mechanisms behind pseudotyping are believed to 
be related to the presence of membrane subdomains in cellular membranes which function 
as sites of viral assembly and/or budding of a mixture of viral types (Briggs, Wilk, & Fuller, 
2003). Since viruses from quite different taxonomical origins are assembled at such sites, 
incorporation of proteins from different virus backgrounds can occur. Additionally, two 
mechanisms have been proposed that lead to the incorporation of glycoproteins in viral 
vectors. These have been classified as active and passive mechanisms. In order for the active 
mechanism to occur, direct interaction of the cytoplasmic tail of the envelope protein and 
components of the virion core must happen or indirect interactions via cellular factors  with 
viral gag proteins are required (Murakami & Freed, 2000a, 2000b; Swanstrom and Wills, 
1997). 
During passive incorporation, a non-specific interaction between the cytoplasmic tail and 
the viral core takes place assuming that there is sufficient amounts of envelope proteins 
present at the site of virus budding and that there is no steric incompatibility between the 
cytoplasmic tail and viral core. 
 Pseudotyping is achieved during viral vector production by expressing the alternative 
envelope protein from a separate plasmid (Cronin et al., 2005). Often, high titre vector 
production can be a problem after pseudotyping and the heterologous viral GP must be 
modified to achieve efficient pseudotyping. Truncation of the intra-cellular domain is an 
effective technique to improve pseudotyping with a heterologous envelope. In addition, 
great improvements in pseudotyping efficiency of Moloney murine leukaemia virus (MuLV) 
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with Ebola envelope GP has been reported by deleting a heavily O-glycosylated region of the 
extracellular domain (Jeffers, Sanders, & Sanchez, 2002). In another study, Carpentier et al.  
constructed several chimeric (RV-G/VSV-G) glycoproteins and found that a construct bearing 
the external/transmembrane domain of RV-G and the cytoplasmic domain of VSV-G showed 
increased incorporation onto HIV-1 lentiviral particles and has increased infectivity in vitro in 
293T cells and in differentiated neuronal cell lines of human, rat and murine origin 
(Carpentier et al., 2011).  
 
1.7.2 Targeting the CNS with pseudotypes bearing Rabies virus (RV) derived 
glycoproteins 
Rabies is a disease of the central nervous system and neuroinvasiveness is the major 
defining characteristic of the classical rabies virus infection. A combination of virulence 
factors  enables the virus to enter neurons at peripheral sites and travel through the spinal 
cord to the brain of the infected host, where it induces aggression that facilitates the 
transfer of the virus to a new host. The capacity of lentiviral vectors to form pseudotypes 
with rabies virus GPs was investigated early on with a view toward designing neurotrophic 
lentiviral vectors. Rabies virus, the prototype of the genus Lyssavirus, is an enveloped 
negative-strand RNA virus encoding five structural proteins including the transmembrane 
GP.  
The first robust pseudotyping of HIV-1 with lyssavirus derived GP including those of the 
rabies virus strain RabSADB19 was described by Mochizuki et al. (Mochizuki et al., 1998). A 
comparison was made between the lyssavirus pseudotypes and VSV-G pseudotypes by 
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analyzing unconcentrated virus stocks on human osteosarcoma (HOS) cells and on Rat-2 
fibroblasts. The lyssavirus GPs produced identical titres, which were 5 times lower than 
those of VSV-G pseudotypes on HOS cells and 4 times lower on Rat-2 cells. In 1999, 
Mitrophanous et al. successfully pseudotyped EIAV vectors with a rabies virus GP 
(Mitrophanous et al., 1999). Once successful pseudotyping of lentiviral vectors with rabies 
virus GP had been demonstrated, the priority shifted to assessing the neurotropism of such 
pseudotypes. 
In one such study, Mazarakis et al., used EIAV vectors pseudotyped with GPs derived from 
the rabies virus ERA strain or from VSV-G which were injected into the striatum of mice to 
compare the spread of the virus as judged from the number and distribution of transgene 
expressing cells. After injection of both pseudotypes, comparable number of transgene 
expressing cells were found in the striatum (Mazarakis et al., 2001). However, at a 
comparable titre, the rabies G pseudotype also produced transgene expressing cells in the 
thalamus along with substantia nigra. This was the first demonstration of rabies 
pseudotyped lentiviral vectors being retrogradedly transported from the synapse via the 
axon to the nucleus where they integrate and express the transgene. In addition, intraspinal 
injections of EIAV vectors pseudotyped with rabies ERA GP have likewise demonstrated 
spread of transgene expression along nerve tracts. This phenomenon was not seen after the 
injection of VSV-G pseudotypes (Mazarakis et al., 2001). This is first ever demonstration of 
viral envelope having a role in retrograde transport implying alternative route of entry . 
The potential clinical importance of EIAV vectors pseudotyped with rabies virus GP have also 
been demonstrated. Intramuscular injection of such EIAV vectors resulted in transgene 
expression in spinal motor neurons. Retrograde transport of lentiviral vectors from 
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injections into peripheral muscle to spinal motor neurons has been used to demonstrate a 
therapeutic effect in an animal model of familial ALS by Azzouz et al. In this study, SODG93A  
mice which have a mutation in the SOD1 gene and experience severe motor neuron 
degeneration comparable to that seen in human ALS, were injected with rabies G 
pseudotyped EIAV vectors encoding vascular endothelial growth factor (VEGF) (Azzouz et al., 
2004). RV-G pseudotyped EIAV/VEGF treated mice showed a delayed disease onset of a 
month, compared with animals given a control vector. EIAV/VEGF vector treatment also 
improved the neuromuscular deficit and extended the lifespan of these animals by 30%. In a 
related study, EIAV vectors expressing either a marker gene or the human survival motor 
neuron (SMN) cDNA and pseudotyped with RVG ERA strain were injected into various 
muscles of spinal muscular atrophy (SMA) mice. Retrograde transport of the virus to the 
spinal motor neurons was confirmed by marker gene expression. In comparison to 
untreated controls, SMN-vector treatment restored SMN protein levels in motor neurons, 
reduced motor neuron death and increased life expectancy by an average of 20% to 38% 
(Azzouz et al., 2004). 
These examples provide strong evidence of the capacity of lentivirus vectors pseudotyped 
with rabies virus glycoproteins to deliver therapeutic genes to rather inaccessible motor 
neurons via a route which is non-invasive to CNS by exploiting the rabies pseudotyped 
vectors ability to induce retrograde transport along axons connected to muscle. 
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1.8 Virus transport 
Viruses are obligate intracellular pathogens and entry into the host cell is a critical step in 
the life cycle of the particle. The journey of a virus particle from the cell surface to the 
cytosol and nucleus consists of a series of consecutive steps that transport it closer to its site 
of replication. Many viruses are capable of activating cellular signal transduction pathways 
after binding to the plasma membrane. This is, in many cases, essential for the endocytosis 
of the virus. 
1.8.1 Advantages of using the endocytosis pathway 
There are several reasons why endocytic entry is advantageous for viruses (Pelkmans & 
Helenius, 2003). First of all, the particles are directed only into cells that have active 
membrane transport. Secondly, endocytic vesicles transport incoming viruses from the 
periphery of the cell to the peri-nuclear area of the host cell, where conditions for infection 
are favourable and the distance to the nucleus minimal. Additionally, this allows viruses to 
bypass obstacles associated cytoplasmic crowding and the cytoskeleton (Sodeik, 2000). For 
viruses that infect neurons via axons, transport in endocytic vesicles is ideal because long 
distances separate axons from the cell body. The maturation of endosomes with gradually 
changing conditions, such as decreasing pH, allows viruses to sense their location within the 
cell  and the pathway and to use this information to set the time of penetration and 
uncoating. Finally, as a result of being endocytosed, viruses can avoid leaving evidence of 
their presence and therefore likely to cause a delay in being detected by 
immunosurveillance. All in all, as a result of endocytosis being so advantageous, viruses such 
as herpes simplex virus 1 and HIV-1 often prefer to use the endocytic pathway for 
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productive entry, even though  they are capable of entering directly (Daecke et al., 2005; 
Nicola, McEvoy, & Straus, 2003). 
1.8.2 Mechanisms of endocytosis 
Endocytosis commences with the formation of primary endocytic vesicles (PEVs), which are 
endocytic vacuoles generated from pinch-offs from the plasma membrane. This multistep 
process involves activation, cargo capture/sorting, induction of membrane curvature and 
scission (Schelhaas, 2010). Following this, cargo is further sorted to destination organelles. 
It was initially thought that receptor mediated endocytosis of viruses comprised of clathrin 
mediated endocytosis (CME). However, there is a body of evidence now which indicates 
other mechanisms in addition to CME (see Figure 1.7); macropinocytosis and caveolar/raft 
dependent endocytosis as clathrin and caveolin-raft independent mechanisms which are 
less well understood. 
1.8.2.1 Clathrin-mediated endocytosis 
Helenius et al. showed for the first time a virus, Semliki Forest virus, using CME for 
infectious entry (Helenius et al., 1980). Since then, many different viruses, both enveloped 
and non-enveloped, has been shown to use a clathrin mediated pathway which occurs 
constitutively in most mammalian cells. Viruses binding to their receptors can trigger the 
formation of clathrin coated pits (CCP) (Rust et al., 2004). For the formation of primary 
endocytic vesicles (PEV), clathrin is recruited to the plasma membrane in response to 
internalisation signals and forms a characteristic coat. Many proteins are involved in coat 
assembly including clathrin adapter proteins (Rust et al., 2004), although their specific 
function still remains to be identified.  
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Fission of the clathrin coated vesicles from the plasma membrane involves the GTPase 
dynamin and the process is rapid- about 1 minute for individual pits (Schelhaas, 2010). 
Following this, synaptojanin, auxilin and HSC70 help to dismantle the clathrin coat from the 
vesicle.  PEV,s then mature into early endosomes. In addition to entry by CME, viruses may 
also use an alternate pathway in the same cell, for example by influenza A virus (Rust et al., 
2004). 
1.8.2.2 Caveolin/ lipid raft mediated endocytosis 
Simian virus 40 (SV40), was the first virus shown to enter via caveolae (L Pelkmans, 
Kartenbeck, & Helenius, 2001). The process is preceded by the activation of several tyrosine 
and other kinases by virus binding leading to the clustering of lipid raft components such as 
glycosylphosphatidylinositol (GPI)- anchored proteins. SV40 moves laterally along the 
plasma membrane until trapped in a caveolae. In addition, SV40 binding seems to recruit 
caveolin-1 containing vesicles to the membrane. In caveolae containing SV40 activates a 
signal that depolymerises the actin cytoskeleton, then both actin and dynamin 2 are 
recruited to it. After internalisation, the caveolar vesicles deliver the viruses to membrane 
bound cytoplasmic organelles, the caveosomes. 
1.8.2.3 Macropinocytosis/phagocytosis 
Macropinocytosis and phagocytosis differ from other endocytic mechanisms in that they 
require extensive actin cytoskeletal reorganisation. These rearrangements result in an 
outward directed formation of the plasma membrane, whereas in other pathways the 
membrane buds into the cell. Vaccinia virus is known to use this mechanism. Phagocytosis is 
quite rarely used by viruses for entry but examples include mimivirus.  
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Figure 1.7: Schematic representation of endocytic mechanisms. Several different 
mechanisms exists for endocytosis in animal cells. These include clathrin-mediated, 
macropinocytosis, caveolar/raft-mediated mechanisms, as well as several novel 
mechanisms. Some of these pathways involve dynamin-2 as indicated by the beads around 
the neck of the endocytic indentations. Phagocytosis is used to take up large particles, a 
process restricted to a few cell types. In addition, there are pathways such as IL-2, the so-
called GEEC pathway, and the flotillin- and ADP-ribosylation factor 6 (Arf6)-dependent 
pathways that carry specific cellular cargo but are not yet identified to be used by viruses. 
Abbreviations: Adeno 2/5, adenovirus 2/5; Adeno 3, adenovirus 3; CME, clathrin-mediated 
endocytosis; HPV-16, human papillomavirus 16; HSV-1, herpes simplex virus 1; LCMV, 
lymphocytic choriomeningitis virus; mPy, mouse polyomavirus; SFV, Semliki Forest virus; 
SV40, simian virus 40; VSV, vesicular stomatis virus. Figure adopted from (Mercer, 
Schelhaas, & Helenius, 2010). 
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1.8.3 Logistics of endosome network 
After being internalised within primary endocytic vesicles, viruses follow the same 
intracellular pathway as those followed by other cargo such as physiological ligands and 
membrane components. Cargo is processed by the endosomal system in terms of molecular 
sorting, recycling, storage, transport, degradation and transcytosis. 
 The endosomal system is composed of an intricate system of organelles (see Figure 1.8) 
These are classed as early endosomes (EE), late endosomes (LE), recycling endosomes (RE) 
and lysosomes. The LE often takes the form of multivesicular bodies. There are also an 
intermediate class of endosomes called maturing endosomes (MEs) because they contain 
both EE and LE markers, Rab5 and Rab7 respectively (see next section). The endosome 
system is also tightly connected with the secretory pathway through vesicle shuttling 
between endosomes and the trans-Golgi network as well as via the plasma membrane. 
Although there are different classes of endosomes in the trafficking pathway and their 
transit through it is asynchronous, nevertheless, the cell uses several strategies to control 
endosomal trafficking. Playing an important role in this control  are a large family of small 
GTPase proteins called Rabs (Ras in brain) that control membrane identity and vesicle 
budding, uncoating, motility and fusion through the recruitment of effector proteins, such 
as sorting adaptors, tethering factors, kinases, phosphatases and motors. Crosstalk between 
multiple Rab GTPases through shared effectors, or through effectors that recruit selective 
Rab activators, ensures the spatiotemporal regulation of vesicle traffic. Functional 
impairments of Rab pathways are associated with diseases, such as immunodeficiencies, 
cancer and neurological disorders. Key members of the family are Rab5 and Rab7. 
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1.8.3.1 Rab5 
Rab5 is a well characterised member of the Rab family and is considered to be a marker of 
early endosome. In the early endocytic pathway Rab5 regulates clathrin coated vesicle 
mediated transport from the plasma membrane to the early endosomes as well as 
homotypic fusion of early endosomes (Zerial & McBride, 2001). It has been reported that 
EEA1 is the Rab effector that mediates tethering/docking of early endosomes and 
collaborating with SNARE proteins in facilitating homotypic fusion events of early 
endosomal membranes.  
For all the important Rabs, well-characterised point mutations exist which can be over- 
expressed as dominant-negative proteins to block a specific point in the endocytic pathway. 
Such dominant –negative Rabs are becoming utilised in studies of virus entry. For example, 
Adenovirus uptake was increased by overexpression of wild-type Rab5 and decreased by 
dominant negative Rab5 (Rauma et al., 1999). 
1.8.3.2 Rab7 
Rab7 is considered to be a marker of late endosomes. The conversion of EE to LE is a 
complex process. Rab5-positive early endosomes have been found to mature into late 
endosomes in a process that involves the exchange of Rab5 for Rab7 in a gradual step called 
Rab conversion (Rink, Ghigo, Kalaidzidis, & Zerial, 2005). The process involves the formation 
of an ME, a hybrid compartment with Rab5 and Rab7 domains. In addition, the repertoire of 
changes include a gradual drop in internal pH (discussed in next section), formation of late 
endosomes filled with vesicles (multi-vesicular bodies), a switch from Rab5 to Rab7 
effectors: a change in predominant phostidyl-inositides from PI(3) to PI (3,5)P2 (Gillooly et 
al., 2000). Furthermore, there is a change in the interaction with cytoskeletal elements 
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(primarily microtubules and their motors) which leads to endosome migration from 
peripheral to the perinuclear area of the cell and eventually to fusion with lysosomes. This 
Rab5 to Rab7 maturation has been shown to be very important in long distance axonal 
transport (Deinhardt, Salinas, et al., 2006) 
1.8.3.3 pH regulation of endosomes 
A unique characteristic feature of the endocytic pathway is the pH variation in different sub 
compartments  (Demaurex, 2002). There is a progressive acidification from plasma 
membrane to endocytic vesicles and early endosomes, through to multi-vesicular bodies, 
late endosomes and ultimately lysosomes (Grabe & Oster, 2001). Conversely, the pH of the 
secretory pathway also becomes more acidic as the cargo travels from ER and the Golgi 
network towards the cell surface (M. M. Wu et al., 2001). Cargo entering cells through the 
endocytic pathway rapidly undergo a drop in pH from neutral, to pH 5.9-6.0 in the lumen of 
early endosomes/recycling vesicles (Watson, Jones, & Stephens, 2005). Subsequently, 
further reduction from pH 6.0 to 5.0 occurs through the transition from late endosomes to 
lysosomes (Watson et al., 2005). 
The regulation of this change in pH in the pathway is controlled by a number of factors, 
which includes vacuolar ATPase, chloride and sodium channels , NaJ-ATPase, passive proton 
leaks and buffering capacity of organelle lumen (Grabe & Oster, 2001). 
From an invading virus point of view, the maturation to late endosomes and lysosomes  
renders the endosomal lumen a hazardous environment. Therefore, many viruses 
fuse/penetrate at mildly acidic pH (approximately 6.0) in early endosomes to avoid a deadly 
fate. Whereas, others exploit the changing environment within endosomes to precisely 
regulate the timing or cellular location of fusion/penetration. Endosomal maturation to late 
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endosomes  (as well as decreasing luminal pH, involves increasing levels of active hydrolytic 
enzymes and alteration of lipid composition) correlates with movement of endocytic 
organelles towards the nucleus by microtubule mediated retrograde transport. Neurons are 
an extreme example where this transport is vitally important because of the vast distances 
that need covering. Viruses may be taken into the cell by endocytosis at a peripheral 
synapse such as the neuromuscular junction but need transport to the cell body which 
maybe many centimetres away. In such cases, viruses may exploit endosomal transport 
along axons and use the lower pH of the late endosomes or exposure to acid hydrolases to 
delay penetration until endosomal delivery to a peri-nuclear location  (Grove & Marsh, 
2011). 
 However, there are instances pH dynamics in cells which are in contrast with the classical 
endosomal pathway. Bohnert and Schiavo  studied the transport of tetanus toxin in motor 
neurons using a chimera of the tetanus toxin binding fragment (TeNTHc) and demonstrated 
that moving retrograde carriers display a narrow range of neutral pH values which is kept 
constant during transport (Bohnert & Schiavo, 2005). In contrast stationary TeNTHc positive 
organelles exhibit a wide spectrum of pH values, ranging from acidic to neutral and 
demonstrated that the lack of acidification in retrograde carriers is due to the absence of 
vacuolar vATPase and not to an altered proton permeability of the membrane bilayer 
(Bohnert & Schiavo, 2005). In contrast, vATPase is likely to be present on stationary 
organelles which can be acidified.   
Salinas et al. built on this work by using a canine adenovirus (CAV-2) to study its transport in 
motor neurons and showed that in contrast to virions in the cell body that can reach acidic 
organelles (pH 5- 5.5), the majority of axonal carriers maintained a neutral pH even though 
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they underwent endosomal maturation detected by Rab5 and Rab7 association (Salinas et 
al., 2009).  
Therefore, viruses can utilize non-acidic endosomes to remain stably and efficiently 
associated with long range carriers in cells such as neurons and escape the endosome when 
they reach their destination- the soma, where acidification occur. 
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Figure 1.8: The endosome network. The main organelles of the endocytic pathway are the 
early endosomes (EEs), maturing endosomes (MEs), late endosomes (LEs), recycling 
endosomes (REs), and lysosomes. EEs are usually located in the periphery of the cytoplasm 
and have several different domains (tubular and vacuolar). The tubular give rise to recycling 
vesicles and vesicles for transport to the REs and to the trans-Golgi network (TGN). The 
vacuolar domains 200–1000 nm in diameter contain most of the volume, the intraluminal 
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vesicles (ILVs), and larger endocytosed particles. The vacuolar domains dissociate (with their 
contents) and undergo microtubule mediated, dynein-dependent movement to the 
perinuclear region. These MEs contain markers of both early and late endosomes, such as 
Rab5 and Rab7. They may also undergo further acidification and conversion to mature LEs, 
which can fuse with each other and eventually with lysosomes, generating endolysosomes 
in which active degradation takes place. The majority of incoming membrane components 
undergo recycling to the plasma membrane. However, membrane proteins destined for 
degradation are first tagged with monoubiquitins, then recognized by ubiquitin-binding 
components of the endosomal sorting complex required for transport (ESCRT) machinery, 
and finally sequestered into ILVs. ILVs are formed by inward budding of EEs and LEs. They fill 
the lumen of the vacuolar domains, forming multivesicular bodies, and are eventually 
degraded in lysosomes. Abbreviation: LAMP-1, lysosomal-associated membrane protein. 
Adopted from (Mercer et al., 2010). 
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1.8.4 Trafficking in the axon 
1.8.4.1 Neuronal architecture 
The nervous system comprises a peripheral collection of neurons  (the peripheral nervous 
system, PNS)  and a central set found in the spinal cord and brain (the central nervous 
system, CNS). Although neurons are central to the system, it is important to fathom that the 
majority of the cells that comprise the nervous system are highly specialised non-neuronal 
cells such as a variety of astrocyte cells  (Y. Zhang & Barres, 2010). In addition, cells of the 
immune system also engage with and signal to the PNS to affect changes in the CNS 
(Trakhtenberg & Goldberg, 2011). PNS neurons provide the interface with the outside world 
by sending and receiving information from it. 
Motor neurons have an unique morphology because of the polarized nature of the cells 
(Figure 1.9). Complex network of vesicular pathways coupling the neuromuscular junction 
with the motor neuron soma are essential for neuronal function and survival. Axonal 
transport constitutes the backbone of long range cross talk in neurons. A demonstration of 
the importance of axonal transport in neuronal homeostasis is the link between defects in 
this process and neurodegeneration. Specifically, key components of retrograde transport 
routes, which is the directional transport of neurotrophins and other cargoes through the 
axon to the soma, have been associated with motor neuron disease in humans and mice 
(Hafezparast et al., 2003).  
The majority of long distance axonal transport occurs on microtubules which are formed 
from heterodimers of alpha- and beta- tubulin (Figure 1.9). They have a dynamic ‘plus’ end 
that can grow and shrink rapidly while the ‘minus’ end is tethered to the microtubule 
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organising centre and is relatively stable (Enquist, 2012). Motors move cargo in an ATP-
dependent directional process: cytoplasmic dynein for retrograde traffic from the synapse 
to the cell body and the kinesin family in the opposite, anterograde direction. Dynein and 
kinesins co-ordinate the transport of several organelles such a mitochondria and 
endoplasmic reticulum (ER). In addition, axonal transport is also modulated by micro-tubule 
interacting proteins and neuronal sub-compartments such as axon initial segment which 
regulates targeting of the cargo to the axons (Salinas, Schiavo, & Kremer, 2010). 
Furthermore, retrograde axonal transport also allows peripheral signals to be translated into 
nuclear responses. A good example of which is receptors that are activated by target 
derived neurotrophins during development leading to the creation of ‘signalling 
endosomes’, which contain neurotrophin receptor complexes as well as downstream 
activated molecules such as extracellular signal regulated kinase 5 (ERK5; also known as 
MAPK7) and the cyclic AMP-responsive element-binding (CREB) transcription factors (Howe 
& Mobley, 2004; Salinas et al., 2010). Delivery of signalling endosomes to the soma ensures 
the survival of neurons that have reached a physiological target, in contrast to cells that do 
not connect with appropriate target and therefore undergo apoptosis (Ibáñez, 2007).  
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Figure 1.9: Neuronal organisation and axonal traffic. Neurons, such as motor neurons, are 
highly polarized cells and can exceed a meter in length in large animals. Axons are enclosed 
in myelin sheath composed of oligodendrocytes or Schwann cells, providing enhanced 
propagation of electrical signals. Polymers of tubulin form microtubules which are major 
cytoskeletal tracks involved in intracellular transport. Motor proteins dynein and kinesin 
move cargo retrogradly and anterogradly, respectively. Neuromuscular junctions and 
sensory nerve endings contain membrane molecules that can serve as receptors for viruses 
such as rabies and toxins such as tetanus. Adopted from (Salinas et al., 2010). 
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1.8.4.2 Transport of a neurotropic virus: Rabies 
The Achilles heel in the protection of the CNS are projections of neurons that cross the 
blood brain barrier and functionally connect peripheral organs and tissue with the soma of 
neurons. Molecules present at the nerve terminals can serve as receptors for pathogens and 
allow them to internalise and gain access to the CNS through axonal transport. 
One such neurotropic virus, rabies, is a RNA virus and is a member of the Lyssavirus in the 
Rabdoviridae family. The virus enters the motor neuron at the neuromuscular junction by 
binding specifically to its receptors and internalising. For this attachment, the rabies 
glycoprotein G (RV-G) is needed and it also plays an important role in the spreading of the 
virus later on (Schnell et al., 2010). To date, three different receptors have been shown to 
interact with the rabies virus.  
It has been reported that the nicotinic acetyl choline receptor (nAChR) is one such receptor 
(Lentz et al., 1983). The nAChR is an integral transmembrane protein which is involved in the 
transduction of chemical signal such as acetyl-choline into an electrical signal. Specific 
binding occurs at the neuromuscular junction. Binding at this site is competitive with 
cholinergic ligands such as the snake venom neurotoxin α-bungarotoxin, which shows 
sequence homology with RV-G. 
Rabies virus also attaches to the neuronal cell adhesion molecule (NCAM) (Thoulouze et al., 
1998a). Pre-incubation of rabies virus with soluble NCAM resulted in the inhibition of the 
virus to infect susceptible cells. Furthermore, transfection of resistant L fibroblasts with 
NCAM encoding genes induces rabies virus susceptibility. In vivo studies have shown the 
infection of NCAM deficient mice by rabies virus slightly delayed mortality and restricted 
brain invasion suggesting its specificity. 
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The low affinity nerve-growth factor receptor, p75NTR is the third reported receptor for 
rabies virus and was identified as a ligand of a soluble form of RV-G (Tuffereau et al., 1998). 
It has important roles in the internalisation and trafficking of neurotrophins during axonal 
transport. The p75NTR is always internalised, independently of ligand binding, suggesting a 
constitutive retrograde axonal transport of the receptor. RV-G interacts with high affinity 
with the first cysteine rich domain of the mammalian p75NTR. Interestingly, rabies virus binds 
to mammalian but not avian p75NTR, which is consistent with the lack of rabies disease in 
birds. Mazarakis et al. have suggested that binding to this receptor not only facilitates entry 
into the cell but also enables fast axonal transport (Mazarakis et al., 2001). Subsequently, 
Lalli and Schiavo published work showing p75NTR and clostridial toxin co-localising in non-
acidic endosomes (Lalli & Schiavo, 2002). They show the clostridial toxin and NGF share the 
same retrograde transport organelles, which are characterised by the presence of the 
neurotrophin receptor p75NTR. The study also reveals a novel axonal retrograde transport 
route that could be used both by physiological ligands (i.e. neurotrophins) and clostridial 
toxin to enter the central nervous system. 
After the uptake of the virus, the rabies virus is transported to the brain. Infection is thought 
to be by motor nerves and does not occur via the sensory nerve pathway as was shown 
using a RV-G pseudotyped lentiviral vector (Mazarakis et al., 2001). This work showed that 
RV-G pseudotyped lentiviral vector is retrogradely transported in neurons and thus it can 
pass to the spinal cord through the motor nerves but not via the pathway in the peripheral 
sensory nerves (Figure 1.10.A).   
The trafficking process is rapid and cannot be only driven by passive diffusion, so the virus 
has to use the active retrograde cellular transport system by hijacking it (Schnell et al., 
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2010). The transport is mediated by the dynein motor protein. Previously, it has been shown 
that the rabies P protein interacts with the dynein light chain 8 (Schnell et al., 2010) 
suggesting the virus maybe transported by direct binding to the dynein motor. However, it 
has also been shown that this interaction is not needed for retrograde transport of the virus 
(Mebatsion, 2001) therefore an alternative, and most likely, mode of transport for the virus 
would be to become encapsulated in endosomes for long range axonal transport to the 
soma (Figure 1.10.B). This is not too dissimilar to the one used by neurotrophins and their 
receptors (Salinas, Bilsland, & Schiavo, 2008). 
In the next step, the envelope of the rabies virus is thought to fuse with the endosomal 
vesicle enclosing it to release the nucleocapsid into the cytoplasm. To bring about this 
fusion, it has been reported that there is a decline in pH inside the endosome from about 7 
to 6 (Roche et al., 2008). This triggers the fusion reaction in which the G protein is also 
thought to be involved. Furthermore, there is a conformational change of the G protein 
along with the decline in pH (Roche et al., 2008). 
To date, there is very little information about the events, immediately following the release 
of the viral nucleocapsid into the cytoplasm and triggering of primary transcription. 
Recently, it has been proposed that low-pH conformational changes in the G protein 
promote acidification of the virus interior, which facilitates the release of matrix from the 
ribonucleoprotein particles during uncoating (Albertini et al., 2012). 
 
 
 
 
69 
 
A  
 
B 
 
Figure 1.10: Rabies virus trafficking pathway to the spinal cord and mechanisms of 
transport. (A) Retrograde transport occurs from the axon terminal at the neuromuscular 
junction towards the cell body of the motor neuron. (B) Two possible hypothesis in which 
rabies virus maybe carried on microtubule motor molecules. By direct attachment to the 
dynein motor or by encapsulation in endosomes which are then attached to the 
microtubule by dynein motors powering retrograde traffic of the virus. Adopted from 
(Warrell & Warrell, 2004).  
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1.9 Motor Neuron Diseases  
Motor neuron diseases (MND’s) are a group of neurodegenerative diseases that selectively 
affect the neurons that control voluntary muscle activity including breathing, speaking, 
swallowing and general movement of the body. MND’s are of the most common 
neurodegenerative diseases of adult onset. In the UK, the incidence of the disease is one to 
two per 100,000 people (Shaw & Ne, 1999). Currently there is no treatment that 
substantially slows the progression of the disease. 
1.9.1 Amytrophic Lateral Sclerosis 
Amytrophic lateral sclerosis (ALS) is a motor neuron disease that leads to progressive 
paralysis and premature death within three to five years of onset (D. B. Williams & 
Windebank, 1991). It was first described by the French neurologist Jean-Martin Charcot in 
1874 (Rowland, 2001). ALS is the most common adult-onset MND with a global incidence of 
approximately 2 per 100,000. The disease typically affects individuals in middle adult life 
with a mean age of onset of 55 years (Shaw & Ne, 1999). 
ALS presents mainly as clinical deficits associated with upper and lower motor neuron 
degeneration, although there is considerable heterogeneity between sufferers. As the 
motor neurons degenerate, muscles loose strength and voluntary movements are 
compromised. Death eventually follows, usually caused by respiratory failure, when the 
diaphragm and intercoastal muscles become disabled. 
1.9.1.2 Etiology and pathogenesis of ALS  
ALS can occur in one of two forms. The most common or sporadic (sALS) affects 
approximately 90% of diagnosed cases. A familial form (fALS) which is clinically 
71 
 
indistinguishable from sALS, affects approximately 10 % of patients and is linked to specific 
genetic mutations (Federici & Boulis, 2006).  
Within the fALS group, approximately 20 % of the cases  are caused by a mutation in the 
Cu/ZN superoxide dismutase type-1 (SOD1) gene (Rosen et al., 1993). Studies involving 
transgenic mice which over-express a mutated form of human SOD1 develop a severe and 
progressive MND closely resembling the human disease (Gurney et al., 1994). Deleterious 
effects of the mutant SOD1 protein arise through an unknown process. Evidence from cell 
cultures and transgenic animal models indicate that the mutant SOD1 gene acquires toxic 
gain of function, but the protein still retains normal enzymatic activity and stability (P. C. 
Wong & Borchelt, 1995). At the cellular level, the neuronal Golgi apparatus becomes 
disrupted or disorganised to form numerous round, smaller, oval and uniform vesicles in ALS 
motor neurons. Golgi apparatus disruption was observed in patients with familial ALS with 
human SOD1 mutations and in transgenic mice expressing human SOD1 and in sporadic ALS 
(Gomes et al., 2008). 
A mutation in the transactive response-DNA binding protein (TARDBP) has been linked to 
approximately 5% of fALS cases. In addition, mutations in other genes, including the 
angiogenin (ANG), vesicle associated membrane protein-associated protein B (VAPB) and 
fusion in malignant liposarcoma/translocated in liposarcoma (FUS/TLS) genes have been 
identified in patients with fALS  (Millecamps et al., 2010). 
More recently, researchers have discovered a new genetic mutation for ALS and a related 
disease called frontotemporal dementia (FTD) that appears to account for more than a third 
of all inherited cases of these diseases (DeJesus-Hernandez et al., 2011; Renton et al., 2011). 
These two groups show that chromosomal region 9p21 form of ALS/FTD is due to an 
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expansion of a GGGGCC hexanucleotide repeat in the intron between non coding exons 1a 
and 1b of the C90RF72 gene (DeJesus-Hernandez et al., 2011; Renton et al., 2011). In the 
wild type alleles there are no more than 23 repeats, whereas affected alleles have greater 
than 30 repeats. In one of the two studies, Renton et al. found that C90RF72 repeat 
expansion is associated with 46% of familial ALS, 21.1% of sporadic ALS and 29.3% of FTD in 
the Finnish population the study was carried out in (Renton et al., 2011). 
The C90RF72 protein remains uncharacterised (Donnelly et al., 2013), although it is highly 
conserved across species. It may be hypothesised that the repeated segments cause disease 
by haploinsufficiency, in which expression or splicing of the target gene is perturbed, or 
through the generation of abnormal amounts of toxic RNA that disrupt normal cellular 
pathways leading to the development of ALS/FTD (Renton et al., 2011). 
Whether sporadic or caused by a specific genetic mutations, the disease invariably leads to 
the death of motor neurons. Reasons for this include oxidative stress, neurofilament 
abnormalities, excitotoxicity, apoptosis, mitochondrial dysfunction, mutations in the RNA 
binding proteins and inflammation. 
In addition, defects in axonal transport have been suggested to play a role in the 
pathogenesis of ALS. Electron microscopy studies have revealed swellings occur in the initial 
segments of motor axons in patients with ALS and these swellings contain vesicles, 
lysosomes, mitochondria and intermediate filaments. These changes are highly suggestive 
of axonal transport defects (Millecamps & Julien, 2013). 
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1.9.2 Spinal Muscular Atrophy 
Another MND, spinal muscular atrophy (SMA), has autosomal recessive inheritance and is 
the second most commonest genetic disease affecting children. Using a combination of 
genetic analysis and physical mapping in patients suffering from SMA, the gene responsible 
for the condition has been identified as SMN (survival of motor neurons).  
Mutation of the SMN1 gene leads to reduced SMN protein levels and a selective dysfunction 
of motor neurons. SMN, together with partner proteins, functions in the assembly of small 
nuclear ribonucleoproteins (snRNPs), which are important for pre-mRNA splicing. It has also 
been suggested that SMN might function in the assembly of other ribonucleoprotein 
complexes. Two hypotheses have been proposed to explain the molecular dysfunction that 
gives rise to spinal muscular atrophy (SMA) and its specificity to a particular group of 
neurons. The first hypothesis states that the loss of SMN's well-known function in snRNP 
assembly causes an alteration in the splicing of a specific gene (or genes). The second 
hypothesis proposes that SMN is crucial for the transport of mRNA in neurons and that 
disruption of this function results in SMA (Rossoll et al., 2003). 
In its severest form, SMA causes paralysis and death and like ALS, is to date incurable. Like 
ALS, the identification of defined mutations causing SMA makes this monogenic disease a 
desirable target amenable to gene therapy. 
1.9.3 Gene therapy for motor neuron disease 
Gene therapy approaches which involve the use of viral vectors offer a promising strategy 
for delivery of genes to enhance motor neuron survival. In murine models, gene therapy 
using lentiviral vectors has been successful in alleviating symptoms and extending survival in 
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both cases of ALS and SMA (M. Azzouz, 2004; M. Azzouz et al., 2004 (1); Ralph et al., 2005; 
Raoul et al., 2005). In these models, lentiviral vectors are targeted to the neurons by 
pseudotyping with rabies-G. The rabies-G pseudotyped lentivectors are ideal for distal 
targeting of neurons in vivo because they are retrogradely transported from the synapse via 
the axon to the nucleus where they integrate and express the transgene (Mazarakis et al., 
2001). In rodent and primate models, transduction of neurons using lentiviral vectors has 
been amply demonstrated (Azzouz, Kingsman, & Mazarakis, 2004; Galimi & Verma, 2002). 
The main strategy in gene therapy is to deliver and integrate wild type versions of the 
defective gene and/or to offer neuroprotection to dying motor neurons by gene based 
delivery of recombinant trophic factors  such as BDNF (brain derived neurotrophic factor). 
To date, MoNuDin (an EIAV based lentiviral vector system for the delivery of VEGF) is the 
only gene therapy technology in preclinical development for the treatment of ALS which 
targets apoptosis as a means of preventing a neuronal cell death. 
In addition, antisense oligonucleotides (ASOs) can be used to alter the splicing of a gene and 
either restore production of a required protein or eliminate a toxic product. Hua and 
colleagues have demonstrated that ASOs directed against an intron splice silencer (ISS) in 
the SMN2 gene alter the full amount of full length SMN transcript in the nervous system, 
restoring SMN levels to levels that could correct SMA in mice (Hua et al., 2010). 
Despite laboratory successes, there have been some obstacles which have prevented the 
introduction of gene therapy based treatments for MNDs. Transduction efficiencies in non-
human primates have failed to reach therapeutic levels sufficient to proceed with clinical 
trials.  
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1.10. Aims of the research project 
Lentiviral vectors which are based on both human immunodeficiency virus (HIV) and Equine 
Infectious Anaemia Virus (EIAV), pseudotyped with the envelope glycoprotein G of rabies 
virus have shown potential as a gene delivery vectors in targeting motor neurones. 
However, transduction efficiencies in non-human primates have failed to reach therapeutic 
levels sufficient to proceed with clinical trials. This is most likely due to either inefficient 
vector trafficking in non-human primates and/or to differential sensitivity to post-entry 
restriction factors (expressed in mammalian cells in cell-autonomous manner that inhibit 
lentiviral replication) such as tripartite interaction motif 5 alpha (TRIM5α) and other such 
factors. 
With the target of investigating retrogradely transported lentiviral vectors, this project 
aimed to characterise the processes involved in the entry and retrograde trafficking of both 
HIV and EIAV vectors pseudotyped with the rabies G protein. This information might allow 
us in the future to increase the efficacy of gene transfer with these vector systems and thus 
develop better tools for gene therapy of MNDs. 
More specifically the project aimed to: 
• Design and construct by bioinformatics and cloning of HIV and EIAV vectors to contain a 
tetracysteine motif within the gag-pol expression cassette to allow visualisation of vector 
capsid trafficking during transduction. 
• Generate and characterise tetracysteine tagged vectors. 
76 
 
• Utilize the tetracysteine tagged and lipid labelled vectors in live cells studies with motor 
neurons in mass cultures and/or microfluidic chambers to characterise trafficking of the 
vector from the point of entry to the soma. 
• Document and characterise the entry and intracellular trafficking of RV-G pseudotyped 
lentiviral vectors by immunofluorescence microscopy. 
• Characterise and identify vector interacting proteins and vector containing organelles by 
magnetic pull down and proteomics analysis. 
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 2.1 Materials 
2.1.1 General chemicals 
All chemicals were of analytical reagent grade and, unless stated otherwise, were obtained 
from Sigma-Aldrich (UK), VWR (UK), Anachem (UK), Fisher (UK) and BDH (UK). All water used 
was double distilled (DDH2O), unless stated otherwise. Recipes for buffers and solutions are 
in section 2.1.2.  
2.1.2 Buffers and Solutions 
All the buffers and solutions were prepared as follows (Table 2.1): 
Ampicillin 50 µg/µl For 20 ml: 1 g Ampicillin powder (Sigma, UK) was dissolved in 20 ml of 
dH2O and sterilised with 0.22 m syrine filter (Nalgene, UK). Aliquots 
were kept at  -20°C. 
Kanamycin 10 µg/µl Per 20 ml: 0.2 g Kanamycin powder (Sigma, UK) was dissolved in 20 ml 
of dH2O and sterilised with 0.22  m syringe filter (Nalgene, UK). 
Aliquots were kept at  -20°C. 
50x TAE Buffer Per 1L: 242g Trisamine (Tris), 57.1 ml Glacial Acetic Acid, 
100 ml 0.5 M EDTA. 
SOC Media Per 250 ml: 5 g Tryptone Peptone, 1.25g Yeast extract, 0.15 g NaCl, 
0.05 g KCl, 0.51 g MgCl2, 2.5 ml MgSO4. Autoclave. Add 10 ml 20% 
glucose after autoclaving. 
LB (Luria‐Bertani) 
Broth 
Per 1L: 10 g NaCl, 5 g Yeast extract, 10 g tryptone peptone. Autoclave. 
LB (Luria‐Bertani) Agar Per 1L: 10 g NaCl, 5g Yeast extract, 10 g tryptone peptone, 15 g bacto 
agar. Autoclave. 
TSSM Buffer Per 104.5 ml: 28.65 ml tissue culture water (Sigma), 19.75 ml 0.1M tris-
HCL pH 7, 26.6 ml of 150 mg/ml lactose (Sigma, UK), 24.4 ml 154 mM 
sodium chloride (Sigma, UK), 5 ml of 20% human serum albumin 
(Alpha Therapeutics, UK) and 100 μl a 5 mg/ml protamine sulphate 
(Prosulf CP Pharmaceuticals, UK).  
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100 X Polybrene Per 50 ml: 40 mg polybrene (Sigma, UK), 50 ml PBS (Sigma), filtered 
using syringe 0.22 μm (Nalgene) and stored in aliquots of 1 ml at -20°C.  
8% PFA  
 
Per 100ml: 8 g of PFA powder (Sigma)  dissolved in 80 ml double 
distilled water (ddH20) by using a heated stirrer (50-60 ◦C) and adding 
3-6 drops of 5 M NaOH solution. Once cooled down, the pH was 
adjusted to 7.4 by adding  NaOH. Volume was adjusted to 100 ml and 
20 ml aliquots made and stored at -20°C.  
PBS Per 1L:  5 PBS tablets (Sigma, UK) were dissolved in 1 L of ddH20 and 
the solution was autoclaved. 
 
 
PBS/BSA/Triton X-100 
(0.1%)  
 
Per 10 ml: 10 μl of Triton X-100 (Sigma, UK) were added to 10 ml of 
PBS/BSA 1% and dissolved by incubating in 37°C water bath for 10 
minutes followed by vortexing.  
Breaking Buffer (BB)  
 
0.25 M sucrose (Sigma), 1 mM EDTA (Sigma), 1 mM MgOAc, 10 μl/ml 
protease inhibitors (Pierce, USA), and 10mM HEPES (Sigma, UK) 
adjusted to pH 7.2 by addition of KOH.  
 
BB, 0.4% BSA or 
Ovalbumin 
 
Per 20 ml: 0.08 g BSA (Sigma, UK) or Ovalbumin dissolved in 20 ml of 
BB.  
BB 100 mM KCl  
 
Per 40ml: 16 ml of 250 mM KCl were added to 24 ml of BB.  
 
10 x Running Buffer Per 500 ml: 15 g Trizma base (Sigma, UK), 72.1 g Glycine (Sigma, UK), 
and 5 g SDS (Sigma, UK) were dissolved in dH2O and made up to 500 
ml.  
 
10 x Transfer Buffer Per 500 ml: 15.15 g Trizma base (Sigma UK) and 72.1 g Glycine (Sigma, 
UK) were dissolved in dH2O and made up to 500 ml.  
 
 
 
2.1.3 Cell Culture Media and Solutions (Table 2.2) 
Complete Dulbecco’s 
Modified Eagle Media 
(DMEM) for  HEK293T cell 
culture 
Per 500 ml: DMEM (Sigma, UK) was supplemented with 10% Foetal 
Calf Serum (FCS) (Gibco, UK), 2mM L-Glutamine (200mM) (Sigma, UK) 
and 1% Penicillin/Streptomycin (100x) (Sigma, UK), stored at 4 °C.  
 
DMEM Media for NSC34 
cell culture 
Per 500 ml: DMEM (Sigma) was supplemented with FCS (Gibco) (10% 
FCS for undifferentiating media and 1% FCS for differentiating media), 
2mM L-Glutamine (200mM) (Sigma), 1% Penicillin/Streptomycin (100x) 
(Sigma) and 1% Non-essential amino acids (NEAA 100x) (Sigma, UK), 
stored at 4°C.  
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Motor Neuron Culture 
Medium 
Per 500 ml: Neurobasal medium (Invitrogen Gibco, USA) was 
supplemented with the following components:  
 2% B-27 serum free supplement (Invitrogen Gibco, UK)  
 25 μM B-mercaptoethanol (Invitrogen Gibco, UK)  
 2% Horse serum (Invitrogen Gibco, UK)  
 0.5 mM L-Glutamine 200mM (Sigma)  
 0.5% Penicillin/Streptomycin (Invitrogen Gibco, UK)  
 0.1 ng/ml hBDNF (Alomone labs)  
 0.1 ng/ml hGDNF (Alomone labs)  
 0.5 ng/ml rCNTF (Alomone labs)  
4% BSA for Motor neurone 
cultures 
Per 100 ml: 4 g BSA (Sigma) dissolved in 100 ml Leibovitz Medium (L-
15) (Invitrogen Gibco, UK), aliquoted in 1.5 ml tubes and stored at -
20°C. 
 
DNase solution 1 mg/ml DNase (Sigma, UK) in L-15 media (Invitrogen).  
 
Laminin 2 μg/ml Laminin (Sigma, UK) in L-15 (Invitrogen).  
 
10.5% Optiprep 
 
For 6 ml: 1.05 ml 60% iodixanol (Axis-shield, USA) in water was diluted 
in 4.95 ml L-15 (Invitrogen).  
 
Trypsin for motor 
neurone culture 
preparation 
2.5 % w/v Trypsin (Sigma, UK) in PBS (Ca²⁺, Mg²⁺ free).  
 
 
2.1.4 Materials used in bacterial cell culture 
Bacterial cell culture plates were purchased from Fisher (UK). Antibiotics used in bacterial 
cell culture were: ampicillin (50mg/ml; Sigma, UK) and kanamycin (10 mg/ml, Sigma, UK). 
They were prepared in DDH2O and filtered through a 0.2µm syringe filter (Thermo Scientific, 
UK). Working concentrations of the antibiotics were 100 µg/ ml for ampicillin and 10 mg/ ml 
for kanamycin. All stocks were aliquoted and stored at -20°C until use. All bacterial media 
were prepared in endotoxin-low glassware and autoclaved prior to use. 
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2.1.5 Materials used in mammalian cell culture 
Tissue culture flasks, disposable pipettes and disposable graduated tubes were obtained 
from Fisher Scientific (UK) or Falcon (UK). The HEPES– buffered RPMI medium 1640 and 
bicarbonate buffered DMEM medium will be referred to as RPMI and DMEM respectively. 
Unless stated otherwise, tissue culture media was supplemented with penicillin (100 IU/ 
ml), streptomycin (100 µg/ ml) and L-glutamine  (2 mM) all from Sigma-Aldrich (UK). Heat 
inactivated foetal calf serum (FCS), Gibco (UK) was used to supplement media at 2-10% v/v. 
 
2.1.6 Commercial kits 
Plasmid miniprep/maxiprep/megaprep kit   Qiagen, UK. 
QIAquick gel extraction kit     Qiagen, UK. 
QIAquick PCR purification kit     Qiagen, UK. 
BCA protein assay kit      Thermo Scientific, UK. 
HIV-1 p24 antigen ELISA kit     Zeptomatrix Corporation, USA. 
Β-gal staining kit (LacZ Assay)     Invitrogen, UK. 
 
 
2.1.7 Centrifuges 
Microcentrifuge     Eppendorf 
Tabletop centrifuge     Sorvall 
Ultra centrifuge      Beckman Coulter 
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2.1.8 Molecular components 
Table 2.3:  Primers (supplied by Invitrogen, UK) 
Primers for PCR 
Name Sequence: 5’ 3’ 
TI001_EIAVgagF CTAACTAGAGAACCCACTGCTTAC 
TI002_EIAVgagR TTCCTCCCACTCCTATTATTCCCG 
TI003_EIAVgagSeq1 CTTGATGCAATTGATAAAATAGCAGAT 
TI004_EIAVgagSeq2 GTTATTGGCAAAAGCACTTCAGAC 
TI005_EIAVgagSeq3 TCTGGTCTTAAATGTCTCATAGCA 
TI006_EIAVgagSeq4 TTCTTCAGAGGGCTCAGACTG 
TI007_MAC-UP GCAGCAACCCGGACAGCAGTTGAGGAACTGCTTTTTATTAGCAGTCTTCTTTTC 
TI008_MAC-DN TGCTGTCCGGGTTGCTGCatggagcccTCTGAGCCCTCTGAAGAATATCC 
TI009_CAN-UP GCAGCAACCCGGACAGCAGTTGAGGAACCCATCTATCATGATTGGATATTCTTCA 
TI010_CAN-DN TGCTGTCCGGGTTGCTGCatggagcccGCTGGAAACAGAAATTTTAGACCTCTA 
TI011_NCN-UP GCAGCAACCCGGACAGCAGTTGAGGAAAAGACCAGTCTGAAGTGCTTTTG 
TI012_NCN-DN TGCTGTCCGGGTTGCTGCatggagcccGCGGGCCCATTTAAAGGTGG 
TI013_P9I-UP GCAGCAACCCGGACAGCAGTTGAGGAAATCCTTCTCCTTGACATTGTATTCCTT 
TI014_P9I-DN TGCTGTCCGGGTTGCTGCatggagcccCAAGTAGAGGATCTCAACCTGGAC 
TI015_P9C-UP GCAGCAACCCGGACAGCAGTTGAGGAACTCCCACAAACTGTCCAGGTTGA 
TI016_P9C-DN TGCTGTCCGGGTTGCTGCatggagcccTAACATATAATCTAGAGAAAAGGCCTACTA 
  
 
2.1.9 Antibodies 
The primary antibodies used in this project and their details are listed below in Table 2.4. 
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Antigen Clone Species Supplier Catalogue 
number 
Dilution 
used 
Rabies Virus 
Glycoprotein 
1C5 Mouse AbCam ab82460 IF: 1:1,000 
HIV-1 p55+p24+p17  Rabbit AbCam ab63917 ICC: 1:2500 
WB 1:1,000 
VSV-G tag  Mouse Chongqing 
Biospecs. Co. 
BTL1023 ICC: 1:250 
Rab5 621.3 Mouse SynapticSystems 108011 ICC: 1:500 
Rab5  Rabbit Cell Signaling 2143S ICC: 1:100, 
WB: 1: 1,000 
Rab5  Rabbit Abcam ab18211 ICC: 1:1,000 
Rab7 8909.S Rabbit CRUK (Schiavo 
lab.) 
 ICC: 1: 1,000 
Rab7  Mouse Abcam ab50533 ICC: 1,000 
p75NTR Intracellular 
portion 
Rb5090 Rabbit CRUK- (Schiavo 
lab.) 
 WB: 1:500-
1:1,000 (dep. 
on protein 
levels). 
ICC:1:1,500 
p75NTR Extracellular 
portion 
Rb5710 Rabbit CRUK- Schiavo 
lab 
 WB: 1:500-
1:1000 (dep. 
on protein 
levels) 
p75NTR labelled with 
Alexa 647 
 Rabbit CRUK- Schiavo 
lab 
 LCI: 1:500 
Nicotinic 
Acetylcholine 
Receptor 
Alpha 7 Rabbit Abcam ab23832 ICC: 1:1,500. 
Neurofilament- 200  Rabbit Sigma-Aldrich N4142 ICC: 1:1,250 
Neural Cell  Rabbit Millipore AB5032 ICC: 1:1,250 
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Adhesion Molecule 
(NCAM) 
EIAV core protein 
antigen (p26) 
reference serum 
Lady Horse Montelaro lab, 
University of 
Pittsburgh 
 WB: 1:500 
Anti-Myc Tag 9E10 Mouse Millipore 05-419 WB 1:1,000 
anti-HA GG8-
1F3.3 
Mouse Miltenyi Biotec 130-091-972 WB: 1:500 
Anti-CHAT  Goat Millipore  ICC:1:100 
O/N 
HB9  Rabbit Abcam Ab90606 ICC: 1: 750 
Anti- Calcitonin 
Gene Related 
Peptide (CGRP) 
 Rabbit Calbiochem PC205L ICC: 1:100 
Anti Islets-1  Rabbit Abcam Ab20670 ICC:1:500 
O/N 
SMI-32 
(Neurofilament H-
NonPhosphorylated) 
SMI-32 Mouse Covance SMI-32R ICC: 1:1,000 
Metabotropic 
Glutamate Receptor 
2+3 
 Rabbit Abcam Ab6438 WB: 1: 1,000 
ICC: 1:500 
Ionotropic 
Glutamate Receptor 
2+3 
 Rabbit Millipore P42262 WB: 1:1,000 
ICC: Immunocytochemistry; WB: Western Blot; LCI: Live Cell Imaging 
Table 2.5 Secondary Antibodies used in this project. 
Recognises Conjugate Species Source Catalogue 
Number 
Working 
Dilution 
Mouse IgG 
(H+L) 
Alexa488 
 
Goat 
 
Invitrogen 
 
A11029 
 
ICC: 1:1,000 
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Rabbit IgG 
(H+L) 
Alexa594 
 
Goat 
 
Invitrogen 
 
A11037 
 
ICC: 1:1,000 
 
Rabbit IgG 
(H+L) 
 
Alexa488 
 
Donkey 
 
Invitrogen 
 
A21206 
 
ICC: 1:1,000 
Rabbit IgG 
(whole 
molecule) 
 
HRP 
 
Goat 
 
Sigma A 0545 WB:1:25,000 
Mouse IgG 
(Whole 
Molecule) 
 
HRP Goat Sigma A8924 WB:1:25,000 
Goat IgG 
 
Alexa594 Donkey 
 
Invitrogen 
 
A11058 
 
ICC 1:1,000 
 
 
 
  
86 
 
2.2 Methods 
2.2.1 Molecular Biology 
2.2.1.1 Agarose gel electrophoresis 
Plasmid preparation products, digests, ligations and polymerase chain reaction (PCR) were 
analysed by agarose gel electrophoresis. Gels were made by adding 1.5% w/v agarose 
(Sigma, UK) to 100ml of 1 x TAE buffer with the addition of 5 µl ethidium bromide  (10 mg/ 
ml) (Sigma, UK). Samples were prepared in 6x DNA loading dye (NEB, UK). Electrophoresis 
was performed in 1 x TBE buffer at 100 volts for approximately 30 minutes. Gels were 
examined and photographed under ultraviolet (UV) light using a gel documentation system 
(GelDoc, BioRad, USA). The size of the products were compared with that of DNA ladders 
ran alongside: 100 b.p. ladder, 1 kB ladder or 2 log DNA ladder from New England Biolabs 
(NEB, UK). 
 
2.2.1.2 Plasmid preparation and characterisation 
Recombinant plasmids in E.Coli bacteria (NEB 5α), required for lentiviral vector production, 
were purified from glycerol stocks kept in a -80ºC freezer. A sterile loop was used to scrape 
a sample from frozen stock which was subsequently used to streak agar plates containing 
the relavant antibiotics for selection. Following overnight incubation, single colonies were 
picked from the plate to inoculate 5 ml starter culture of TB or LB media containing the 
appropriate selective antibiotic. Following 8 hours of incubation in a shaker (approx. 300 
rpm) at 37°C, the culture was diluted 1 in 500 into selective media and grown for 16 hours 
at 37°C, again with vigorous shaking. The following day, the plasmids were purified using 
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commercially available plasmid purification kits, according to supplied protocols (Mini-,Midi-
, Mega- kits; Qiagen, USA). Precipitated DNA was dissolved in an appropriate volume of TE 
buffer (10 mM Tris-Cl, 1 mM EDTA, pH 8.0). Purified plasmid DNA was quantified using 
spectrophotometry. Absorbance at 260 nm was used to determine concentration as nucleic 
acids have an absorption maximum at this wavelength. The ratio of absorbance at 260 nm 
and 280 nm was used to determine purity. Proteins and other impurities have a peak 
absorbance at 280 nm that reduces the A260/A280 ratio. A ratio between 1.7 to 2.0 indicates 
DNA without significant impurities. 
2.2.1.3 Supercoiled plasmid quantification 
A quantitative agarose gel analysis was performed to estimate the proportion of supercoiled 
DNA in each plasmid preparation. This enables the determination of the mass of supercoiled 
DNA out of total mass for the purposes of transfections. The purified plasmid samples were 
run on a 1% agarose gel alongside known amounts of DNA from 1 kB DNA ladder (NEB, UK). 
A digital image of the gel was taken with the gel doc system. The amount of sample DNA 
loaded was estimated by comparison of the band intensity with the DNA standards utilizing 
an imaging system (Scion Image, USA). Then, a standard curve of DNA concentration was 
drawn from the ladder intensity, the concentration of supercoiled DNA was determined 
from this. 
2.2.1.4 Restriction enzyme digestion of plasmids 
For restriction analysis, restriction enzymes from (NEB), UK, were used according to the 
manufacturer’s instructions. DNA was incubated in a 1.5 ml reaction tube with 10-20 
units/µg of the respective enzyme, the corresponding buffers, double distilled water and, if 
necessary 0.1 volume of BSA. The restriction digest samples were incubated at the optimum 
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temperature for the enzyme for 2-4 hours. Restriction enzyme digested fragments were 
then resolved by agarose gel electrophoresis. 
2.2.1.5 Isolation of DNA from Agarose gels 
DNA fragments were cut out of the agarose gel on an ultra violet (U.V.) transilluminator box 
using a sharp, sterile scalpel blade and the bands were transferred into a 1.5 ml reaction 
tube and purified using the QIAquick Gel Extraction Kit according to the manufacturer’s 
instructions. 
For DNA deemed sensitive to UV light, an alternative protocol was used. This involved 
dividing the sample loading lanes of the agarose gel into three segments. A central section 
(the analytical segment) was loaded with 7 µl of molecular weight marker along with 10 µl 
of restriction digested plasmids to be used for analytical purposes. Adjacent to this was an 
empty lane. On either side of this central segment were the preparative segments where 
the joined together larger wells were loaded with 50 µl of preparative restriction digested 
samples. The sample loaded gel was run so that the dye front was approximately halfway 
down the gel. Then, using a scalpel blade, the central segment of the gel was excised cutting 
along the empty lanes. The central analytical segment was examined under UV light to 
confirm that the vector digest has worked. The bands in this segment was excised and 
disposed of. The excised gel was then repositioned and aligned with rest of the gel. Then 
using a scalpel blade, the desired bands in the preparative gel part were cut, using the 
central part of the gel as a guide and placed in sterile 1.5 ml reaction tube. 
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2.2.1.6 Splicing by Ovelap Extension Polymerase Chain Reaction (SOE by PCR) 
For cloning tetracysteine tagged gag constructs, primers were designed to clone gag-4C 
constructs by splicing by overlap extension (Horton, Hunt, Ho, Pullen, & Pease, 1989; 
Warrens, Jones, & Lechler, 1997) using the plasmids pMD2-LgpRRE (for HIV-1 4C) and 
pEV53B (for EIAV 4C). The primers gag-SeqF and gag-SeqR were designed to amplify the 
region containing the Clal-BcII fragment of pMD2-LgpRRE and SacII/AscI-Xbal of the EIAV 
vector, pEV53B. PCR reactions were performed with the gag-SeqF with SOE Up or gag-SeqR 
with SOE down primers in a total volume of 50 µl containing the mix of components listed in 
Table 2.4. Typical cyling conditions are listed in Table 2.5. The PCR products (known as SOE 
fragments) were resolved by electrophoresis through 1.5% w/v agarose gels in 1 x TAE 
buffer. The DNA was then extracted from the agarose using a QIAquick gel extraction kit as 
per manufacturer’s instructions. 
The second PCR step (SOE PCR) utilised the products of the first as the templates in a 
reaction volume of 50 µl of which 24 µl was the template volume and 26 µl the PCR master 
mix (16.6 µl ddH2O, 5 µl of 10x polymerase buffer, 1.5 µl of 10 mM deoxynucleotide mix 
(dNTP), 1 µl of 50 mM MgSO4, 0.75 µl of 10 mM gagSeqF and 0.4 µl Platinum pfx high fidelity 
polymerase, 0.75 µl of 10 mM gagSeqR). This generated gag-4C fragments which were 
cloned into pCRII (Invitrogen, UK) by TOPO cloning as per manufacturer’s instructions. This 
was followed by restriction enzyme analysis and sequence analysis to identify clones with 
correct inserts. The gag-4C fragments were then subcloned into their respective pMD2-
LgpRRE and pEV53B vectors. 
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Ingredients Amount 
Double distilled water 39.6 µl 
10x polymerase buffer 5 µl 
10 mM deoxynucleotide mix (dNTP) 1.5 µl   
50 mM MgSO4 1 µl 
Forward primer (10 mM) 0.75 µl 
Reverse primer (10 mM) 0.75 µl 
DNA template (1 µg/µl) 1 µl 
Platinum pfx high fidelity polymerase 0.4 µl 
 Total volume 50 µl 
Table 2.5: PCR mix 
Step Temperature Time 
Denaturation 94 °C 5 min 
Denaturation 94 °C 15 sec 
Primer annealing 52 °C 30 sec 
Extension 68 °C 1 min, 30 sec 
Extension/Gap filling 68 °C 10 min 
Hold 4 °C ∞ 
Table 2.6: PCR cycling programme 
 
 
30 x 
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2.2.1.7 Ligation 
For ligation, 50-200 ng of vector DNA was used for each reaction. The ratio of vector 
backbone to insert were either 1:6 or 1:9. Vector and insert DNA was mixed in a 1.5 ml 
reaction tube and the volume adjusted to 10 µl with dH2O. In addition, 10 µl of 2x quick 
ligation buffer was added and the mixture mixed by flicking the tube. This was followed by 
the addition of 1µl of T4 DNA ligase and the mixture mixed thoroughly followed by 
centrifugation and incubation at room temperature for 5 minutes. The ligation mixture was 
then chilled on ice then used to transform bacteria or stored at -20°C.  
2.2.1.8 Transformation of bacteria 
For transformation, NEB 5-alpha competent E.coli cells were thawed on ice for 10 minutes. 
This was followed by the addition of 1-5 µl containing 1pg- 100 ng of plasmid DNA to the cell 
mixture, followed by careful flicking of the reaction tube 4-5 times to mix the cells and the 
DNA. The mixture was then placed on ice for 30 minutes. Following this, a heat shock of 
42°C was performed for exactly 30 seconds in a preheated water bath followed by further 
incubation on ice for 5 minutes. Then, 950 µl of room temperature SOC media was pipette 
into the sample followed by vigorous shaking (250 rpm) of the tube in a shaking incubator 
heated to 37°C. The suspension was added to LB-Agar plated containing antibiotic selection, 
spread evenly and incubated overnight at 37°C in an incubator. 
2.2.1.9 Cultivation of bacteria 
Culture plates: Bacteria were cultured on LB plates containing ampicillin (50 µg/ml) by 
adding the bacterial suspension onto the plate and incubation overnight at 37°C until 
bacterial colonies were visible. Plates with bacterial colonies were stored for up to 6 weeks 
at 4°C by wrapping them with cling film (Saran, UK).  
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Liquid culture:  Bacteria were cultured in liquid LB medium containing ampicillin (conc.) 
overnight at 37°C on a shaking incubator (200 rpm).  
2.2.1.10 DNA sequencing 
Plasmids were sequenced by the DNA core facility at Imperial College London. Samples were 
prepared in a volume of 30 µl containing 50 ng/ µl DNA and mixed with 30 µl of appropriate 
sequencing primers (10 pmol/ µl) in 1.5ml reaction tubes. 
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2.2.2 Cell Biology and Virology 
2.2.2.1 Production, concentration and labelling of lentiviral vectors 
Lentiviral vectors were produced using the modified calcium phosphate precipitation 
transfection protocol (Professor John Olsen, University of Pittsburgh, USA, personal 
communication with Professor Nicholas Mazarakis). 150 mm cell culture dishes (Becton 
Dickinson, Europe) were seeded with 1.7 x 107 HEK 293T cells in 15ml of complete DMEM 
media and incubated overnight in a 37°C incubator with 5% CO2. Prior to the transfection 
process, TVM1 and TVM2 were freshly prepared and pH measured. Both media were used 
at room temperature. 24 hours post seeding of cells, transfections were carried out. HIV 
based lentiviral vectors were produced using a four plasmid system. Each plate was 
transfected with 15 µg pLV-LacZ (Addgene) or Sin-cPPT-PGK-eGFP-WHV (obtained from 
Professor Mimoun Azzouz, University of Shefield, UK), 15 µg HIV-1 GagPol (pMD2-LgpRRE or 
pMD2-Lgp (4C-MAC)RRE), 3 µg HIV-1 Rev (pRSV-Rev obtained from Professor James Uney, 
University of Bristol, UK) and 5.1 µg of the envelope plasmid (pMD2-VSVg or pMD2-B2C) 
which were prepared in a 50 ml Falcon tube.  
For the production of EIAV vectors (both wildtype and tetracysteine tagged), each plate was 
transfected with 22.5 µg GagPol (pEV53B or pEV53B 4C MA-C), 22.5 µg SIN 6.1CZW-LacZ 
(obtained from Professor John Olsen, University of North Carolina, USA) or SIN6.1CeGFPw 
and 13.5 µg pMD2-B2C.  
To the plasmid cocktail, 2.66 ml of TVM1 (pH 7.1) media was added. This was followed by 
the addition of 136.66 µl 1M CaCl2 in two steps; first 2-3 drops by drop wise and mixed by 
flicking, then the rest of the solution was added without any agitation. The reaction mixture 
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was allowed to incubate at room temperature for 10 minutes before the addition of 10.83 
ml of TVM2 (pH 7.9) media to the DNA mix which was then mixed thoroughly by repeat 
pipetting.  The media from the 150 mm dish containing the HEK-293T cells was removed. 
Then 13.5 ml of the transfection mix was added to each plate taking care not to detach the 
cells. The pates were incubated overnight in a 37°C incubator with 5% CO2. Sixteen hours 
post transfection, vector expression was induced by replacing the media in the dishes with 
DMEM containing 2% FCS, 1% pen/strep, 1% L-glutamine and 10mM Sodium Butyrate.  
36 hours after the addition of sodium butyrate, the viral vectors were harvested and 
concentrated. The media was collected into a 50 ml Falcon tube and centrifuged at 750 rpm 
to spin down cell debris. The supernatant was then filtered through a 0.45 µm filter and 1 ml 
sample of the unconcentrated virus kept for vector titration (unconcentrated vector). The 
remaining lentiviral vector sample was concentrated by ultracentrifugation at 87,000 x g for 
2 hours at 4°C through a 20% sucrose cushion (Carpentier et al., 2012). The viral pellet was 
then re-suspended in 50µl TSSM buffer, alaquoted into cryovials and stored at -80°C. 
Metabolic labelling of tetracysteine tagged vectors with the biarsenical dye FlAsH: 
Tetracysteine tagged vectors were produced as per standard vector production protocol 
(see above). 1µM FlAsH-EDT2 dye premixed with 12.5 µM 1,2 Ethanedithiol (EDT; Sigma, UK) 
and added to media during sodium butyrate induction (16 hours post transfection). 
Labelling vectors with lipophillic dye: To label packaging cells (293T) with DiD, DiI or DiO 
(which will be incorporated into budding vector particles) during vector production, the 
media on the cells of each plate is replaced with 12 ml optimem containing 3.75 μM of 
lipophillic dye 3 hours prior to sodium butyrate induction. Subsequently, the media is 
replaced with media containing sodium butyrate. 
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2.2.2.2 Titration of Lentiviral vectors by FACS analysis, p24 assay and quantitative real 
time PCR (qPCR) 
FACS analysis: Biological activity of Lentiviral vectors carrying the eGFP reporter gene was 
determined by flow cytometry. HEK 293T cells were seeded in 12 well plates at 5 x 105 
cells/well. At 16-24 hours after seeding, the cells in a single well were trypsinised using 1 x 
Trypsin-EDTA (Sigma)  and the cell number was quantified using a haemocytometer. For the 
unconcentrated vector, the cells in the 12 well plate were transduced with a serial dilution 
of the vector: 495 µl, 250 µl, 50 µl and 20 µl of crude supernatant made up to 500 µl with 
DMEM + 10% FCS (HEK 293T growing media) in the presence of 8 µg/ml of polyprene. For 
the concentrated vector, the cells were transduced with a serial dilution of the vector: 10-2, 
10-3 and 10-4, again made up to 500 µl with growth media and a final concentration of 8 
µg/ml of polybrene (Sigma Aldrich, UK). The media in the wells were replaced with 450 µl of 
the serially diluted vector samples and allowed to transduce the cells for 6 hours in a 37 °C 
incubator. After this incubation, the transduction volume in the wells was replaced with 1 
ml of fresh complete medium and the wells were incubated for a further 72 hours at 37°C 
with 5% CO2. 
At 72 hours post transduction, the cells were harvested. The media from each well was 
gently aspirated, followed by 1 x wash with PBS. The cells were then detached by 
trypsinisation with 1 x Trypsin/EDTA and transferred to 1.5 ml tubes. They were spun at 
2,000 rpm for 5 minutes and the pellet of cells was re-suspended in 200 µl 4% PFA and fixed 
for 15 minutes at room temperature with regular flicking of the tube to agitate the cells. 
Following fixation, the cells were again pelleted by centrifugation at 2,000 rpm for 5 minutes 
followed by re-suspension in 400 µl PBS. The percentage of eGFP positive cells was 
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determined by flow cytometry (Becton Dickinson LSR Benchtop Flow Cytometer; Argon-ion 
488 nm laser with 20 mW power output for eGFP). This figure was used to determine the 
number of Transduction Units/ml (TU/ml). 
Biological activity of vectors carrying the LacZ reporter gene was done using an adopted 
protocol. HEK 293T cells were plated in a 12 well plate at 300,000 cells per well. 24 hours 
post seeding, the cells were transduced with serially diluted vector plus 8 µg/ml of 
polybrene.  48 hours post transduction, cells were washed and fixed in 4% PFA and LacZ 
expression detected using a β-gal staining kit (Invitrogen, UK). The total number of foci of 
transduction (consisting of 1-8 LacZ positive cells each) per well were counted manually 
under a light microscope. The values from serial dilutions of vectors giving between 30 and 
300 foci of transduction were used to calculate the original vector titre expressed as LacZ 
forming units per ml (LFU/ml). 
p24 assay: The number of physical lentiviral vector particles present in a preparation was 
estimated using a HIV-1 p24 antigen ELISA (RETROtek from ZeptoMetrix, Franklin, USA) as 
per manufacturer’s instructions. 
qPCR analysis: For determination of lentiviral genomic RNA titers in the samples, RNA was 
purified from 150 μl of concentrated vector supernatant (diluted 1:100 in DMEM) using 
NucleosSpin® RNA Virus Kit (Macherey-Nagel Inc., USA) according to the protocol contained 
in the Viral RNA Isolation user manual. Isolated RNA was eluted in 50 μl of RNase-free 
water. Subsequently, a DNase I step was included in the column purification procedure 
following the Lenti-X™ qRT-PCR Titration kit (Clontech Laboratories, USA) instructions to 
remove any residual plasmid DNA that may have been carried over from transient 
transfection of the packaging cells. The eluted and treated RNA was processed as explained 
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in the Lenti-X™ qRT-PCR Titration kit (Clontech Laboratories). The qPCR instrument 
(Stratagene Mx3000P) was programmed for the following qRT-PCR reaction cycles: RT 
reaction (42ºC, 5 min; 95ºC, 10 sec), qPCR x 40 cycles (95ºC, 5 sec; 60ºC, 30 sec), and a 
dissociation cycle (95ºC, 15 sec; 60ºC, 30 sec; all 60ºC-95ºC).  
2.2.2.3 Cell Culture- Cell lines 
HEK 293T cells 
Transfection optimized human embryonic kidney cells transformed by expression of the 
large T antigen from SV 40 virus, HEK 293T cells,  were acquired from ATTC UK and cultured 
in DMEM supplemented with 10% FBS and 1% Penicillin/Streptomycin (Sigma, UK) and 1% L-
Glutamine (Sigma, UK) in an incubator at 37°C, 5% CO2 and saturated water atmosphere. 
Media was changed three times a week. They were allowed to grow till about 70% 
confluency before being passaged by removing the spent media and washing the cells with 
PBS before the addition of 1x Trypsin and incubation for 3 minutes in a 37°C, 5% CO2 
incubator. Following this, the tissue culture flask containing the cells were tapped gently on 
the side to detach the cells. HEK 293T growth media was added to the cells to neutralise the 
trypsin. The cells were then pipette into a 50 ml tube and centrifuged for 5 minutes at 750 
rpm. After this, the supernatant was aspirated and the cell pellet was re-suspended in 
growth media before being seeded into a new cell culture flask containing fresh media at 
the desired dilution and incubated in a 37°C, 5% CO2 incubator.  
NSC-34 (mouse motor neuron like cell line) 
Neuroblastoma x spinal cord cells NSC34 were obtained from Professor Pam Shaw 
(University of Sheffield, UK) and maintained in undifferentiating media consisting of  DMEM 
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media supplemented with 10% FBS, 1% non essential amino acids (Sigma, UK), 1% 
Penicillin/Streptomycin (Sigma, UK) and 1% L-Glutamine (Sigma, UK) and routinely passaged 
every 72-96 hours or when they were about 60% confluent. The passage these cells, 2/3 of 
the media was removed from the culture flask and it was tapped vigorously on the side to 
detach the cells. The detached cell suspension was then pipette gently to break up any 
clumps and seeded into tissue culture flasks containing fresh media.  
To differentiate the NSC-34 cells, media was replaced with DMEM media supplemented 
with 1% FBS, 1% non essential amino acids (Sigma, UK), 1% Penicillin/Streptomycin (Sigma, 
UK) and 1% L-Glutamine (Sigma, UK), 24 hours post seeding. Cells were cultured for a 
further 96 hours till they had become differentiated. This included a half change of media at 
48 hours post addition of the differentiating media. 
2.2.2.4 Cell Counting 
In order to count cell numbers in a given suspension, a small aliquot of cell suspension 
diluted 1:5 in Trypan blue (Sigma Aldrich, UK) and incubated at room temperature for 5 
minutes. A small aliquot was pipetted into a Neubauer haemocytometer chamber and cells 
counted under an inverted light microscope with 10x objective. Cells which were in each 
large (1mm) square, were counted, including those which lied on the top and right hand 
perimeter. Those touching the bottom or left hand perimeter were excluded. A mean 
number of cells from 5 larger squares counted was calculated. From this the cell 
concentration (cells/ml) was deduced by multiplying the mean number of cells per large 
square by 104 and correcting for the dilution factor. Dead cells which stained blue were 
excluded from the count. 
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2.2.2.5 Cell lines storage: cryopreservation and recovery 
Cells for storage were frozen from healthy, growing cultures. Cells from 75 cm2 a 70-80 % 
confluent monolayer were detached and pelleted by centrifugation at 1000 rpm in a table 
top centrifuge for five minutes. The supernatant was then carefully aspirated and the cell 
pellet was re-suspended in 5 ml of freezing medium (20% FCS, 10% dimethylsulfoxide and 
70% growth medium). Following this, the cell suspension was aliquoted into cryovials in 1 ml 
aliquots. Cells were then cooled slowly at 1°C/minute, overnight, to -80°C in an isopropanol 
freezing box and then transferred to liquid nitrogen storage bank. 
In order to revive frozen cells, aliquots in cryovials were thawed rapidly in a 37°C water bath 
and transferred to a Falcon tube containing 9 ml growth medium. The cells were pelleted at 
1000 rpm in a centrifuge to remove the freezing medium containing dimethylsulfoxide and 
then resuspended in culture medium and cultured in tissue culture flasks. 
 
2.2.2.5 Primary rat motor neuron culture 
Pre-coating of slides/dishes: The day before the start of the motor neuron culture, the 
slides/dishes were coated with 5 mg/ml poly-L-Ornithin (Sigma Aldrich, UK) overnight. The 
following day, the slides/dishes were washed x3 with tissue culture grade water (Sigma 
Aldrich, UK) and allowed to air dry. The slides/dishes were then incubated with Laminin 
(Sigma Aldrich, UK), 3 µg/ml, in neurobasal medium for two hours in a 37°C incubator. 
Following this, Laminin was removed and the slides/dishes washed x3 with PBS (Sigma, UK) 
ready for the seeding of primary motor neurons. 
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Isolation of motor neurons from embryonic rat spinal cord:  
Two timed pregnant Wistar rats (Charles River, UK) on the 14th day of pregnancy (E14) were 
rendered unconscious by inhalation of liquid anaesthetic Isofluorane (Merial Animal Health 
Ltd., UK) and subsequently killed by an overdose (200 mg/kg) of the anaesthetic sodium 
penobarbitone (Pentoject Animalcare Ltd., UK) administered by intra-peritoneal injection. 
The embryos from the rats were immediately removed by dissection and transferred into 
Falcon tubes containing sterile HBSS solution and kept on ice. Under sterile conditions, 
spinal cords from the embryos were dissected and batches of 6 were placed in 1 ml of 
Phenol red free Hank’s Balanced salt Solution (also without sodium bicarbonate, calcium 
chloride and magnesium sulphate).  
Under a dissecting microscope (Zeiss, Germany) head and tail of the embryo were removed 
using two straight end jeweller forceps. The end of the forceps were then used to tease out 
the internal organs before placing the embryo flat on the dish.  The spinal column was 
exposed by cutting the skin on the back. This was then cut open by its dorsal end and gently 
detached from the embryo by lifting. Meninges, dorsal horns and dorsal root ganglia were 
carefully removed from the dissected spinal cord with micro dissecting forceps to extract 
the ventral horn which was placed in dish containing 1 ml of ice cold HBSS. 
Six spinal cords were extracted at a time and pooled together and cut into small pieces with 
a sterile, sharp scalpel (Johnson and Johnson, UK). Following this, the pooled spinal cords 
were transferred to a 15 ml Falcon tube digested with 0.025% Trypsin (Sigma Aldrich, UK) 
for 10 minutes in a water bath at 37°C. Half way through this incubation, the tube was 
agitated to prevent the spinal cord fragments from settling at the bottom of the tube. After 
the digestion, 800 μl L15 media containing 100 μl DNase (1mg/ml) and 100 μl of BSA (4% 
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w/v) were added to the tube and agitated vigorously by hand until tissue fragments were 
disaggregated and then titurated twice with a P-1000 tip. The fragments were allowed to 
settle for 3 minutes. Following this, the supernatant was transferred to a fresh 15 ml tube. 
900  μl of L15 containing 20 μl DNase (1mg/ml) and 100 μl BSA  (4% w/v) was added to the 
spinal cord fragments and titurated 6 times with a P-1000 tip and again allowed to settle for 
3 minutes. The supernatant was removed and pooled with the first volume of supernatant 
collected. This step was repeated one more time. 
 Following this, 1 ml of 4% BSA cushion was layered to the bottom of the Falcon tube which 
contains the pooled supernatants and the cells were centrifuged at 1500 rpm for 5 minutes. 
Subsequently, the supernatant was discarded and the pellet was resuspended in 2 ml L15 
media containing phenol red and the cell suspension equally split into two 15 ml Falcon 
tubes.  
A density gradient was prepared by applying 1 ml 10.5% cold Optiprep at the bottom of 
each Falcon tube containing the cells. The tubes were then centrifuged at 760 g for 15 
minutes with brakes off to prevent vibrations. Following this, the tubes were very carefully 
removed from the centrifuge. A white turbid band was visualised at the interface between 
the L15 media and Optiprep solution. The turbid layer is composed of the larger cells 
corresponding to motor neurons, whilst the small and intermediate sized cells pelleted at 
the bottom of the Optiprep gradient. The motor neuron rich layer from the interface was 
collected from both tubes by gently pipetting with a 1 ml pipette and pooled together in a 
15 ml Falcon tube containing 1 ml of motor neuron growth media. After counting the cells 
using a haemocytometer, they were seeded in pre-coated plates or dishes. They were 
incubated at 37°C, 5% CO2. The media was half changed 24 hours following seeding with a 
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motor neuron growth media which was 1:1 diluted with astrocyte conditioned media. 
Medium was again changed 72 hours following this and the cells used for experimentation 5 
days post seeding.  
All animal procedures were approved by the local Ethical Committee and performed in 
accordance with United Kingdom Animals Scientific Procedures Act (1986) and associated 
guidelines. All efforts were made to minimise the number of animals used and the suffering. 
The animals were housed under a 12 hour light/dark cycle (light phase, 7pm to 7 am) with 
food and water available ad libitum. 
 
2.2.2.6 Vector binding and internalisation of vectors experiment 
Primary rat motor neurons were seeded into two 8 well glass slides and allowed to grow 
and mature for 5 days. On the day of the experiment, both slides were placed on a tray of 
ice for 5 minutes to stop endocytosis by the cell. One was labelled 4°C and the other 37°C. 
The growth media in the wells was replaced with 200 μl of media containing FlAsH labelled 
RVG vectors, sufficient to give a MOI of 25. The cells were allowed to incubate with the 
vectors on ice for 15 minutes. This permitted the binding of the vectors to the cell surface 
but prevented their internalisation as the endocytosis process was halted. Following 
incubation, the unbound FlAsH RVG vectors were washed off with 2 x washes with ice cold 
PBS.  
The cells in the slide labelled 4°C was fixed with 4% ice cold PFA and quenched with 0.1M ice 
cold glycine. Fresh media was added to the wells in the 37°C labelled slide and it was put in 
a 37°C, 5% CO2 incubator for 45 minutes. This enabled the bound vectors to internalise by 
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endocytosis. This was followed by 2 x PBS wash with PBS and fixation with 4% PFA and 
quenching with 0.1 M glycine. The fixed cells were then immunostained with anti-rabies 
antibody and vectors imaged with confocal microscopy. 
 
2.2.2.7 Production of streptavidin displaying lentiviral vectors for magnetic pull down 
studies 
RVG and SinMu pseudotyped lentiviral vectors displaying streptavidin are produced using 
the Olsen modified Calcium phosphate transfection protocol. This protocol was slightly 
adopted to accommodate the two additional plasmids encoding streptavidin (pWW1051 
and pWW1058) which is incorporated in the viral envelope. 
Transfections (/3plates) 
 DNA quantities: 
o 22.5 ug gag-pol  
o 45ug Vector  
o 22.5ug pRSV-Rev  
o 22.5 ug env (RVG or SinMu) 
o 67.5 ug pWW1051 (encoding membrane anchored streptavidin) 
o 67.5 ug pWW1058 (encoding secreted streptavidin) 
As FCS contains biotin, transfections and subsequent culture of 293T cells need to be in 
biotin free media to prevent saturation of streptavidin by free biotin from the media. This is 
achieved by mixing the FCS containing media Streptavidin Agarose beads from Novagen, UK, 
(0.4% v/v) and stirring for 15 minutes. Subsequently the agarose beads were removed by 
filtration through a 0.22µm filter.  
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The harvested vector particles are concentrated on 20% sucrose cushion and physical titre 
determined by FACS titre. 
Lentiviral surface expression of Streptavidin is examined on Western blots using antibodies 
against the myc-tag or HA-tag on lentiviral extracts. 
2.2.2.8 Quantification of lentivirus association with magnetic nano particle 
Quantification of streptavidin displaying lentivirus association was done using a 
sedimentation assay adopted from (Sanchez-Antequera et al., 2011).  The stock suspension 
of the magnetic nanoparticles (MNPs) was diluted in the range of 500 fg to 10,000 fg in 
biotin free media and added to a 96 well plate. A blank containing only media is used as the 
control well. Lentiviral stock is added to each well. This was mixed by pipetting and 
incubated at room temperature for 5 minutes to allow vector- MNP complex formation. To 
sediment the vector-MNP complexes, the sample containing plate was placed on a magnetic 
plate (Oz Bioscience, France) for 30 minutes. Following this, 100 µl of the sample was 
removed, which contained the unbound vector. The concentration of the unbound vector 
was determined using the QuickTiter Lentivirus Quantitation Kit as per manufacturer’s 
instructions.  
 
2.2.2.9 Transduction of motor neurons 
Primary motor neurons were seeded into 8 well chambered slides at a density of 1x 105 cells 
per well. On day 5 after seeding, they were used in experiments. To allow coupling between 
the lentivirus and MNP, they were mixed in a 1.5 ml reaction tube tube and incubated at 
room temperature for 30 minutes. The vector-MNP complex was then added to the motor 
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neuron cells in a MOI range from 5 to 50. The chambered slide was placed on a magnetic 
plate inside a 37°C, 5% CO2 incubator for 1 hour. A parallel experiment was set up where 
only vector samples without magnetic nanoparticles were used and this served as a control. 
After the incubation period, the vector sample was replaced with fresh motor neuron 
growth media and the cells cultured for a further 72 hours. Following this, under a 
fluorescence microscope, all motor neurons and motor neurons expressing GFP were 
counted in 5 fields of view to determine transduction efficiency. 
 
2.2.2.10 Magnetic Pulldown 
Minimum of 1 x 107 primary motor neuron cells (this equates to 12-13 pups) were seeded 
onto Poly-D-ornithine and laminin coated 10 cm dish. The growth media was half changed 
24 hours after seeding of the cells which were allowed to mature for 48 hours in total. 
For the main experiment a MOI of 25 was used to infect the primary motor neurons. 10 fg 
biotin coated magnetic nano particles (Kisker, Germany) per transduction unit (MNP/ TU) of 
vector was mixed in an 1.5 ml reaction tube with 1 ml complete neurobasal media. 
 It is important to ensuring beforehand that free biotin is removed from media prior to use. 
This is achieved by mixing the FCS containing media with Novagen Streptavidin Agarose 
beads (Merck, UK), (0.4% v/v), and stirring for 15 minutes. The beads are removed by 
filtration through a 0.22 µm filter.   
The vector and MNP mixture was incubated at room temperature for 15 minutes to allow 
the formation on MNP-vector complex. This was then diluted further in 5 ml neurobasal 
media. 
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Following this, motor neurons in 10 cm dishes were incubated with MNP-vector complexes 
for 30 minutes on ice. This was followed by 2 washes with HBSS, 0.4% (w/v) ovalbumin. The 
cells were then incubated for a further 45 minutes in complete medium in an incubator at 
37°C, 5% CO2.  
Following incubation, cells on the dish were scrapped in 1ml HBSS supplemented with a 
protease inhibitor cocktail (Thermo scientific, UK) and centrifuged on a bench top centrifuge 
at 170 × g for 5 mins at 4°C. The cell pellet was then resuspended in 1 ml breaking buffer 
and passed 15 times through a cell cracker (18 µm clearance, EMBL, Germany) and then 
centrifuged on a bench top centrifuge at 690 × g for 10 minutes at 4°C. The supernatant 
(post nuclear supernatant) was collected in a 1.5 ml reaction tube.   
MS columns (Miltenyi Bioscience, France) were equilibrated with 2 ml breaking buffer + 
0.4% (w/v) ovalbumin followed by washing with breaking buffer. This was repeated 10x to 
ensure ovalbumin is washed off. The column was then placed inside the magnetic field of 
Super Mac II magnet (Miltenyi Bioscience, France) and the post nuclear supernatant was 
loaded three times onto the column to maximise binding of MNP-vector complex to the 
column.  
The column was then washed with 2 ml of breaking buffer and removed from the magnetic 
field. Organelles associated with MNP-vector were serially eluted with 1 ml of breaking 
buffer containing 300 mM KCL (5 elutes) into endotoxin free 1.5 ml. reaction tubes. 
The elutes were pooled and proteins were precipitated with 6.5% trichloroacetic acid (Sigma 
Aldrich, UK) using 0.05% (w/v) sodium deoxycholate (Sigma Aldrich, UK) as a carrier. The 
precipitated proteins were then spun down on a bench top centrifuge at 690 × g for 10 
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minutes at 4°C and the pellet resuspended /solubilised in sample buffer containing 0.7135 
M (5 %, v/v) β-mercaptoethanol. 
The protein samples were run on a pre-cast 4-20% SDS-PAGE gel (Bio-Rad, UK) and were 
stained with colloidal commassie (Invitrogen, UK) overnight at 4°C on a shaker with gentle 
motion. This was followed by destaining in MilliQ water for 7 hours, with changes of the 
water every hour. During destaining, the shaker was moved into a class I hood to avoid 
contamination when the gel containing container was opened for changes of destaining 
solution. 
The stained protein bands were cut out with a scalpel blade and collected in sterile 
eppendorf tube containing distilled water (200 µl per tube). Extreme care was taken when 
cutting out gel bands as there is high risk of contamination with proteins such as keratin. For 
this, all containers, tools and gloves were washed with distilled water and gel bands cut in a 
Class I hood. The cut out bands were sent for peptide mass fingerprinting at Imperial College 
Proteomics Core facility, South Kensington, London.   
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2.2.3 Biochemistry 
2.2.3.1 Preparation of cell lysates 
Cells were grown in 6 well plates. The growth media was removed and the cells washed with 
2 ml ice cold PBS. Then 200 µl of RIPA lysis buffer (Pierce, UK) containing protease inhibitor 
cocktail was added to each well and the plate incubated on ice for 5 minutes. After 
incubation, each well was carefully scrapped with a cell scrapper and the lysate transferred 
to 1.5 ml reaction tube. The samples were centrifuged at 13,000 rpm for 10 minutes at 4°C 
in a pre-cooled centrifuge. The supernatant was pipetted and placed in a fresh tube and 
either used immediately or stored at -20°C. 
 
2.2.3.2 SDS-PAGE 
SDS-PAGE sample buffer (final dilution 1 x) was added to equal amounts of protein from 
lysed cells or vector preparations. The samples were then boiled at 95°C for 5 minutes on a 
heat block (Grant Instruments, UK). Following this, they were allowed to cool on the bench 
top and spun down on a bench top centrifuge (Thermo Scientific, USA). Samples were then 
run on a polyacrylamide gel or stored at -20°C if not immediately run.   
Proteins were separated using a discontinuous stacking/separating gel electrophoresis 
system (BioRad, USA) according to the method described by Laemmli (Laemmli, 1970). The 
resolving gel comprised 380 mM Tris-HCl pH 8.8, 0.1% (w/v) SDS and 10 or 12% acrylamide. 
Protein samples were loaded onto the stacking gel along with Novex prestained protein 
standards (Invitrogen, UK) in the Mini Protean II SDS PAGE system (BioRad, USA). The 
system was then connected to an electrical power pack (BioRad, USA) and proteins were 
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separated by gel electrophoresis, typically at 100V constant for 1 hour. Gels that were not to 
be used for Western blotting were stained with Coomassie Blue (Invitrogen, UK) to visualise 
the separated protein bands. This was done by immersing the gels in sufficient amount of 
Coomasie solution and shaking in a cold room overnight. Gels were destained the following 
day by gently shaking in dH2O for 5-7 hours with regular changes of the destainer. 
 
2.2.3.3 Western Blotting 
For Western Blot analysis, proteins separated on polyacrylamide gel were transferred onto a 
0.45 µm nitrocellulose blotting membrane by using a wet transfer system utilizing the mini 
trans-blot cell (Bio-Rad, USA) tank transfer system filled with 1 x Transfer buffer and 
connected to a power pack. The proteins were transferred for 1 hour at 100V constant. 
Following transfer, the membrane was blocked in 5% (w/v) Marvel (non-fat dried milk 
powder) in PBS-Tween, overnight at 4°C (cold room) with gentle agitation on a shaking 
platform.  This was followed by incubation with the primary antibody at the appropriate 
dilution in 0.5% Marvel PBS-T for 1 hour at room temperature with agitation on a shaking 
platform. Following this, membranes were washed vigorously in PBS-T four times for 15 
minutes each times. The membranes were then incubated with the appropriate dilution of 
horse radish peroxidase (HRP) conjugated secondary antibody in 0.5% Marvel for 1 hour at 
room temperature. The membrane was again washed vigorously four times with PBS-T. 
Bound antibody was visualised by enhanced chemiluminescence (ECL) (GE Healthcare, UK) 
following the manufacturer’s instructions. The blot was mounted on a cassette (Sigma, UK) 
and developed in the dark room on Kodak Biomax X-ray film (Sigma Aldrich, UK). 
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2.2.3.4 Stripping and re-probing Western Blots 
In situations where the membrane needed to be re-probed with a different antibody, they 
were agitated vigorously with 1 x stripping buffer (Thermo Scientific, USA) for 15 minutes. 
Membranes were then washed four times for 15 minutes by agitating on a shaking platform 
before re-blocking for 1 hour at room temperature. The process of incubating with primary 
and secondary antibody was followed (as described in previous paragraph) followed by 
visualisation with ECL and transfer of the signal onto X-ray film. 
2.2.3.5 Trichloroacetic acid (TCA) protein precipitation 
Sodium deoxycholate (NaDOC), (Sigma, UK) was added to the sample at a final 
concentration of 0.05% (w/v) and mixed rapidly. This was followed by the addition of TCA at 
a final concentration of 6.5% (v/v). NaDOC must be added first and is a carrier which helps 
the proteins to precipitate with the TCA. The sample was then vortexed and then incubated 
on ice for 30 minutes. 
The sample was then centrifuged at 15,000 g for 10 minutes on a table top centrifuge with 
the temperature set at 4 °C for ten minutes. This is followed by the careful removal of the 
supernatant and retention of the pellet. The protein pellet was then re-suspended in 40 µl 
of Laemili buffer. This makes the sample turn yellow in colour as the buffer is acidic. 10 µl of 
Tris 1M, pH 8.3 was added and the sample vortexed. This increases the pH and the sample 
becomes blue in colour. The samples are then boiled on a 95 °C heating block, cooled down 
and briefly centrifuged. The sample is then either loaded on a gel or frozen at -20°C for 
future analysis. 
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2.2.3.6 BCA protein assay 
Protein concentrations were measured by BCA protein assay kit (Pierce, USA). The 
microplate procedure was used according to the manufacturer’s instructions.The BCA 
protein assay combines the well-known reduction of Cu2+ to Cu1+ by protein in an alkaline 
medium with the highly sensitive and selective colorimetric detection of the cuprous cation 
(Cu1+) by bicinchoninic acid. Absorption of protein samples were measured in a 
spectrophotometer at a wavelength of 562 nm. A standard curve was drawn from the 
measurements of standards of known concentrations. From this the unknown protein 
concentrations were determined. 
 
2.2.4 Immunostaining and Live Cell Imaging 
2.2.4.1 Single particle imaging 
Acid washed coverslips were placed in 12 well plates and coated with Poly-D-Lysine (Sigma, 
UK). 50 µl of lentiviral vector suspension was gently pipetted to the centre of the coverslip 
and allowed to bind for two hours at RT. This was followed by 2 x washes with ice cold PBS 
to remove unbound vectors. The bound vectors were fixed with 2% PFA for 15 minutes at 
RT. The coverslips were rinsed twice with ice cold PBS and the vectors immunostained with 
appropriate antibodies, mounted on slides with Mowiol (Sigma, UK). The immunostained 
vectors were visualised and imaged with a Leica SP5 (Leica, Germany) confocal microscope. 
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2.2.4.2 Immunocytochemistry 
Just before the commencement of the procedure, 1x PFA-PEM was prepared by mixing 
equal volumes of ice cold 8 % PFA with 2x PEM/MTS  (microtubule stabilisation buffer). Cells 
grown on coverslips or chambered slides.  
Media from the wells were gently aspirated and the cells washed 1 x with PBS. Then the 1 x 
ice cold PFA-PEM fixative was added to each well and incubated at RT for 10 minutes. 
Following fixation, the cells were washed 3 x with PBS. The fixative was then quenched by 
the addition of ice cold PBS with 0.1 M glycine to each well followed by a 10 minutes 
incubation at room temperature. The glycine was aspirated and 3 x PBS wash was 
performed. If the need arose, the cells were then permeabilised by the addition of PBS/ 
BSA/ Triton X-100 (0.1% v/v) to the wells and allowed to incubate at RT for 10 minutes. After 
3 x washes with PBS, blocking solution, PBS/BSA (1% w/v), was added to each well and 
blocked for 10 minutes. The blocking solution was replaced with primary antibody diluted in  
PBS/BSA (1% w/v) and incubated for 1 hour at RT normally (see antibody table in materials 
section for exceptions). This was followed by 3 x washes with PBS/BSA (1% w/v). Staining 
was visualised with the addition of AlexaFluor secondary antibodies (Invitrogen, UK), diluted 
in PBS/BSA (1% w/v) and further incubated at RT for 1 hour. The cells were then washed 
three times with PBS and the coverslips/slides mounted in Mowiol for at least two hours 
under a sheet of aluminium foil (or O/N in the dark). The slides were then viewed and 
images acquired under fluorescence or confocal microscopes.  
For short term storage (up to a week), the slides were places in a slide box and placed in the 
4°C. The slide box was placed in the -20°C for long term storage (for up to six months). 
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Acquired images were processed using ImageJ software and enhanced using 1.0 pixel 
median filter and brightness/contrast adjustments. 
2.2.4.3 Live Cell imaging of lentiviral vector trafficking 
For the live cell imaging of the motor neuron like cell line NSC-34, cells were plated onto 
glass well petri dishes (Matek Corporation, USA) coated with 100 µg/ml Poly-D-Lysine, 10 
µg/ml laminin and fibronectin (Sigma Aldrich, UK). The normal growth media was replaced 
with differentiation media 24 hours after seeding. The cells were usually differentiated and 
ready for imaging 4/5 days after the addition of differentiation media. Primary motor 
neurons were plated onto Poly-L-Ornathine and laminin coated glass welled Matek dishes at 
a density of 50,000 cells per well. They were normally ready for imaging 5 days following 
plating. 
Imaging was done with a Leica SP5 II confocal microscope with an environmental chamber 
(the Cube) which maintained an environment of 37°C and 5% CO2. Two hours before the 
commencement of imaging, the heater on the chamber was switched on and the CO2 supply 
line was opened so that the environmental parameters reached the desired levels. Cells 
were incubated with labelled lentiviral particles at a multiplicity of infection 10 (MOI 10) for 
30 minutes in a 37°C, 5% CO2 incubator with or without Alexa 647 labelled anti- p75
NTR 
antibody. Following incubation, the cells were gently washed with HBSS before fresh growth 
media was added. Dishes containing the cells were then placed on a Leica SP5 II confocal 
microscope with environmental chamber and imaged. 
Images were taken every 5 seconds using either the 488 nm laser (FlAsH or Vybrant DiO) or 
the 633 nm laser (Alexa 647 or Vybrant DiD) with the PMT detection range of 500-550 nm 
(FlAsH and Vybrant DiO) or 660-800 nm (Vybrant DiD and Alexa 647). 
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Images were processed using the software Image J and enhanced using 1.0 pixel median 
filter and brightness/contrast adjustments. As there were some movements of short 
distances which may not necessarily be inside the cells, analysis was restricted to particles 
moving >20 µm in a single direction. Particle analysis was done using the Image J plugin 
MTrackJ and multiple kymograph plugins. Fixed images and kymographs were rendered 
using Photoshop (Adobe, USA). 
2.2.4.4 Imaging of motor neurons in microfluidics chambers 
Fixed imaging: primary rat MNs were purified and plated at a density of 200,000 cells in a 
defined somatic compartment of the microfluidics chamber (MFC). Seven days post plating 
in MFC’s, the MNs were incubated with labelled vectors/labelled tetanus toxin/labelled 
p75NTR in the defined axonal side of the compartment and incubated for 2 hours at 37°C. 
This was followed by PBS wash of the cells and fixation and imaging. 
Live cell imaging in MFCs: Live cell imaging was performed in MFCs, 7 days post plating. An 
excess of viral particles were added to the axonal side of the chamber with or without 
Alexa-647 labelled p75NTR. (kind donation from Schiavo group, CRUK), used at 1 µl per 
channel (from a 1:100 dilution) and incubated at 37°C for 20 minutes. Following this, the 
chamber was filled with complete neurobasal media and left to incubate for a further 40 
minutes. Following this, confocal live cell imaging was performed in an environmental 
chamber. 
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Tetracysteine Tagged Lentiviral Vectors 
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3.1 Introduction 
Wild type viruses are simple in structure, hence, they exploit the cellular machinery to gain 
entry and traffic within cells. The development of methods to visualise viruses in live cells 
(single particle tracking) has lead to an explosion of knowledge of the mechanisms involved 
in virus entry and likewise cellular transport and membrane dynamics. To follow viruses by 
live cell microscopy, virions need to be fluorescently labelled. Initially, biochemical studies 
of virus entry provided the foundations for our understanding of the processes. Utilizing 
electron microscopy and wide-field fluorescence microscopy, it was shown that viruses 
employ many different cellular entry mechanisms to gain access to the interior of the cell 
and that the intracellular locations for virus uncoating and subsequent intracellular 
trafficking of the nucleocapsid is virus specific and very varied. 
Historically, the visualisation of virus particles during entry by direct flurophore labelling and 
microscopy started in 1980, when Helenius and colleagues described the binding of 
rhodamine labelled Semliki Forrest Virus to BHK-21 cells (Helenius et al., 1980).  
Subsequently, Lipophilic dyes, which incorporate into and label viral membranes, were used 
to visualize the site where membrane fusion of enveloped viruses occurred (Blumenthal et 
al., 1987; Stegman et al., 1987). Since then a range of lipophilic dyes have been developed 
which could be applied to label enveloped viral particles. Of those, the long chain lipophilic 
dialkylcarbocyanines (DiI, DiO, DiD and DiR, see Table 3.1) have often been used. These dyes 
are weakly fluorescent in water but highly fluorescent and photostable when incorporated 
into membranes. In addition, using a dye like DiD has the added advantage at longer 
excitation wavelengths the cell auto-fluorescence background levels are low, reducing 
signal-to-noise ratio (Brandenburg & Zhuang, 2007).  However, the loss of the viral envelope 
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and release of viral genomes in the cytosol are the hallmarks of enveloped virus infection 
(Mercer et al., 2010; Pelkmans & Helenius, 2003). As a result, this approach cannot be used 
to track the release of the viral capsid after membrane fusion and envelope loss, thus 
resulting in the potential loss of critical information about late transport events. Therefore, 
a need arose to label and track different viral components to understand the complete 
infection mechanisms. This has always been a challenge owing to the inaccessibility of the 
viral genome after completion of the viral assembly and the absence of an ideal nucleic acid 
probe.  
Dye Absorbance (nm) Emission maxima (nm) 
Dil 549 565 
DiD 644 665 
DiO 484 501 
DiR 750 780 
Table 3.1: Spectral characteristics of lipophilic dyes 
The discovery of auto-fluorescent proteins, such as green fluorescent protein (GFP) and its 
colour variants provided the next technological breakthrough that allowed imaging of virus 
entry and transport in real time. For this application, GFP (or an xFP variant) is fused in 
frame with a structural protein of the virus to generate particles that are fluorescent due to 
incorporation of the GFP fusion protein. Infection of cells with the GFP tagged particles 
allowed the following of individual particles during the entry process and the subsequent 
trafficking of the viral capsid after uncoating (Campbell et al., 2007; D. McDonald et al., 
2002). However, GFP is a relatively large protein (27 kDa), whose folding is far from 
instantaneous and whose incorporation into viral proteins has limited application due to its 
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potential impact on assembly of viral proteins into virions and alteration of normal 
trafficking and infectivity. 
To diminish the problems that can arise by fusing GFP or its variants to proteins , Tsien and 
colleagues developed a novel genetic tag/labelling system in which a small peptide 
sequence consisting of four cysteines in the sequence Cys-Cys-Xaa-Xaa-Cys-Cys (where Xaa 
is any amino acid except cysteine) is fused in frame to a protein of choice (Griffin, 1998). The 
tetracysteine motif (TC tag), which is only about 1 kDa in size, is less likely to interfere with 
the structure or biological activity of the protein. 
The TC tag by itself is not fluorescent. It requires one of several biarsenical compounds: 
FlAsH-EDT2 [4’,5’-bis(1,3,2-dithioarsolan-2-yl) fluorescein] or ReAsH-EDT2 [4’,5’-bis(1,3,2-
dithioarsolan-2-yl) resorufin] which in themselves are not fluorescent. However, when they 
come into contact with the TC tag, covalent binding of the compound via the two arsenic 
moieties to the free thiol pairs in the tag converts converts FlAsH or ReAsH to a fluorophore 
such that the proteins becomes more than 50,000 times more fluorescent (Adams et al., 
2002).  
Both FlAsH-EDT2 and ReAsH-EDT2 can be made in house (Adams et al., 2002) or can be 
purchased commercially (Invitrogen). Other advantages of the TC-tag system over the use of 
conventional genetically encoded auto-fluorescent protein fusion constructs is that labelling 
can be performed either before (Das et al., 2009; Pereira et al., 2011; Rudner et al., 2005) or 
after virion assembly and release (Arhel et al., 2006). Additionally, differential labelling with 
green FlAsH-EDT2 or red ReAsH-EDT2 allows for discrimination of newly synthesized proteins 
from pre-existing protein pools (Perlman & Resh, 2006). 
119 
 
However, the TC system is not without its disadvantages. First of all, there are reports of 
high background fluorescence (Stroffekova, Proenza, & Beam, 2001) and the fact that the 
target cysteines in the TC tag must be in their reduced states prior to binding of the 
biarsenical dyes (Rudner et al., 2005) which may not be suitable for all virus systems. 
The aim of this part of the project was to specifically TC tag all of the structural proteins 
encoded by the lentiviral gag gene in the context of a full length vector and then to 
characterise the constructs and assess their biological activity in terms of transduction 
efficiency.  
We decided to TC tag the structural proteins, encoded by the gag gene, of both HIV-1 and 
EIAV vectors. This strategy was followed in order to compare and contrast the two specific 
lentiviral vector platforms in terms of trafficking characteristics. 
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3.2 Results 
3.2.1 Generation of tetracysteine (TC) tagged lentiviral vectors 
Lentiviruses are mammalian retroviruses known to infect cattle, cats, horses, sheep and 
primates (Durand & Cimarelli, 2011). During the lentiviral assembly process, thousands of 
copies of viral structural polyproteins multimerize via non-covalent, low affinity interactions 
to form virus particles. Expression of lentiviral gag polyprotein precursor (Pr55) in the 
cytoplasm is generally sufficient for the assembly and release of non- infectious virus like 
particles (VLP). The Gag plolyprotein consists of the structural components: matrix (p17 in 
HIV-1 and p15 in EIAV) , capsid (p24 in HIV-1 and p26 in EIAV), nucleocapsid (p7 in HIV-1 and 
p11 in EIAV) and core proteins (p6 in HIV-1 and p9 in EIAV) and is cleaved into distinct 
structural proteins by autocatalytically activated viral protease upon virus maturation 
(Demirov & Freed, 2004; Leroux, Cadoré, & Montelaro, 2004; Morita & Sundquist, 2004). To 
identify the mechanisms of lentiviral retrograde trafficking and transduction, we chose to 
label the major structural proteins of the virus using the small tetracysteine tag in 
combination with biarsenical dyes. 
3.2.1.1 Bioinformatics 
Gag protein sequences from all lentiviral genome reference  sequences were obtained from  
National Center for Biotechnology Information (NCBI) sequence bank (Table 3.2). 
Abbreviated 
Name 
Full Name Refseq Gag Acc-No Primate 
BIV Bovine immunodeficiency virus NC_001413 NP_040562 n 
CAEV Caprine arthritis-encephalitis 
virus 
NC_001463 NP_040938 n 
121 
 
EIAV Equine infectious anaemia virus NC_001450 NP_056901 n 
FIV Feline immunodeficiency virus NC_001482 NP_040972 n 
HIV-1 Human immunodeficiency virus 
1 
NC_001802 NP_057850 y 
HIV-2 Human immunodeficiency virus 
2 
NC_001722 NP_056837 y 
OLV Ovine lentivirus NC_001511 NP_041249 n 
S/H-IV Simian-Human 
immunodeficiency virus 
NC-001870 NP_046122 y 
SIV Simian immunodeficiency virus NC_001549 NP_054369 y 
SIV-mnd2 Simian immunodeficiency virus -
mnd2 
NC-004455 NP_758886 y 
Visna Visna/Maedi virus NC_001452 NP_040839 n 
Table 3.2. Lentiviral gag sequences obtained from NCBI. 
 
Bioinformatics analysis was then carried out on all lentiviral gag genome sequences in order 
to understand the relationship between the members of the family paying particular 
attention to HIV and EIAV, as the lentiviral vectors used in this project were derived from 
them. The sequences in Table 1 were completely aligned using the computer program 
Clustal X (obtained from www.clustal.org). This generated multiple sequence alignment data 
which was then used to do phylogenetic analysis and draw a phylogenetic tree using the 
software Treeview X (obtained from http://darwin.zoology.gla.ac.uk/~rpage/treeview/). 
Phylogenetic trees illustrates the relationships among taxa (a group of biological entities at 
any level in the taxonomic hierarchy). Phylogenetic analysis of all the lentiviral gag 
sequences from primates and non-primates (Figure 3.1) showed HIV-1, HIV-2 and EIAV to be 
distantly related. The distances between primate lentiviruses, such as HIV-1 and HIV-2, as 
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compared to other mammalian lentiviruses, suggests that the lentiviruses originated in a 
non-primate mammal. A single transfer of virus from a non-primate mammal into primates 
was followed by the spread of the virus into a range of primate species (Foley, 2000).  
Although our knowledge of the origin and early evolution of HIV has grown exponentially 
over the past few years, much remains unknown about the deeper relationships between 
primate and non-primate lentiviruses and their mode of structural evolution over long 
periods of time. This is because these viruses evolve extremely rapidly.  
Lentiviruses have been estimated to mutate at a rate as much as 106 to 107 times the rate 
of mutations found in eukaryotic germ line DNA (Sala & Wain-hobson, 2000). Although this 
high mutation rate provides vast information documenting their recent history, it also 
rapidly erases evidence of their deeper ancestry. 
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 0.1 substitutions/nucleotide site  
Figure 3.1: Phylogenetic relationship among lentiviruses. The above tree was drawn using 
all lentiviral gag sequence alignment data. Branch points on the tree are called nodes, which 
represent evolutionary events which result in the separation of one group of the virus from 
the rest. Taxa that are connected by a single branch point are sister taxa. The more nodes 
separating two taxa, the more distantly related they are. The scale bar represents 0.1 
substitutions per nucleotide site.   
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Multiple sequence alignment of HIV with primate gag and EIAV with other lentiviral gag 
sequences revealed regions of conservation and regions of variability (see Figures 3.2 and 
3.3). It can be hypothesised that the variable regions would be more suited to the insertion 
of the TC tag. In other words regions which would not affect the biological activity of the 
vector. Based on this, six locations were selected in HIV-1 gag and five locations in EIAV into 
which the 4C tag was to be inserted (See Figures 3.2 & 3.3 and Tables 3.3 & 3.4). The 
strategy involved inserting tags upstream or downstream from protease cleavage sites in 
the Gag precursor protein. These sites are critical for processing of the precursor protein 
and has subsequent roles in viral entry. The PTAP (Pro-Thr-Ala-Pro core sequence) motif in 
the C-terminal p6 core protein of HIV-1 was avoided  as it is essential for the detachment of 
budding virions from the cell surface (Bieniasz, 2009).  EIAV does not have the PTAP motif, 
however, the equivalent is the YPDL (Tyr-Pro-Asp-Leu core sequence) motif in the p9 core 
protein region and this was also avoided as this is important for release of the budding  
virion from the host cell plasma membrane (Puffer, Parent, & Wills, 1997). 
In order to visualise, potentially weakly expressed or dilute proteins,  we used the higher 
contrast twelve amino acids TC motif- FLNCCPGCCMEP (Martin et al., 2005). The DNA 
sequence to be used for the 4C tag was reverse transcribed and codon optimised in silico 
using the UpGene software package which is freely downloadable from the internet (Gao et 
al., 2004). 
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Figure 3.2: Multiple sequence alignment of HIV with other primate gag reference 
sequences. The colours correspond to the following: red= matrix, green= capsid, purple= 
nucleocapsid and black= p6 core protein. 
 
Description Tetracysteine 
position 
Construct name Alternative 
(short) name 
tetracysteine tagging 
matrix C-term 
S125-N126 gag-4C126 (MA-C) MAC 
tetracysteine tagging 
capsid N-term 
N137-I138 gag-4C138 (CA-N) CAN 
tetracysteine tagging 
spacer-1 C-term 
P373-A374 gag-4C374 (SP1-C) SP1C 
tetracysteine tagging 
nucleocapsid N-term 
K380-G381 gag-4C381 (NC-N) NCN 
tetracysteine tagging 
p6 C-term 
Q500-* gag-4CCterm (p6-C) p6C 
tetracysteine tagging 
p6 internally 
G466-E467 gag-4C467 (p6-I) p6I 
Table 3.3: HIV-1 gag tetracysteine tagged construct summary.  
MA 
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Figure 3.3. Multiple sequence alignment of EIAV with other lentiviral gag reference 
sequences. The colours correspond to the following: red= matrix, green= capsid, purple= 
nucleocapsid and black= p9 core protein. 
 
Description Tetracysteine 
position 
Construct name Alternative 
(short) name 
tetracysteine tagging 
matrix C-term 
Q116-S117 gag-4C116 (MA-C) MAC 
tetracysteine tagging 
capsid N-term 
G129-A130 gag-4C129 (CA-N) CAN 
tetracysteine tagging 
nucleocapsid N-term 
L363-A364 gag-4C363 (NC-N) NCN 
tetracysteine tagging 
P9 core protein 
Internally 
D474-Q475 gag-4C474 (p9-I) P9I 
tetracysteine tagging 
P9 core protein C-
term 
E486-* gag-4CCterm (p9-C) P9C 
Table 3.4: EIAV gag tetracysteine tagged construct summary 
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3.2.1.2 Cloning tetracysteine tagged gag constructs 
Oligos were designed to clone gag-4C constructs by Splicing by Overhang Extension (SOE) 
PCR utilising the gag expression plasmids pMD2-LgpRRE (for HIV-1 4C) and pEV53B (for EIAV 
4C). These were used as both the template for PCR cloning and the final destination vector 
for the construct. The primers gag-SeqF and gagSeqR were designed to amplify the region 
containing the Clal-Bcll fragment of pMD-LgpRRE and SacII/AscI-XbaI of EIAV vector, 
pEV53B. These primers were used to generate gag-4C fragments which were cloned into 
pCRII (Invitrogen, UK) by TOPO cloning. Following this, restriction enzyme digests and 
sequence analysis was performed to identify clones with correct inserts listed in Table 3.3 
and 3.4. 
 The gag-4C fragments were then sub-cloned into their respective pMD2-LgpRRE and 
pEV53B  vectors. This was done by double restriction enzyme digestion to generate the 
backbone and insert using the enzymes ClaI and BclI (for HIV-1) (Figure3.4) and SacII and 
Xbal (for EIAV)(Figure 3.5). After the digestion, the digests were electrophoresed and the 
back bone and 4C tagged inserts extracted by a commercial gel extraction kit. For pEV53B 
(EIAV), this was done in a different manner as it was discovered that exposing the gel, and 
therefore DNA, to direct ultraviolet light resulted in reduction of the ligation efficiency of 
backbone with insert.  The bands of DNA on the agarose were excised by using an indirect 
method which did not expose the bands of interest containing the DNA to ultraviolet light 
(see materials and methods for details).  
The extracted backbone and the 4C tagged insert DNA were subsequently ligated at a ratio 
of 1 backbone: 6 tetracysteine tagged gag insert using the Quick ligation kit according to the 
manufacturer’s instructions (Invitrogen, UK). The products of the ligations were then 
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transformed into DH5 alpha competent cells according to the suppliers quick transformation 
protocol (NEB, UK) and plated on LB agar plates containing ampicillin. Many colonies (of 
ligated products) were seen on the selective agar plate. Bacterial colonies were picked from 
each plate and their DNA was extracted using a QIAgen miniprep kit. The extracted plasmids 
were analysed by restriction digestion and were also sequenced to confirm the successful 
insertion of the tetracysteine tag in the 6 selected positions for HIV-1 and 5 positions for 
EIAV. Additionally, for the EIAV 4C constructs, the sequencing revealed a conserved 
mutation in the capsid (CAN) region. Furthermore, a non-conserved mutation was 
discovered in all gag-4C except for the tagged CAN where the primer is assumed to have 
corrected the mutation. Since this mutation appeared in all the constructs, it may have 
arisen from errors in the pEV53B sequence obtained. Once the 4C constructs were 
generated, they were characterised in terms of their ability to produce biologically active, 
fluorescent vectors.    
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Figure 3.4: Restriction map of the HIV-1 plasmid pMD2-LgpRRE. The map shows the 
restriction sites (highlighted in red) which were used to replace the gag ORF with a 4C gag 
fragment generated by SOE PCR (acknowledgement D. Carpentier). 
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Figure 3.5: Restriction map of the EIAV plasmid pEV53B. The map shows the restriction 
sites in blue which were used to replace the gag ORF with a 4C gag fragment generated by 
SOE PCR. 
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3.2.1.3 Production of tetracysteine tagged vectors 
Once the tetracysteine tagged constructs were made, we proceeded to viral vector 
production utilizing the modified Olsen protocol (see materials and methods). HIV-1 based 
lentiviral vectors were produced using a four vector system, whereas EIAV vectors were 
produced using a three vector system (excluding the rev plasmid). Initially, three plate 
preparations of each of the tetracysteine tagged constructs were made. The aim of this 
experiment was to check the biological activity of the tetracysteine tagged constructs. All 
the vectors made using the constructs were made using the CMV-GFP genome and 
pseudotyped with the RV-G. 
3.2.2 Characterisation and Analysis of tetracysteine tagged vectors 
The transfection efficiency when using the HIV-1 and EIAV constructs as part of 4 or 3 
plasmid transfection protocol were documented 48 hours post transfection. Co-transfection 
of a GFP expression construct was used and transfection efficiency measured by GFP 
expression. It was assumed that at the particular time point when imaging was done, the 
GFP detected was expressed from GFP construct and in the cell rather than that which had 
been incorporated into the virus (which any case would not be detectable by fluorescence 
microscopy and would require confocal microscopy to detect). It was also assumed that at 
that time point, virus assembly hadn’t occurred in significant levels and there being not 
enough time for the produced viruses to transduce the producer cells, hence the GFP 
detected was likely to be from the GFP expression construct. The levels of GFP expression 
were consistently high in cells co-transfected with all the HIV and EIAV constructs (see 
Figures 3.6 and 3.7), indicating the transfection protocol for vector production was 
satisfactory. 
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Next, the efficiency of transduction with each of the HIV-1 and EIAV tagged vectors were 
analysed (Figures 3.8 and 3.9). For the HIV-1 vectors, MAC was the only construct that 
showed transduction levels similar to the wildtype vector while CAN and p6C showed 
absolutely no transduction. Vectors tagged in the SP1C, NCN and p6I showed significantly 
lower levels of transduction compared to the wildtype. Similarly, for the EIAV tagged vectors 
MAC was the only construct with a transduction efficiency comparable to the wildtype gag. 
Vectors produced with the constructs CAN, NCN and p9I had a reduced transduction 
efficiency. Transduction was totally absent when utilizing vectors made with p9C construct.  
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   a) Wild Type gag 
   b) MAC 
  c) CAN 
   d) NCN 
  e) SP1C 
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  f) p6I 
  g) p6C 
  h) Control- non transfected cells 
 
Figure 3.6: Transfection efficiency of calcium phosphate protocol using different HIV-1 
constructs. a) Wild type gag, b) MAC, c) CAN, d) NCN, e) SP1C, f) p6I, g) p6C and h) Control- 
non transfected cells. 293T cells were transfected using the 4 plasmid system (Olsen 
modified calcium phosphate transfection protocol) with GFP being used as a marker of 
transfection. Cells were imaged 48 hours after initiation of transfection. Magnification of 
objective x20. 
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a) Wild type gag      b) MAC 
   
c) CAN                d) NCN 
   
e) p9I        f) p9C 
 
g) Control- non transfected cells 
Figure 3.7: Transfection efficiency of calcium phosphate protocol using different EIAV 
constructs. a) Wild type gag, b) MAC, c) CAN, d) NCN, e) p9I, f) p9C and g) Control- non 
transfected cells. 293T cells were transfected using 3 plasmid system (Olsen modified 
calcium phosphate transfection protocol) with GFP being using as a marker of transfection. 
Cells were imaged 48 hours after initiation of transfection. Magnification of objective x20.  
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  a) Wildtype 
  b) MAC 
  c) CAN 
  d) SP1C 
  e) NCN 
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  f) p6I 
  g) p6C 
 
Figure 3.8: Efficiency of transduction of HIV-1 vectors. a) Wild type gag, b) MAC, c) CAN, d) 
SP1C, e) NCN, f) p6I and g) p6C. 293T cells, seeded at a density of 500,000 cells per well 
were transduced with 250    of unconcentrated, unstained vectors together with 245 µl of 
complete medium and 5 µl of polybrene. The vector suspension was kept on the cells for 6 
hours, followed by replacement with complete media. Transduction of the cells (marked by 
GFP expression) was documented 48 hours post transduction by phase contrast and 
fluorescence microscopy. Magnification of objective: x10. 
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a) Wildtype        b) MAC 
   
c) CAN                     d) NCN 
   
e) p9I          f) p9C 
 
g) Not transduced control 
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Figure 3.9: Efficiency of transduction of EIAV vectors.  a) Wild type gag, b) MAC, c) CAN, d) 
NCN, e) p9I, f) p9C and g) Not transduced. 293T cells, seeded at a density of 500,000 cells 
per well were transduced with 250 µl of unconcentrated, unstained vectors together with 
245 µl of complete medium and 5 µl of polybrene. The vector suspension was kept on the 
cells for 6 hours, followed by replacement with complete media. Transduction of the cells 
(marked by GFP expression) was documented 48 hours post transduction by fluorescence 
microscopy. Magnification of objective: x20. 
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The vectors were further characterised quantitatively in terms of their biological titre. This 
was done by quantifying by FACS the proportion of cells transduced by the vectors (Figure 
3.10. E and F). The results back up the qualitative data presented in Figures 3.8 and 3.9 in 
that only vectors produced with MAC tagged construct produces a biological titre similar to 
that produced with the untagged wildtype construct. This was true for both HIV-1 and EIAV 
MAC tagged constructs. For the other constructs, one sees significantly reduced titres. For 
HIV-1, there is a total absence of biological titre for the CAN and p6C constructs. For EIAV, 
only the p9C construct produces zero biological titre. The quantitative analysis is a better 
reflection of the ability of the vectors to transduce cells as the FACS procedure allows one to 
count total proportion of GFP expressing cells above a certain threshold even if they are not 
quite visible by the eye in the qualitative image. 
In order to investigate the reasons behind differences in biological titres, western blots of 
sucrose cushion purified vectors made with the various tetracysteine tagged gag constructs 
as well as untagged gag was done (see Figure 3.10 C and D).For the HIV-1 gag Western blot 
(Figure 3.10 C), the HIV-1 p55+p24++p17 (polyclonal) antibody (Abcam Cat. # 63918) was 
used. The antibody detected at least 5, potentially more, distinct bands corresponding to 
vector associated gag (Figure 3.10 C): 
 p55 gag polyprotein showing as a band at ~55kDa 
 p41 (migrating at around 37-39 kDa). Probably corresponding to the MA-CA-SP1 
fragment generated by cleavage at the SP1-NC cleavage site (the first site cleaved 
during maturation). 
 p26 corresponding to CA-SP1 fragment. 
 p24 corresponding to the capsid fragment 
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 p17 corresponding to the matrix fragment 
 For the MAC lane, one could also see a band at p15, which is probably a MAC break 
down product or the antibody recognising a p15 fragment i.e. NC-SP2-p6 
The matrix tagged protein showed a slightly slower electrophoretic mobility compared 
with the wildtype protein, which is likely due to the additional 12 amino acid 
tetracysteine tag. Apart from MAC tagged vectors which had a band profile similar to the 
wildtype, the presence of the tetracysteine tag near the termini of individual domains 
appears to affect the processing efficiency of the nearest proteolytic site (note the 
presence of higher levels of certain intermediates and of additional intermediates in 4C 
tagged lanes). The presence of the tag in p6C completely prevents proteolytic cleavage 
which explains the vast amounts of p55 precursor proteins detected but no proteolytic 
breakdown products. Hence, the effect of the tag in gag maturation would go a long way 
to explain these vectors reduced ability to transduce cells and generate a biological titre.  
For the Western blot of EIAV vector associated gag (see Figure 3.10D), a serum 
(polyclonal) antibody, ‘Lady’, was utilized (a gift from Prof. Montelerro, University of 
Pittsburgh, USA). This antibody detects a lot less of the cleaved/breakdown product of 
gag compared with the anti-HIV-1 gag antibody. It revealed that the gag p55 of the MAC 
tagged vector underwent proteolytic cleavage in a similar manner to the wildtype gag. 
This would explain the similarities in biological titres obtained when these two 
constructs were used to produce vectors. The presence of the 4C tag in other domains 
appears to affect the processing efficiency of the nearest proteolytic sites. This would 
explain the low biological titres obtained with some of these tagged Gag constructs. 
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 In conclusion, for both HIV-1 and EIAV, only the matrix tagged construct remains 
unaffected by the tag in terms of Gag maturation and comparable biological titres to 
that obtained with untagged Gag. Therefore, for the production of vectors to be used in 
live cell studies, the MAC tagged constructs were used. 
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Figure 3.10. Characterisation of tetracysteine tagged constructs. (A,B) Diagram of HIV-1 
and EIAV gag showing the position where the 4C motif was inserted. (C,D) Lentiviral vector 
associated gag was detected by western blot showing the effect of the tetracysteine tag on 
the efficiency of Gag processing by proteases. (E,F) Unconcentrated vector samples were 
used to transduce 293T cells. The transduced cells were harvested and fixed 72 hours after 
the addition of vectors and transduction levels were measured by FACS to generate the 
biological titres of the various tagged constructs. 
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3.2.3 Labelling of tetracysteine tagged vectors with biarsenical dye 
Preliminary experiments of labelling tetracysteine tagged HIV-1 vectors post production  
with biarsenical dyes according to a specific protocol (Rudner et al., 2005) gave weakly 
labelled vectors and this labelling was not consistent. It was thought that the problem was 
in the extracellular labelling of the TC tagged vectors under acutely reducing conditions (the 
method used involved three reducing steps involving as many reducing agents). Therefore, 
this method was unusable for the purposes of this project. 
An alternate protocol published by Pereira et al showed that vector production in the 
presence of biarsenical dye FlAsH followed by removal of unbound dye and non-specifically 
labelled cellular debris  through a sucrose gradient is an efficient method for the labelling of 
viral proteins containing a TC tag (Pereira et al., 2011). However, this metabolic labelling 
approach had one significant drawback in that a drop in vector titre (around 40%) was 
reported in the Pereira et al. paper compared with non FlAsh labelled vectors produced at 
the same time. Nevertheless, this method was used with some modifications, such as 
centrifuging the vectors through a 20 % sucrose cushion instead of a sucrose gradient 
(which resulted in reduced loss of vectors). 
Both the tetracysteine tagged and non-tagged vector particles (acting as a control) were 
labelled with FlAsH and characterised by single particle imaging. Undiluted vector particles 
were coated onto poly-D-lyseine coated coversilps. In the 4C tagged vector slides, majority 
of MAC tagged vectors also had a signal co-localisation with anti-RVG stain (see Figure 3.11) 
but the FlAsH stain was absent in the WT vectors containing no 4C tag. This suggests that 
the vectors were successfully labelled and what is visualised is genuine, specific 
fluorescence from the labelled 4C tag. Note that some non-specific large cell debris labelling 
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by FlAsH is seen in the images however, this is rare and is very easy to distinguish from 
labelled lentiviral vectors because of their irregular shape and size. 
In addition, the biological titres obtained (see table in Appendix C) were satisfactory and 
were usable in the studies. 
 
.   
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Figure 3.11. Single particle imaging of Matrix tagged vector particles. Tetracysteine 
tagged and labelled with FlAsH (top panel) and untagged vectors labelled with FlAsH 
(bottom panel). The circles denote vector particles. Scale bar represents 1 µm. 
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3.3 Discussion 
Probing the dynamic interactions and movement  of lentiviral vectors in cells by live cell 
imaging is not only  satisfying in terms of actually visualising the vectors but will also yield 
novel and crucial information on the mechanism of this process which will be important in 
optimising them for retrograde transduction in motor neurons. 
Historically, studying trafficking of mature HIV-1 or EIAV particles has been a challenging 
process because insertion of traditional tags such as eGFP into viral capsid has resulted in a 
significant reduction of viral titre (Müller et al., 2004). Alternatively, although labelling of 
the vector envelope with lipophilic dye is a viable alternative producing  high titre labelled 
vectors, it is still possible that the dye would stay within the endosome following vector 
fusion and escape from the vesicle. To rule this out, we chose to use a small tetracysteine 
tag and the biarsenical dye FlAsh. These tags are analogous to fluorescent fusion proteins 
yet offer several unique capabilities such as consisting of only a few amino acids and thus, 
far smaller and less likely to affect the biological activity of the vector than the incorporation 
of a larger auto fluorescent protein. Additionally, biarsenical dye attached tetracysteine tags 
are detectable immediately following tetracysteine translation, allowing the visualisation of 
early events of vector transport in contrast to intrinsic delays required for fluorescent 
protein maturation. 
The initial work involved extensive bioinformatics analysis of gag protein sequences from all 
lentiviral genome reference sequences to find regions of variability with both the HIV-1 gag 
and EIAV gag (see Figure 3.2). We hypothesised that regions of variability would be more 
amenable to the insertion of the tetracysteine tag. Based on the bioinformatics results, 6 
regions of HIV-1 gag and 5 regions of EIAV were chosen to position the 4C tag.  Successful 
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constructs were made which contained a 4C tag in each of the regions of matrix, capsid, 
nucleocapsid and core proteins of HIV-1 and EIAV gag. Additionally, for HIV-1, a tag was also 
inserted in the SP1 spacer region (See Figure 3.10, A). This could enable us to compare and 
contrast the characteristics of the trafficking pathways taken by the two separate lentiviral 
vector systems. Furthermore, having a tagging strategy where multiple regions of gag are 
tagged enables one to have some flexibility as tagging in certain sites results in problems in 
processing of the gag protein thus affecting the biological activity of the vector. 
Once the 4C tagged constructs were generated it was essential to determine whether the 
tag adversely affected the protein. The ultimate test is whether the vector particle 
containing the tagged protein has the same biological activity as the standard wildtype 
vector. So, once vectors were produced with the 4C tagged constructs steps were taken to 
characterise them. 
Transduction and biological titre deduction studies were done on 293T cells. This showed 
that the biological activities of the 4C tagged vectors, in comparison with the wildtype 
(untagged) vectors, only remained unaffected when the tag was inserted in the matrix and 
an internal p9 site for the EIAV vectors and matrix and an internal p6 region of the HIV-1 
vectors (see Figure 3.10). So, even with the addition of the relatively small 4C tag, tagging of 
the capsid led to significantly reduced biological titres. There have been previous reports 
where, for example, insertion of the 4C tag at both the N- and C- terminus of the capsid 
protein of HIV-1 completely abolished viral infectivity (Campbell et al., 2008). This would 
suggest that the stability of the highly ordered capsid lattice might be compromised by the 
tetracysteine tag. Interestingly, insertion of the tag in the EIAV capsid, unlike HIV-1, did not 
completely abolish its ability to transduce, indicating that regions of variability in the gag 
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sequence is not the only criterion for the successful insertion of the tetracysteine tag 
without affecting the biological titre. So, it would appear that both EIAV and HIV-1 vectors 
share similarities but also differences in terms of both lack of effect and detrimental effect 
of the 4C motif at certain regions of gag protein. 
To further study and explain the similarities and differences in biological titre obtained with 
the various tagged constructs, western blots of vector associated gag were done (Figure 
3.10, E and F). For the HIV-1 vectors, overall, the presence of the tetracysteine tag near the 
termini of individual domains appears to affect the processing efficiency of the nearest 
proteolytic site (note the presence of higher levels of certain intermediaries and of 
additional intermediate bands in tetracysteine tagged gag lanes). For the EIAV vector 
associated gag, far fewer intermediary bands were detected, probably due to limitations of 
the primary antibody used. However, like HIV-1, with the exception of the matrix tag, gag 
maturation is affected and explains the reduced biological titres seen. 
A major limitation of the biarsenical-tetracysteine system is the high degree of background 
fluorescence often observed (Stroffekova et al., 2001). Initially, we attempted to label our 
vectors post production which gave disappointing results in terms of not being able to see 
the vectors. This was likely due to the sequestration of the tetracysteine tag after the matrix 
is incorporated into the vector, therefore reducing the accessibility of the tetracysteine tag 
for binding with the biarsenical dye. These issues were resolved by so called ‘in vivo’ 
labelling of the vectors during production following which, the labelled vectors were 
ultracentrifuged, which results in the removal of free, unincorporated biarsenical dye 
responsible for background fluorescence. It has been reported that in vivo labelling results 
in virus preparations that have approximately 60 fold more fluorescence than virus grown in 
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cells in which labelling reagent was not added (Mire et al., 2009). Characterisation of the 
fluorescent vector is important so that one can be confident that the trafficking events 
imaged during live cell imaging are similar to that occurs with the wildtype virus. 
In conclusion, this part of the project has generated novel tools for the live cell imaging of 
HIV-1 and EIAV lentiviral vectors during their natural trafficking and retrograde transduction 
in cells. Additionally, the labelling process has been optimised so as to generate 
fluorescently visible vectors whose biological activity remains comparable to the untagged 
vectors. 
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Chapter 4: Trafficking Studies in NSC-34 Motor Neuron Like 
Cell Line 
 
 
 
 
 
 
 
 
 
 
 
 
  
152 
 
4.1 Motor neuron cell lines in research 
Motor neuron diseases such as ALS and SMA are still incurable and therefore are of 
significant importance in medical research. Ideally, studies involving neuronal physiology 
and disease should be performed in primary motor neuron cultures. However, there has 
always been difficulty in obtaining and growing primary motor neuron cultures (Deinhardt & 
Schiavo, 2005). 
Therefore, clonal cell lines which have been derived from specific neuronal populations with 
somatic cell fusion techniques have been extensively used to identify and characterise 
properties specific to those neurons (Biedler, Roffler-tarlov, Schachner, & Freedman, 1978; 
Encinas et al., 2000; Greene & Tischler, 1976). The use of established cell lines holds many 
advantages such as being relatively easy to grow and they can be more readily manipulated, 
infected, transfected or microinjected for the expression of introduced products (Kaplan, 
1998). In particular, the PC12 rat pheochromocytoma cell line (Greene & Tischler, 1976) has 
been widely used and has become the most commonly used neuronal cell line model and 
has been instrumental in the development of the signalling endosome hypothesis (Grimes et 
al., 1996; Howe & Mobley, 2004). 
In contrast to the PC12 and other neuronal cell lines, there is a distinct lack of well 
characterised motor neuron like cell lines. It is thought only four cell lines exist with motor 
neuron like characteristics. Three of these hybrid cell lines have been produced through 
somatic fusion between the N18TG2 neuroblastoma and isolated embryonic spinal cord 
enriched cells. These include NSC-34 and NSC-19 (Cashman et al., 1992), MN-1 (Salazar-
Grueso, Kim, & Kim, 1991), and rat ventral spinal cord (VSC 4.1) motor neuron cells (R. G. 
Smith et al., 1994). Other motor neuron like cell lines to be reported in literature are the 
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human spinal cord cell lines (HSP1, HSP2, and HSP4) which were immortalized using a 
retroviral vector method (Li et al., 2000). However, as primary cell proliferation is thought to 
be essential for retroviral integration, the immortal lines produced by this strategy may be 
more likely to reflect the poorly differentiated state of proliferating neuroepithelial 
precursor cells. 
Although the MN-1 and VSC 4.1 cell lines have been described as motor neuron likes, their 
extensive characterisation has been lacking. Both these cell lines express the cholinergic 
marker choline acetyl transferase (ChAT) (Salazar-Grueso et al., 1991; R. G. Smith et al., 
1994). However, the expression of ChAT is not a definitive motor neuron marker as it is not 
exclusive to this cell type as well as the extension of neurite like processes. In contrast, the 
NSC34 cell line has become the best characterized and the most routinely used to 
investigate motor neuron biology and pathology.  
4.2 Characterisation of motor neuron properties and markers in NSC-34 cells  
The murine neuroblastoma x spinal cord (NSC) cell lines were developed by Neil Cashman 
and colleagues as a robust model to be utilized in the in the study of motor neuron biology 
(Cashman et al., 1992). The NSC hybrids were produced through somatic fusion between the 
N18TG2 aminopterin sensitive neuroblastoma and motor neuron enriched day 12-14 
embryonic spinal cord cells (Cashman et al., 1992). From the pool of clones, the NSC-34 
clone expressed many properties of primary motor neurons. These include extension of 
processes similar to axons, formation of contacts with cultured myotubes, induction of 
myotube twitching, support of action potentials. Biochemical characteristics include 
expression of neurofilament proteins and synthesis and storage of acetylcholine (Ach). 
Interestingly, NSC-34 cells are also able to induce ACh receptor (AChR) clustering when they 
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are co-cultured with myotubes, suggesting these cells maybe able to model early 
neuromuscular synapse formation (Martinou et al., 1991; Matusica et al., 2008). In addition, 
it has also been shown that these cells adhere specifically to the leucine-arginine-glutamate 
(LRE) motif of S-laminin which is a neuromuscular synapse specific basal lamina glycoprotein 
(Matusica et al., 2008). 
Since the availability of the NSC-34 cell line, many groups have reported the expression of 
numerous receptors to motor neuron growth factors which includes CNTF (Usuki et al., 
2001) as well as responsiveness to NGF, BDNF and NT-4 (Turner et al., 2004). Additionally, 
Eggett and colleagues have used NSC34 cells in the development of a glutamate sensitive 
motor neuron cell line (Eggett et al., 2000). 
In addition, there have been a number of studies involving NSC-34 cells which have reported 
the presence of a number of motor neuron markers in this cell line (See Table 4.1). This 
includes the presence of cholinergic marker ChAT (Cashman et al., 1992) and Hb9 (Matusica 
et al., 2008).  
In brief, the NSC-34 cell line represents to date the best characterized motor neuron like cell 
line. In addition, their close morphological resemblance to primary motor neuron cells 
makes them a relevant and suitable candidate for trafficking studies. 
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Table 4.1: A summary of studies which have identified some of the neuronal characteristics 
and markers in the motor neuron like cell line NSC-34 (Matusica et al., 2008). 
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4.3 Trafficking studies in NSC-34 cells 
Matusica et al. looked at neurotrophin receptor trafficking in NSC34 cells (Matusica et al., 
2008) where they established that the internalisation and intracellular transport of the 
p75NTR is regulated by exogenous neurotrophins at the cell surface where ligand binding 
and internalisation occurs as well as in endosomal compartments where the bulk of 
receptors and ligands are targeted to their specific destination. 
In another study, lentiviral vectors pseudotyped with the neurotropic Venezuelan equine 
encephalitis virus glycoprotein (VEEV-G) was observed trafficking retrogradedly in 
differentiated NSC34 cells (Trabalza et al., 2012) and this was over long distances. This is 
consistent with kinesin mediated retrograde pathway previously described for tetanus toxin 
and confirms the ability of lentiviral vectors to undergo trafficking in this cell type. 
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4.4 Results 
4.4.1 Growth and differentiation of NSC-34 cells 
Early in the project, it was decided to use NSC-34 cells as an in vitro system in which to set 
up and optimise the experiments prior to carrying out the experiments in primary motor 
neuron cells (whose extraction and growth was yet to be optimised in the our laboratory). 
NSC-34 cells were kindly provided by Professor Pam Shaw’s lab at the University of 
Sheffield, UK. They were grown in high glucose DMEM with all the additives (P/S, L-Glu and 
NEAA) with 10% FCS. Cells grew and morphologically there were two different types of 
populations (see Figure 4.1). The majority (over 90 %) appeared like small fibroblasts with 
rounded morphology and no neurite processes. A sub population of cells (approximately 5-
10 % of total cells) appear to undergo full differentiation into neuronal morphologies 
possessing axons and dendrite like structures (see Figure 4.1). The levels of differentiation 
varies and was determined by taking five representative phase contrast images and then 
counting the number of differentiated cells as a proportion of total cell count  and then 
averaging the figures obtained from the five images. Cultures at 50-65 % confluency were 
split in the ratio of 1:4 to 1:8 and they grew 3-4 days in the same medium before a media 
change was needed. From then on, the media was half changed every two days till 
passaging. If the media is changed completely, the cells appear to round up and show signs 
of apoptosis leading to massive loss of cells followed by surviving cells sprouting extensive 
neurite projections in the time span of 5-8 days. pH of the media is also critical and 
exposure to basic pH media is harmful for the culture. 
For the differentiation of NSC-34 cells into motor neuron morphology, there are several 
publications which suggest a differentiating medium of 1:1 DMEM plus Ham’s F12, 1 % FCS, 
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1% PSG and 1% of non essential amino acids (NEAA) (Eggett et al., 2000; Matusica et al., 
2008).  In experimentation, we discovered that DMEM ((with P/S, L-Glu and NEAA) 
containing 1% FCS results in the best differentiation. Using DMEM/F12 media combination 
(as suggested in publications) results in good differentiation but also undifferentiated cell 
growth. 
Cells for differentiation are seeded quite sparsely using complete medium and left to settle 
for 24 hours.  Medium is then replaced with differentiation medium.  Over the next 3-4 days 
the cells will rapidly expand and gradually adopt a more neuronal morphology from then on 
and the media was partially replaced every 2-4 days.  This was accompanied by several 
cycles of cells dying (mostly undifferentiated cells).  From 5 days to 7 days post 
differentiation (dpd) the timing varies with each culture) the cells possessed a differentiated 
morphology that were used for experiments (see figure 4.1,E and F).  Cultures have been 
used within this time frame for imaging experiments.  Some cultures have been successfully 
maintained for up to 17 days after differentiation (although the cultures started to look 
poorly with many dead cells after about 15-16 dpd). 
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Figure 4.1: Growth and differentiation of NSC-34 cells. Cells for differentiation are seeded 
quite sparsely using complete medium and allowed to settle and attach for 16-24 hours. A 
heterogeneous, neuroblastic (arrow head) and substrate adherent (arrow) population of 
cells can be observed (A). Medium is then replaced with differentiation medium containing 
1% FCS and the cells imaged on the days stated. Differentiation levels of 75-95 % can be 
achieved by day 5 (E, green arrows showing differentiated cells). By day 11 cultures become 
unhealthy with many dead cells and irregular morphologies (G). Scale bar = 50 μm.  
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4.4.2 Surface coating for optimal NSC-34 differentiation 
As FCS contains numerous adhesion factors, it was noticed that cells cultured for 
differentiation in reduced serum resulted in reduced adhesion. Poor substrate adhesion had 
previously been a  documented characteristic of NSC-34 (Durham, Dahrouge, & Cashman, 
1993). This posed a considerable obstacle as these cells needed to be cultured and 
differentiated on cover slips and dishes and subsequently used for fixed and live cell imaging 
which requires multiple treatment steps.  
Usually, for live cell and fixed cell imaging, NSC-34 cells are grown on poly-d-lysine and 
laminin coated material to promote attachment and neurite outgrowth. Previously, 
Mazarakis et al. reported that neuronal cells grown on poly-d-lysine and fibronectin 
adhesion promoting peptide (10 μg/ml)(Sigma Aldrich, UK) coverslips show better 
attachment and faster growth (Mazarakis et al., 2001). An experiment was performed to 
determine the best substrate combination for the attachment, growth and differentiation of 
the cells (Figure 4.2) 
24 hours post seeding, most NSC-34 cells had a rounded morphology (defined as non-
differentiated). This cell morphology is representative of over 90% of cells in the total 
population. With the change to 1% FCS differentiation media, many of these cells develop 
multiple axon-like processes. A cell with developed axon(s) was determined as 
differentiated. After 5 days in differentiation media, it was observed that the best growth 
and differentiation was with coverslips coated with poly-D-lysine + Laminin + Fibronectin 
Adhesion Promoting Peptide (Figure 4.2.C). This combination gave the densest population of 
cells was observed with approximately 80 % of the total population showing differentiated 
morphology (Fig 4.2.D). The next best matrix is poly-D-lysine + Laminin, with approximately 
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70% of the cells in differentiated state (Figure 4.2, B and D). Poly-D-lysine + Fibronectin 
Adhesion Promoting Peptide combination gave the least cell growth as well as the lowest 
proportion of differentiated cells (approximately 60 % of total) (Figure 4.2, A and D). 
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D 
  
Figure 4.2 Surface coating for optimal NSC-34 differentiation. 12 well cover slips were 
coated in the combinations of A) Poly-D-Lysine + Fibronectin Adhesion Promoting Peptide 
(PDL+FAPP), B) Poly-D-Lysine + Laminin (PDL+Lam), C) Poly-D-Lysine + Fibronectin Adhesion 
Promoting Peptide + Laminin (PDL+FAPP+Lam). Cells were seeded onto the coverslips at a 
density of 2,000 cells/ coverslip and allowed to attach and grow in full serum media for 24 
hours. Following this, the media in each well was changed 1 % FCS differentiation media. 
Cells were grown and differentiated for 5 days before images were taken. For each 
combination of substrate, 3 fields of view were captured, the number of differentiated cells 
were counted and represented as a proportion of total cells (D). Scale bar= 50 μm. (n=3, 
mean ± SEM; one way ANOVA analysis of difference with Tukey’s multiple comparison 
test,*, p<0.05;**, p<0.01; ***, p<0.001) 
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4.4.3 Characterisation of NSC-34 cells 
It was decided to characterise these cells by immunostaining and Western blotting with a 
selection of motor neuron specific markers to determine whether our stocks of these cells 
express the markers reported in the literature (Matusica et al., 2008).  
Immunostaining with the cystoskelatal protein neurofilament-200 showed a positive stain 
(Figure 4.3.A). The staining above was done with an anti-neurofilament 200 antibody (Sigma 
N4142) at an optimised dilution of 1:500. The staining is fibrous in nature with a 
concentration of the filaments in the axons of the NSC-34 cells. This pattern was seen in all 
the cells on the slide. 
Neuronal cell adhesion molecule (NCAM), the first cell adhesion molecule to be 
characterised, is expressed on all neurons from very early in development. It binds 
homophilically to NCAM on adjacent cells and has a variety of functions during neuronal 
development. One of these important functions is to hold developing neurites together 
during neuron outgrowth and formation of neural connections.  
Immunostaining was carried out with a rabbit polyclonal antibody from Millipore (AB5032) 
at an optimised dilution of 1:1000 (Figure 4.3.B). As the image shows, the staining was 
patchy in nature with a concentration at the periphery of the cells, as was expected and 
typical of adhesion molecules.  
Nicotinic acetylcholine receptors, or nAChRs are cholinergic receptors that form ligand-
gated ion channels in the plasma membranes of certain neurons and on the postsynaptic 
side of the neuromuscular junction. Immunostaining was done using a rabbit polyclonal 
antibody to nAChR (Abcam ab23832) at an optimised dilution of 1:1000. The staining was 
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punctate in nature with a particular concentration in the axons of the NSC-34 cells (Figure 
4.3.C). 
Next, Western blots were set up using cell lysates made from differentiated NSC-34 cells. 
Glutamate is the most abundant excitatory neurotransmitter in the central nervous system 
and plays a crucial role in several pathways in the human motor system. It had been 
reported that serum depletion of the growth media of NSC-34 cells promotes the expression 
of functional glutamate receptors as the cells mature into a form characteristic of motor 
neurons (Eggett et al., 2000). Using an anti-metabotrophic glutamate receptor 2+3 antibody 
to probe the blot, one could see a thin, specific band at the expected 100 kDa size (see 
Figure 4.3.D). The abundance of the receptor was lower than expected but one can explain 
this by the reported fact that expression of glutamate receptor increases with days in 
culture with peak levels seen in cells which had been in low serum media for 4 weeks 
(Eggett et al., 2000). This is in stark contrast to non-detectable levels seen in cells grown in 
full serum media. As the cell lysates were made from NSC-34 cells which had only been in 
differentiation media for 5 days, one expects to have a relatively low expression of the 
receptor at this time point. 
 
Western blotting for the p75 neurotrophin receptor (p75NTR) gave a specific band at the 75 
kDa molecular weight and this expression profile is consistent with developing motor 
neurons (Figure 4.3.D). The band obtained was a doublet which represents the glycosylated 
and non-glycosylated forms of the protein. 
 
Finally, a Western blot was done to confirm the expression of the early endosomal marker 
(Rab5) and late endosomal marker (Rab7) in this cells line and to compare their expression 
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with a range of other cells. As can be seen in Figure 4.3.E, NSC-34 cells express both Rab5 
and Rab7. However, the amounts expressed are at relatively low levels compared with the 
PC12 and 293T cell lines. 
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                                                                                           42 kDa  β-actin 
Figure 4.3: Characterisation of NSC-34 cells. Immunocytoshemistry was performed to 
confirm the neuronal properties of NSC-34 cells. Cells were seeded onto glass cover slips 
and allowed to differentiate for 5 days before fixation and staining with the relavant 
antibodies. The cells stained positive for the neuronal markers Neurofilament-200, NCAM 
and nicotinic acetyl choline receptor (A,B and C). Western blotting was performed with 5 
day old differentiated NSC-34 cell lysates (D) which showed the presence of glutamate 
receptor 2+3 and p75 neurotrophin receptor. Western blot analysis was also performed to 
detect the presence of early (Rab5) and late (Rab7) endosomal markers in NSC-34 cell lysate 
and lysates from panel of cells as well as beta actin loading contro (E) with equal amount 
standardised as per BCA protein assay. 
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4.4.4 Co-localisation studies 
Initial studies to determine the retrograde trafficking characteristics of lentiviral vectors 
were done in the NSC-34 cell line. Co-staining studies were done with RV-G pseudotyped 
HIV-1 vectors to identify trafficking partners. Undifferentiated NSC-34 cells were seeded 
onto poly-d-lysine+laminin+fibronectin adhesion peptide coated coverslips in 12 well plates 
at a density of 10,000 cells per well. These are allowed to attach and grow in full media for 
24 hours. Following this, the media were replaced with low serum differentiation media. In 
the next 2-3 days the cells have a growth spurt and from about day 5 onwards 
approximately 80% had differentiated. At this stage the cells were utilized in immune 
fluorescence studies. Although, over 90% differentiation can be achieved by maintaining the 
culture in low serum media for greater than 7 days, this usually resulted, among other 
things, in the cells becoming loosely attached from the coverslips which ultimately results in 
them lifting off during the immuno-staining process. 
4.4.5 Visualisation of vector by immunofluorescence 
The initial studies were to optimise the conditions to visualise the vectors inside NSC-34 
cells by confocal microscopy. This was done using the anti-gag (Abcam ab63917) and anti-
rabies G (Abcam ab82460) antibodies. The Rabies-lacZ HIV-1 vector was used for this 
purpose. Although, the rabies-GFP vector was tested initially, it was decided to use the 
rabies-LacZ vector due to potential interference from the GFP.  
Generally it was discovered that a multiplicity of infection or MOI of 10 T.U. or greater or 10 
lacZ forming unit (l.f.u) per cell or greater was needed to visualise internalised vectors of any 
significance in the axon (see Figure 4.4). This is important as the study aims to characterise 
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the trafficking of the vectors in the axon. For experiments using the rabies-LacZ-HIV vectors, 
one did notice that the poly-d lysine and laminin coating did result in free vectors binding to 
the coverslips which were picked up by the anti-rabies G antibody and the anti-gag 
antibody, to a lesser strength. It was also noticed that a greater number of vector particles 
were stained with the anti-rabies-G antibody compared with the anti-gag antibody and the 
later also appear to produce more non-specific background stain. It could be that the anti-
gag antibody had not been optimised for immunofluorescence. So, the anti-rabies antibody 
was used for the co-localisation studies presented here as it showed good staining of 
vectors within cells. 
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Figure 4.4: Visualisation of RVG-HIV-1 vector by dual staining with anti-rabies and anti-HIV 
gag antibodies in NSC-34 cell. The top left panel shows the vectors staining with the anti-
gag antibody used in conjunction with an Alexa 488 secondary antibody. Vectors can be 
seen in the axon (green arrows). Top right panel shows the staining for anti-rabies G 
antibody in conjunction with Alexa 594 secondary antibody staining the same vectors in the 
same cell (red arrows). Bottom right panel shows vector signal co-localisation when images 
are superimposed. n=3, image is representative. 
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4.4.6 RV-G pseudotyped HIV-1 vectors internalise and traffic with p75NTR , 
NCAM and nAChR 
The first step in the life cycle of a wild type virus is its interaction with receptors present on 
the surface of a cell. An understanding of these interactions is crucial to understanding viral 
tropism, spread and pathogenesis and therefore knowledge which can be utilized in the 
improvement of gene therapy vectors. For the rabies virus, the attachment of the G protein 
of the viral envelope is needed and it is also important in the spreading of the virus later on. 
For the interaction of the viral G protein with the host cell membrane, specific receptors 
play a role (Schnell et al., 2010). Such a receptor can only be considered as a specific if its 
interaction with the virus leads to the internalisation and infection of the cell (Lentz et al., 
1983).  
It had been previously reported that the wild type rabies virus is able to bind and enter 
neuronal cells following interaction with one or more of p75NTR (Lafon, 2005; Tuffereau et 
al., 1998), NCAM (Lafon, 2005; Thoulouze et al., 1998b) or nAChR (Lentz et al., 1983; Lentz, 
1990). In addition, there may still be many unknown receptors which are involved in the 
process of internalisation (Schnell et al., 2010). 
For this study, the initial question that needed to be answered was whether the RV-G 
pseudotyped HIV-1 vectors interact, internalise and traffic with the above mentioned 
receptors in NSC-34 cells. Dual immunostaining was done to determine this (Figure 4.5). This 
fixed imaging data demonstrates, for the first time, the association and internalisation of 
the RV-G pseudotyped lentiviral vector with the three specific rabies receptors: p75NTR 
(Figure 4.5.A), NCAM (Figure 4.5.B) and nAChR (Figure 4.5.C) as seen by the co-localisation 
of the signal between RV-G and receptor giving a yellow puncta.  
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Figure 4.5: RV-G pseudotyped HIV-1 vectors internalise and traffic with p75NTR , NCAM 
and nAChR. NSC-34 cells were incubated with RV-G pseudotyped HIV-1 vectors at a MOI 10 
for 10 minutes at low temperature to allow to bind before unbound vector was washed off 
and replaced with fresh media. The cells were moved to 37 °C incubator and vectors 
allowed to internalise before being fixed at various time points. This was followed by 
immunostaining with anti-RV-G and potential receptor for RV-G HIV-1 (A) anti- p75NTR, (B) 
NCAM and (C) nAChR followed by visualisation with Alexa 594 and Alexa 488 conjugated 
secondary antibodies. Cell nuclei were visualised with DAPI (blue). Images were visualised 
with confocal microscopy and the right column showing co-localisation of RV-G HIV-1 
vectors with all three receptors. n= 3 experiments, images are representative. 
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Following the demonstration that the Rabies G pseudotyped HIV-1 vectors co-localised with  
the three receptors in what appears as vesicles, it was decided to quantify them and 
determine whether the proportions changed with time. The method involved putting the 12 
well plate containing the differentiated cells on coverslips on a tray of ice for 5 minutes in 
order to slow down the endocytosis process. Following this, the vector solution was added 
to each well at a MOI of 10 l.f.u  per cell, whilst on ice. The vector was allowed to bind to the 
cells but not internalise by incubating for a further 10 minutes on ice. No detrimental effect 
was observed on the cells from this incubation on ice although the lower temperature 
caused the media to turn more basic as deduced from the change in its colour. After   
incubation on ice, unbound vectors were washed off and fresh media added and the plate 
was put in a 37°C incubator for a range of time points from 0 mins to 60 mins. At each time 
interval, the specified coverslip was removed from plate and placed in the well of a new 12 
well plate in which the cells were fixed with 4% paraformaldehyde  and then quenched 
(0.1M Glycine) and permeabilised (0.1% Triton). The cells were then co-stained with anti- 
Rabies G and Anti- receptor antibodies.  
Confocal images were taken of cells at all the time points following internalisation and the 
number of stained vector containing compartments were counted in the axons.  The criteria 
used for double positive compartments are similar to those used by the Schiavo group at 
CRUK namely, (i) the compartment was labelled in both channels i.e. green and red, (ii) the 
morphology and location of the carrier was similar in both channels. 
As Figure 4.6.A shows, the association of the RV-G pseudotyped vector and p75NTR is seen 
from the first time interval (5 minutes) following vector internalisation. There appears to be  
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Figure 4.6: Quantification of RV-G HIV-1 vector co-localisation with receptors in NSC-34 
cells. Vector co-localisation with receptors was quantified by analysing confocal images 
taken at six different experimental time points. A count was done of total vectors in the 
axons visible with anti-RV-G immunostain followed counting of vectors with co-localised 
signal with (A) p75NTR, (B) NCAM and (C) nAChR. Vector co-localisation was then expressed 
as a percentage of total vectors. (n= 3 experiments, 15-20 vectors per time point). 
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a peak at the 10 minutes time interval, however, there is always an association of 25 % or 
over between the vector and p75NTR throughout the recorded time intervals. 
Similarly, for NCAM (Figure 4.6.B) and nAChR (Figure 4.6.C) significant vector association 
was observed with these receptors from the first recorded time interval following vector 
internalisation and this association continued until the last recorded time interval (60 
minutes). Again, this association is over 20 % of total vectors recorded in the axons. 
Although, there is an indication that by 60 minutes, the association with nAChR begins to 
decline relative to the other receptors. 
The levels of association between the RV-G lentiviral vector and the three receptors stays 
relatively the same throughout the recorded time points, and suggests that the vector 
traffics with its specific receptors throughout the axonal pathway. 
 
4.4.7 RV-G pseudotyped HIV-1 vectors follow a sequential Rab5 to Rab7 
maturation along the axonal endocytic pathway in NSC-34 cells 
Endocytosed cargo undergoes a well characterised journey through distinct early and late 
endosomal populations on its way to the lysosome (Zerial & McBride, 2001). These are 
characterised by the enrichment with either of the small GTPase protein Rab5 (early 
endosomes) or Rab7 (late endosomes) (Rink et al., 2005). To determine if the trafficking RV-
G pseudotyped vectors traverse this pathway, NSC-34 cells were incubated with vectors for 
increasing periods of time before fixing, permeabilising and probing the cells with anti-RV-G 
and either anti-Rab5 or anti-Rab7 antibodies (see Figure 4.7). The RV-G pseudotyped vector 
can be seen co-localising with both Rab5 (Figure 4.7.A) and Rab7 (Figure 4.7.B). The co-
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localisation with Rab5 peaks very early on (5 minutes) after the start of vector 
internalisation followed by a decline in association with the vector over the recorded time 
points. In contrast, co-localisation with Rab7 continued to increase over time and peaked at 
40-60 minutes after the internalisation of the vector. These data are consistent with the RV-
G pseudotyped lentiviral vector entering an endosomal pathway of sequential, transient 
association with Rab5 positive early endosomes and then accumulation within a Rab7 late 
endosomal compartment. 
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Figure 4.7: RV-G pseudotyped HIV-1 vectors associate and traffic with early endosomal 
(Rab5) and late endosomal (Rab7) markers in NSC-34. Cells were incubated with RV-G 
pseudotyped HIV-1 vectors at a MOI 10 for 10 minutes at low temperature to allow binding 
before unbound vector was washed off and replaced with fresh media. The cells were 
moved to 37°C incubator and vectors allowed to internalise before being fixed at various 
time points. This was followed by immunostaining with anti-RV-G and (A) Rab5 (B) Rab7 
antibodies followed by visualisation with Alexa fluor conjugated secondary antibodies and 
DAPI (blue). Vector co-localisation with Rab5 (D) and Rab7 (E) was quantified from confocal 
images and expressed as a percentage of total vectors. (n= 3 experiments, 15-20 vectors per 
time point). 
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4.4.8 Characterisation of RV-G pseudotyped lentiviral vector trafficking in 
NSC-34 cells using live cell imaging 
As a first attempt to determine the characteristics of vector trafficking, we deployed the live 
cell imaging technique to study these vectors in NSC-34 cells. Differentiated NSC-34 cells 
were incubated with RVG-HIV-1 tetracysteine tagged vectors labelled with the biarsenical 
dye FlAsH for. Unbound vectors were washed off before imaging by time lapse confocal 
microscopy of the axons. Initially, effort was put into optimising the parameters under 
which the labelled vectors can be visualised and live movies can be recorded. Some of the 
optimised acquisition parameters are:  
 Optimal vector concentration appeared to be at 10-20 TU (293T LacZ) per cell, 
though, the experiments were performed with a MOI of 10. 
 Binding was done at RT for 10 minutes and cells imaged from post binding onwards. 
Particle movement could be seen up to and beyond 90 minutes post binding. Beyond 
this time frame the cells began to suffer the effects of photo bleaching. 
 To limit photo-bleaching the laser transmission was lowered to 8%-10%. 
 Confocal pinhole was opened up to acquire an optical section of ~3-6 μm. This 
allowed imaging of more of the axon (which is never completely within the focal 
plane) and helped keep the axon in the imaged optical slice even when it moved 
around. 
 63x oil immersion objective was used. 
 Time lapse acquisition was done by taking images every 5 seconds for as long as 
particles were seen moving along axons. 
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 Only axons were imaged. As much of the axon as possible was included. If possible 
the axon was imaged from the growth cone to the axonal hillock. 
It was first observed that a number of the particles were associated with the cells but did 
not undergo much movement. It was difficult to determine whether these particles were 
non-productive viral vectors associated with the outside of the cell and unable to undergo 
endocytosis (poorly pseudotyped vectors) or endocytosed particles that are unable to 
traffic. Therefore, these particles were excluded from further track analysis. As a control, 
NSC-34 cells were infected with untagged (wild type) vectors labelled with FlAsH. No vectors 
were visible during live cell imaging indicating specific labelling of the capsid and their 
imaging. 
A large number of vectors were visualised which showed appreciable displacement from the 
point of origin (Figure 4.8.A circles and kymograph B). These vectors varied in both the 
distance and speed travelled. Next, extensive track analysis of moving vector particles were 
manually tracked post acquisition using the MTrackJ ImageJ plugin and kymographs were 
generated using the Kymograph plugin. MTrackJ extracted positional coordinates were used 
to calculate the displacement of each imaged carrier.  
The analysis revealed that the vast majority of the vectors trafficked in a retrograde 
direction from the axonal tip towards the soma (Figure 4.8.C). Although the overall direction 
the vectors travelled was retrograde, within some tracks one could see start and stop 
movement with instances of temporary movement in the anterograde direction which 
ultimately reversed towards the retrograde direction. This is characteristic of microtubule 
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associated movement and also reflects the bidirectional nature of the microtubules in the 
NSC-34 cells.  
The speed of individual movement (speed between frames) was calculated (Figure 4.8.D). 
The majority of events are static to slow (0-0.3 μm/sec). A second group of events appeared 
to fall in the Intermediate speed category (0.5-0.7 μm/sec) previously associated with Rab7 
+ve vesicles (Deinhardt, Salinas, et al., 2006). A third group of events fell in the fast (1.3-1.7 
μm/sec) category. The average speed of individual movements was approximately 0.2 
µm/second, however over 10 % of all the measured movements were of 0.8 µm/second or 
more which is also suggestive of active microtubule mediated transport.  
This demonstration that RV-G pseudotyped HIV-1 vectors can undergo long range 
retrograde transport in the axon raises the possibility that pseudotyping is not a 
requirement for retrograde trafficking rather the HIV-1 capsid alone is sufficient. To test this 
hypothesis DiD labelled HIV-1 lentiviral vectors pseudotyped with the VSV-G. This 
pseudotype has been shown not to induce retrograde transduction in vivo (Mazarakis et al., 
2001). Extensive live cell studies were performed in NSC-34 cells. Although a large number 
of vectors were seen within the axons, very few of these were observed to show 
displacement from the origin during the time course of imaging (only 6 out of 106 vectors).  
As the track data and speed profiles show (Figure 4.8, E and F) the VSV-G pseudotype 
vectors remains mostly stationary. The very little movement that is seen is in a mixture of 
retrograde and anterograde direction raising the possibility that even this minority of 
moving vectors enter a trafficking pathway which is different to the long range retrograde 
transport observed with RV-G pseudotype which enables the cell to be transduced. So, in 
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conclusion the ability of the vector to undergo long distance axonal retrograde transport is 
bestowed by the pseudotyping of the RV-G. 
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Figure 4.8: Trafficking of FlAsH labelled RV-G pseudotyped HIV-1 particles in NSC-34 cells. 
Differentiated NSC-34 cells were incubated with FlAsH labelled RV-G pseudotyped HIV-1 
vectors for 10 minutes (MOI) before time lapse confocal microscopy. A) Representative time 
series from live cell movie 1 (Appendix B), showing retrograde trafficking particles (red 
circles, cell body is to the left). B) The same time series is represented as a kymograph. C) 
Single vector analysis showing the displacement from the origin of each particle analysed 
(17 tracks). D) Speed distribution analysis of individual particle movements (speed between 
frames), 488 individual events. (E) NSC-34 cells incubated with VSV-G pseudotyped HIV-1 
vectors labelled with Vybrant DiD (MOI 10) before time lapse confocal microscopy.  Graph 
shows the single particle track analysis of the displacement from origin of VSV-G HIV-1 
particles (104 tracks). (F) Speed distribution analysis of individual particle movements 
(speed between frames).  
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4.5 Discussion 
The NSC-34 cell line as an in vitro model for motor neuron studies was based on many of its 
inherent morphological and physiological properties resembling primary motor neuron 
cultures in neuronal development. Characteristics such as poor adhesion and difficulties in 
differentiating them, which had been previously reported, presented obstacles to  their use 
in this project. The effect of low serum on growth and differentiation was analysed. NSC-34 
cells maintained in DMEM (with P/S, L-Glu and NEAA) with 1% FCS resulted in the highest 
proportion of cells differentiating into the motor neuron morphology. 
Next, the substrate onto which the cells attached was looked at to see if improvements can 
be made in terms of getting a higher proportion of cells in the culture to differentiate. It was 
observed that the coating the growth surface with a combination of poly-D-lysine + Laminin 
+ Fibronectin Adhesion Promoting Peptide produced the most notable improvements in 
terms of adhesion and the amount of neurite sprouting and the level of differentiation was 
quantified and found to be statistically significant. So, with an improved, standardised 
method for growing stably adherent and highly differentiated NSC-34 motor neuron like 
cells, we utilized them in further studies. 
Following on, the cells were characterised for motor neuron properties. Immunostaining 
revealed that the differentiated cells expressed the proteins neurofilament-200, NCAM and 
nicotinic acetyl choline receptor. Western blot analysis confirmed the presence of the 
neurotropin receptor p75 as well glutamate receptor 2+3. In addition, the blots also 
confirmed the presence of the small GTPases Rab5 and Rab7 which are components of the 
endocytosis pathway. Previously, Matusca et al. confirmed the presence of markers of 
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intracellular trafficking, in particular markers of the regulated endocytic pathway such as 
clathrin, AP-1, EEA-1 and acidic organelle/lysosomal markers Lamp-1 and Lamp-II (Matusica 
et al., 2008). The group also reported the presence of motor neuron specific markers HB9 
and ChAT. 
Next, the project looked at the interaction of the RV-G HIV-1 vectors with reported 
receptors of wild type rabies virus. As of now, there are three different receptors known to 
interact with the RV-G. Firstly, there is evidence indicating that nAChR acts as a receptor for 
the wildtype rabies virus (Lentz et al., 1983). The nAChR receptor is an integral 
transmembrane protein which is involved in the transduction of a chemical signal such as 
acetyl choline into an electrical signal. Interestingly, the receptor can be found at 
neuromuscular junction and its role is reported to accumulate the rabies virus at the 
neuromuscular junctions, thereby enhancing the probability of the virus gaining access to 
the central nervous system so that a more efficient infection can occur (Lentz et al., 1983; 
Schnell et al., 2010).  
Another protein that is proposed to play the role of a rabies virus receptor is NCAM 
(Thoulouze et al., 1998b). This group demonstrated that preincubation of rabies virus with 
soluble NCAM inhibited its ability to infect susceptible cells. Additionally, the transfection of 
resistant L fibroblasts with NCAM encoding gene induces rabies virus susceptibility.   
Finally, p75NTR was identified as a ligand of a soluble form of RV-G (Tuffereau et al., 1998). 
This receptor is normally specific for neurotrophins. It has important roles in the 
internalisation and trafficking along axons of neurotrophins. The binding to p75NTR may 
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allow the virus to avoid the endocytotic degradation pathway so that it gains access to the 
fast axonal transport route which enables it to travel to the soma.  
A receptor can only be considered a specific receptor if it’s interaction with the vector leads 
to its internalisation. For the first time, we demonstrate the co-internalisation of RV-G 
pseudotyped lentiviral vectors with the three specific receptors in the NSC-34 motor neuron 
like cell line. The fact that following internalisation the levels of association remains more or 
less constant suggests that the interaction remains throughout the vectors journey along 
the axon. Also, as not all the internalised vectors are co-localised 100% with a given receptor 
at a given time, this may indicate that each of these receptor is a co-receptor or that binding 
to any of these receptors puts the vector in the same axonal pathway.  
Furthermore, the study showed that lentiviral vectors follow a sequential Rab5 to Rab7 
endosomal maturation along the axonal endocytic pathway. This axonal trafficking pathway 
is responsible for the retrograde transport of RV-G pseudotyped lentiviral vectors, and, by 
extension likely to mediate the trafficking of wild type rabies virus. The early association of 
RV-G lentiviral vectors with Rab5 positive early endosomes and then with Rab7 positive late 
endosomes is similar to that observed for the tetanus neurotoxin and this enables the toxin 
to enter a fast axonal trafficking pathway (Deinhardt et al., 2006). Rab GTPases and their 
effectors are primary determinants of compartmental specificity in eukaryotic cells. It has 
been amply demonstrated before that in the endocytic pathway Rab5 and Rab7 act in a 
sequential manner (Rink et al., 2005; Vonderheit & Helenius, 2005), with Rab5 controlling 
early steps including clathrin dependent endocytosis, targeting of cargoes to early 
endosomes and endosome fusion. Rab7 acts at later stages and plays a crucial role in 
regulating cargo progression from early to late endosomes (Pfeffer, 2003; Zerial & McBride, 
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2001). In HeLa cells, Rab7 effectors RILP and ORP1L can mediate the recruitment of 
cytoplasmic dynein motors to endosomes (Johansson et al., 2007) and this may indicate that 
only those vectors undergoing this endosome maturation undergoes efficient, long range 
axonal transport. Also, the fact that the RV-G vectors are shown to undergo this conversion 
is further proof that RV-G pseudotyped vectors are endocytosed into trafficking 
compartments rather than being carried on microtubular motors by direct attachment to 
the dynein motor, which is one of the hypothesis regarding the transportation of rabies 
virus (Warrell & Warrell, 2004).    
Next, the project looked at the trafficking of RVG-HIV-1 vectors in NSC-34 cells under a live 
cell imaging set up. The tetracysteine tagged vectors labelled with FlAsH were utilized for 
this purpose.  Initially, conditions for visualisation and imaging of the vectors in the axons 
were optimised. The confocal microscope was enclosed with an environment controlling 
chamber which maintained a 37°C/5% CO2 atmosphere.  Among other things, it was found 
that a MOI of 10 was the optimal concentration of vector to allow the visualisation of 
trafficking in the axon. Having more vectors increases the chances of observing more 
trafficking events in the axons. However, this is compromised as one also sees a lot of 
vectors which had bound to the cover slip and which makes it difficult to view moving 
particles in the axon. One could visualise trafficking events for up to 90 minutes after the 
addition of vectors. Beyond this period, the effects of photo bleaching begins to affect the 
experiment. This includes axons detaching from the coverslip and ultimately being torn from 
the cell body. The parameters optimised with the NSC-34 cell line will also be applicable in 
the next set of studies involving primary motor neurons. 
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The trafficking results show that a proportion of the RV-G pseudotyped HIV-1 vectors 
undergo fast, long range axonal transport and this category has a vector speed range of  1.3-
1.7μm/sec. However, the majority of the vectors were seen to move at an intermediate 
speed or were static within the axons. The overall movement of the vectors were in the 
retrograde direction. 
In order to show that the RV-G pseudotype is a requirement for trafficking rather than the 
HIV-1 capsid alone, a trafficking study was done using a VSV-G  pseudotyped HIV-1 vector. It 
had been reported before that this pseudotype  do not induce retrograde transduction in 
vivo (Mazarakis et al., 2001). It was found that a large number of vectors were seen in the 
axons indicating the ability of the VSV-G pseudotyped vectors to internalise. However, very 
little trafficking was observed  (6 out of 106 vector tracks) which may explain the inability of 
these vectors to induce retrograde transduction of motor neurons.  
Overall, the results suggest that the ability of a vector to undergo retrograde transport is 
bestowed by pseudotyping with the RV-G. In fact, studies involving rabies virus gene 
deletion mutants had previously demonstrated the RV-G protein is an absolute requirement 
for the rabies virus entry into cells and spread between neurons (Etessami et al., 2000; 
Wickersham, Finke, Conzelmann, & Callaway, 2007). In addition, the sequence of RV-G 
proteins determines the neuroinvasiveness of rabies virus variants (Finke & Conzelmann, 
2005), which may be related to differential receptor usage of viruses (Coulon et al., 1998) 
and to differential induction of apoptosis after expression of  RV-G in infected cells. 
These results are also in agreement with previous observations in cells lines that RV-G 
protein can confer retrograde axonal transport to the pseudotyped lentiviral vectors. 
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Klingen et al. RFP tagged the a domain of RV-G and observed individual particles inside 
endosomes in which the complete enveloped particle was carried and these were trafficked 
over long distances in NS20Y neuroblastoma cells (Klingen, Conzelmann, & Finke, 2008a). 
Furthermore, they showed that varying the level of RV-G expression on envelope reduced 
viral infectivity. 
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Chapter 5: Trafficking Studies In Motor Neurons 
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5.1 Introduction 
5.1.1 Motor neurons 
Spinal cord motor neurons are highly differentiated post mitotic cells that arise from the 
ventral section of the neural tube and are among the first cells generated in the spinal cord 
(Altman & Bayer, 1984). A large proportion of these cells undergo apoptosis during 
development.  
Lower motor neurons are characterised by large soma which can be two or three times 
larger than other neurons. Additionally, they have the potential to form very long axons and 
wide ranging dendrites (Figure 5.1.A). A motor axon arising from the lumbar spinal cord with 
its target muscle in the foot can reach a length of up to 1 meter in humans. 
Lower motor neurons are located in the ventral horn (anterior horn in human), throughout 
the spinal cord and in the brain stem nuclei (Figure 5.1.B). They are responsible for inducing 
voluntary movement via acetyl choline release at the neuromuscular junction on skeletal 
muscle fibres. Each muscle fibre is supplied by a single axon terminal, and a single motor 
neuron can form synapses with as few as ten or as many as several hundred muscle fibre 
(Carp,J.S., Wolpaw, 2001). Direction for voluntary movement is received from neurons in 
the supraspinal regions (predominantly in the primary motor cortex), interneurons, sensory 
neurons and even other lower motor neurons. The sum of the ongoing inhibitory (i.e. GABA) 
and excitatory (i.e. glutamate) signals determines the motor neuron’s firing rate and 
resultant muscle fibre contraction (Carp, 2001). 
In spite of their shared function, motor neurons can actually be subdivided into further sub 
types. Co-ordinated control of muscle contraction requires the involvement of multiple 
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motor neuron classes and subtypes. The human body, for example, has more than 300 
bilateral pairs of muscles which contain more than 100 million muscle fibres, which are 
innervated by more than 120,000 motor neurons in the spinal cord alone. 
Motor neurons in the adult can be classified into functionally diverse groups. One division is 
according to the type of muscle fibres each class innervated: alpha (α), beta (β) and gamma 
(γ) motor neurons. Alpha motor neurons innervate extrafusal skeletal muscle and drive 
muscle contraction. Gamma motor neurons innervate intrafusal muscle fibres of the muscle 
spindle and play a complex role in motor control. The third group, beta motor neurons, are 
less well defined. They innervate both intra and extrafusal fibres (Figure 5.1.C). 
Of the three classes, alpha motor neurons are the most abundant and this class can be 
further subdivided according to the contractile properties of the motor units that they form 
with target muscle fibres: fast twitch fatigable (FF), fast twitch fatigue resistant (FR) and 
slow twitch fatigue resistant (S) (Burke, Levine, Tsairis, Zajac, 1973).  
There are also differences in morphology and size between the subtypes of motor neurons. 
On one end, the S motor neurons have smaller cell bodies and axons. At the other end, FF 
type motor neurons are large, with large diameter, fast conducting axons. The average 
membrane area for FF motor neurons is >20% larger than S motor neurons, reflecting more 
axonal and dendritic branches and more presynaptic neuromuscular terminals per motor 
neurons (Cullheim et al., 1987). It is assumed FR motor neurons form an intermediate 
group. 
In terms of molecular markers, which may distinguish each subtype, very little has come 
about in terms of molecular differences between the corresponding motor neurons. 
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Although levels of succinate dehydrogenase (SDH) and calcitonin gene related peptide 
(CGRP) have been proposed to differ between fast and slow motor neurons, however, this is 
likely to reflect a size difference rather than a genetic distinction (Kernell, Bakels, & Copray, 
1999; Piehl et al., 1993).  
The motor neuron subtypes –  alpha and gamma, slow and fast- are found at all levels of the 
spinal cord. However, in order for their functions to be exerted in a co-ordinated way, they 
are spatially grouped in a way that reflects both their developmental history and adult 
function.  
During development, newly post-mitotic motor neurons are grouped into motor columns. 
Within a given column, the collective motor neurons that innervate a single skeletal muscle 
is defined as a motor pool. A given motor pool contains a characteristic ratio of fast, slow, 
alpha and gamma motor neurons adapted to its function. Although they retain their subtype 
specific characteristics, motor neurons within a pool also share a certain molecular, 
morphological and connectional properties. These include characteristic profiles of 
transcription factor expression (Dasen & Jessell, 2009). In addition, there are also pool- 
specific combinations of cell surface molecules such as axonal guidance receptors and 
adhesion molecules (Dalla Torre di Sanguinetto, Dasen, & Arber, 2008) as well as 
neurotransmitter receptors (Rekling et al., 2000). 
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Figure 5.1: Morphological characteristics and spatial organisation of motor neurons. (A) 
Schematic representation of a motor neuron cell comprising a cell body containing core 
cytoplasmic components and a nucleus with all the transcription machinery. They also have 
highly specialised extensions of their cell body cytoplasm called dendrites and axons. (B) 
Diagram showing the spatial organisation of motor neurons (C) Distinct motor units within 
skeletal muscle. Alpha motor neurons innervate extrafusal muscle fibres to form three 
subtypes of motor unit: slow-twitch (S) units control Type I fibres, fast-twitch fatigue 
resistant (FR) units control Type IIa fibres, and fast-twitch fatigable (FF) units control Type 
IIb fibres. Gamma motor neurons control intrafusal muscle fibres.(adopted from Kanning, 
Kaplan, & Henderson, 2010). 
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5.1.2 Viral invasion of central nervous system through motor neurons 
Neurotropic viruses, such as rabies, exploit the neuronal circuitry of the CNS to cross the 
blood brain barrier and infect the brain where they often induce aggression in the host that 
facilitates the transfer of the virus to a new host (Charlton, 1994; Warrell & Warrell, 2004). 
Initially, the virus enters a motor neuron at the neuromuscular junction by binding to its 
cognate receptors and internalising.  
After uptake into motor neurons by specific receptors, the rabies virus is transported to the 
brain via the neuronal system. The reason for this is because the site of entry of the virus, 
the axonal tip, does not offer the right biochemical environment for replication. This is in 
contrast to the neuronal cell body where transcription and replication can take place. Rabies 
virus traverses the axon by retrograde transport. This process is rapid and cannot be only 
driven by passive diffusion, so the virus has to use the active retrograde cellular transport 
system by hijacking it (Schnell et al., 2010). The transport is mediated by the dynein motor 
protein. Previously, it has been shown that the rabies P protein interacts with the dynein 
light chain 8 (Schnell et al., 2010). However, it has also been shown that this interaction is 
not needed for retrograde transport of the virus (Mebatsion, 2001).  
So, a question that arises is why does the rabies virus makes use of neurons on its route to 
the brain? The fastest mode of transport in a mammal is generally via the circulatory system 
carried in blood. However, as well as the blood brain barrier, blood cells lack the 
environment for the virus to replicate. The neuronal cell body contains the core cellular 
components and the nucleus with all the cellular RNA transcription machinery. So, this 
would be the most favourable route to the brain. Additionally, neurons are highly 
specialised cells that expend a great deal of energy maintaining their elaborate structures 
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through the trafficking of all their cellular constituents (Enquist, 2012). This transport works 
on the basis of the neuronal cytoskeletal architecture. Viral proteins and complex structures 
such as enveloped particles must therefore engage the neuronal transport machinery to 
move about the cell (Smith & Enquist, 2002). Neuroinvasive viruses express viral proteins 
that redirect or embellish existing traffic control that replicate and disseminate viral 
material to perpetuate the infection. Moreover, viral proteins/particles move in the context 
of extensive endogenous neuronal traffic whose cargo must continue to be sorted to the cell 
body , dendritic and axonal compartments to keep the neuron alive (Enquist, 2012). 
Thus, neurons provide a fast and efficient retrograde transport mechanism and also a 
facilitating environment for transcription and replication of the particle. Therefore, they 
fulfil the replication needs of neurotropic viruses such as rabies and are an ideal route for 
transport from the periphery to the brain. Characterising and understanding this type of 
traffic not only provides a means of tracing the neural circuitry but also provides us with 
valuable information which can be used in gene therapy strategies using the RV-G 
pseudotyped lentiviral vectors.  
5.1.3 Culture of spinal cord motor neurons 
Being able to isolate and culture spinal cord motor neurons is crucial to the understanding 
of neurobiology of motor neurons. In particular, they are an important tool for the study of 
mechanisms in motor neuron survival, degeneration, regeneration and motor neuron 
disorders such as amyotrophic lateral sclerosis and spinal muscular atrophy. 
Cultures may be studied pure, or mixed with other cells depending on the experimental 
design. Such cultures have been used to study axonal transport (Deinhardt, Salinas, et al., 
2006), glial-neuronal interaction (Ullian, Harris, Wu, Chan, & Barres, 2004), mitochondrial 
196 
 
movement (Stommel et al., 2007), neurotrophin function (Hanson & Shen, 1998)   and 
neuronal degeneration/apoptosis/necrosis (Hanson & Shen, 1998). 
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5.2 Results 
5.2.1 Isolation and growth of rat embryonic spinal cord motor neurons 
Culturing spinal cord motor neurons was an essential part of this project and time was spent 
initially to optimise isolation and growth parameters.  
The method used takes advantage of several distinct properties of lower motor neurons to 
isolate them away from their neighbouring cells. First of all primary motor neurons were 
dissected from E14 (embryonic day 14 during rat gestation) embryos. This is reported to be 
the ideal age to obtain maximal yields of motor neurons as after E15, motor neuron 
numbers are lower because of the commencement of normal programmed cell death 
(Wiese et al., 2010). In addition, this period is prior to extensive axonal extension (i.e. still 
stem cell stage). After dissecting out embryonic spinal cord tissue dorsal root ganglia and 
associated meninges were removed with a pair of tweezers which ensured a much purer 
motor neuron culture. At this stage the cord contained motor neurons as well as other cell 
types. So cells are separated using an Optiprep (density) gradient which exploits the 
uniquely large size of motor neurons. 
In terms of growth of motor neurons on coverslips and imaging dishes, it was noticed that 
seeding density and the composition of the growth media played an important role. A 
starting seeding density of 10,000 cells/cm2 was found to be too low and the cells were too 
sparse which resulted in considerable cell death. At a seeding density of 100,000 cells/cm2 
the cells were much healthier and grew well as determined by axonal growth and the 
formation of neuronal networks. It is probable that plating the cells at the lower density 
deprived the motor neurons of growth factors secreted from the non-neuronal cells in the 
culture. So, with this in mind, astrocytic cultures were set up from which conditioned media 
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was harvested. It was noticed that 50% supplementation of motor neuron growth media 
with astrocyte conditioned media resulted in much better growth and functionality than 
motor neurons grown in non-supplemented media. 
At plating, the neurons showed a bright and ovoid cell body which was relatively larger in 
size than other cells. Most of the cells became adherent to the substrate within two hours 
of seeding and extended several short processes 12 hours after plating. It was noticed that 
the cells attached better on glass coverslips compared with plastic ones. The growth of the 
motor neurons continued and the somas became larger and the axons began to extend. 
After 48 hours in culture, the somas were predominantly triangular or polyangular. At this 
stage one could see the formation of dense and complex neuronal networks (see Figure 
5.2.A). By Div 5, these cells became mature and were used in imaging studies. In addition to 
the motor neurons, there were astrocytes in the culture which can be readily distinguished 
by their distinct morphologies. If the cultures were allowed to grow further than Div 5, the 
astrocytes expanded in numbers and formed a monolayer by Div 7/ Div 8. The motor 
neurons grew on this layer of astrocytes and can still be distinguished morphologically.  
5.2.2 Characterisation of rat embryonic spinal cord motor neurons 
The cultured neurons displayed the characteristic morphology of motor neurons, however, 
it was important to characterise these cultures, immunocytochemically, with previously 
reported markers of motor neurons. The cultures were assessed with the markers SMI-32 
and neuropeptide calcitonin gene related peptide (CGRP) in combination. The SMI-32 
antibody recognises an epitope on non-phosphorylated neurofilaments expressed in motor 
neurons. Dual immunostaining with SMI-32 and CGRP (Figure 5.2.B) specifically labels the 
cells which morphologically look like motor neurons. This co-localisation of the two signals, 
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which were more intense in the long axons, was deemed specific as other cell types (whose 
nuclei was stained by DAPI and are thought of as astrocytes) did not stain positive for these 
two markers.  
Additional immunocytochemistry analysis in our laboratory of spinal cord motor neuron 
cultures generated using a similar method, when double stained with ChAT (selective 
marker for cholinergic motor neurons in the ventral horn) and anti-mouse GFAP (astroglial 
marker), revealed, after quantification of representative confocal images, approximately 
90% were motor neurons (ChAT positive) with the remaining cells being astrocytes (GFAP 
positive). In doing experiments with these cultures, there is always a risk that some 
interneurons are in the culture but close attention was paid to the morphology of the cells 
in all experiments presented in this chapter to ensure they were motor neurons i.e.  cells 
had long axons and shorter dendrites.  
It has also been reported that motor neurons generated and cultured using a similar 
methodology used in this project exhibit electrical activity which are largely similar to those 
measured in vivo (Zhang & Robinson, 2009). Using motor neurons from E15 rat embryos 
grown on multielectrode probes, the cultures showed characteristic spiking and bursting 
activity. Other properties shown by these cultures include inhibition by GABA, activation by 
glutamate through both NMDA and non-NMDA receptors and little spontaneous activity in 
the absence of glutamatergic activation and the authors concluded that this makes a good 
model system for studying motor neuron development, physiology and pathology (H. Zhang 
& Robinson, 2009). 
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Figure 5.2 Characterisation of motor neurons isolated and purified from rat embryonic 
spinal cord. (A) Representative brightfield images showing motor neurons (yellow arrows) 
and the formation of neuronal networks 48 hours after seeding (DIV 2). Glia cells can be 
seen attached to the substrate (white arrows) which tend to divide and increase with the 
progression of time. (B) Characterisation of purified motor neuron cultures by 
immunocytochemistry. Reported motor neuron markers SMI-32 and CGRP were used in 
double labelling of the cells. Secondary antibodies were conjugated with either Alexa Fluor 
488 (green) or Alexa Fluor 594 (red). They selectively immunostained motor neuron cells 
and there is co-localisation of respective signals in double labelled cultures. Blue represents 
4’,6-diamidino-2-phenylindole (DAPI) and was used to stain the nuclei of all cells in culture. 
(Scale 25 µm).  
A
B
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5.3.3 RV-G pseudotyped HIV-1 vectors internalise and traffic with p75NTR, 
NCAM and nAchR in motor neurons 
Earlier in the project, it was shown that in the NSC-34 motor neuron like cell line, the RV-G 
pseudotyped vectors internalise and traffic with the three reported receptors of rabies 
virus, namely, p75NTR, NCAM and nAchR. So, the question arose whether the RV-G 
pseudotyped HIV-1 vectors can interact, internalise and traffic with the three cognate 
receptors in primary motor neurons. 
Dual immunostaining was done to determine this. The fixed imaging data demonstrates 
what was seen in the NSC-34 cells. For the first time in motor neurons, it can be seen that 
the RV-G pseudotyped vectors co-localise with all three receptors within 5 minutes after 
vector internalisation (Figure 5.3 A, B and C ). When this association was quantified, by 
counting double positive compartments in the axons and representing them as a percentage 
of total vectors seen (Figure 5.3.D), it was shown that this association is visible from the first 
recorded time interval following vector internalisation and continued until the last recorded 
time interval (60 minutes). 
Although there is some fluctuation in association between the vector and receptor 
throughout the course of the experiment, the levels of association stays relatively the same 
throughout the recorded time points suggesting that the RV-G pseudotyped vector traffics 
with its specific receptors throughout the axonal pathway. 
The same experiments with the receptors were repeated with VSV-G pseudotyped HIV-1 
vectors to determine if the observed results were reproducible with VSV-G or were specific 
to the RV-G pseudotype. VSV exhibits a robust and pantropic infectivity mediated by its 
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surface glycoprotein VSV-G. Genetic, biochemical and immunostaining studies have shown 
that VSV-G is necessary for VSV binding to its putative receptor, its internalisation and its 
fusion with the target cell membrane (Bishop et al., 1975; Harrison, 2008; Volk et al., 1982). 
Following binding, VSV undergoes clathrin mediated endocytosis (X. Sun et al., 2005), which 
indicates that it gains access to cells through binding of VSV-G to an as yet unidentified 
cellular receptor. However, there is evidence that the Low density lipoprotein (LDL) receptor 
serves as the major point of entry of VSV and VSV-G pseudotyped vectors in human and 
mouse cells (Finkelshtein et al., 2013).   
As Figure 5.3.E shows, there is very little association between the VSV-G pseudotyped HIV-1 
vector and the three receptor proteins. The level of association was quantified in a similar 
method to that of RV-G pseudotyped vectors and show consistently less than 10% co-
localisation for NCAM and nAchR and p75NTR, with the later only just crossing this mark on 
two time points. At the 5 minutes time interval after vector internalisation, there is no 
association at all. This is in stark contrast to the level of association seen between RV-G 
vectors and its three cognate receptors (Figure 5.3.D) and indicates that p75NTR, NCAM and 
nAchR are specific receptors for the RV-G HIV-1 vector. In addition, it also suggests, 
although VSV is pantropic, its receptor(s) is/are likely to be to be different, for example LDL 
receptors, as was mentioned earlier.   
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
)LJXUH(QGRF\WRVHG59*SVHXGRW\SHGYHFWRUVFRORFDOLVHZLWKFRJQDWHUHFHSWRUV
IRU UDELHV DQG FRWUDIILF ZLWKLQ WKH VDPH FRPSDUWPHQW. (A-D) Primary motor neurons 
(DIV3) were incubated with RV-G HIV-1 vectors at a MOI of 10 for 10 minutes before 
unbound vector was washed off and replaced with fresh media. The cells were moved to 
37°C incubator and vectors allowed to internalise before being fixed at various time points. 
This was followed by immunostaining with anti-RV-G and (A) p75NTR (B) NCAM and (C) 
nAchR followed by visualisation with Alexa 594 (for RV-G) and Alexa 488 (for cognate 
receptor) Images were captured with confocal microscopy. Within (A,B,C) top panel shows 
anti-RV-G stain, middle panel anti- receptor stain and bottom panel represents overlay of 
the signal from the two channels. Co-localisation with the indicated receptors was 
quantified and expressed as a percentage of total vectors detected in axons (D, n=3, 15-20 
particles per time point). Similar experiments were repeated with VSV-G pseudotyped HIV-1 
vectors and the data quantified using anti-p24 gag (E). 
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5.3.4 Endocytosed RV-G pseudotyped lentiviral vectors undergo Rab5 to Rab7 
maturation along the axonal transport pathway in motor neurons 
Many viruses use endocytosis as a route of entry into host cells. Following its binding to cell 
surface receptors, the virus is internalised into the endocytic network in a manner that is 
generally considered to be clathrin dependent (Sieczkarski & Whittaker, 2003). Endocytosed 
cargo undergoes a well characterised journey through distinct early and then late 
endosomal populations. These cargo containing endosomes are characterised by 
enrichment with either of the small GTPase proteins Rab5 (early endosomes) or Rab7 (late 
endosomes) (Rink et al., 2005; Vonderheit & Helenius, 2005). Rab5 control of the early 
stages include clathrin dependent endocytosis, targeting of cargoes to early endosomes and 
endosome fusion. Rab7 functions at the later stages regulating cargo progression from early 
to late endosomes (Pfeffer, 2003; Rink et al., 2005).  
Previously, work done with Semliki forest virus (an enveloped RNA virus) have shown that in 
a classical clathrin mediated endocytic pathway, these viruses progressed from Rab5 
positive early endosomes to a population of early endosomes (about 10% of total) that 
contained both Rab5 and Rab7. The virus was then sequestered into Rab7 domains and they 
were sorted away from early endosomes when these domains detached as separate late 
endosome transport carriers devoid of Rab5 (Vonderheit & Helenius, 2005). 
As it was shown in the previous chapter, in NSC-34 cells, RV-G pseudotyped HIV-1 vectors 
follow a sequential Rab5 to Rab7 maturation along the axonal endocytic pathway, the 
question was asked whether these small GTPases were also associated in the trafficking of 
these vectors in primary motor neurons. To study the distribution of these two markers in 
endosomal compartments and their association with RV-G pseudotyped HIV-1 vectors, 
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double immunofluorescence experiments were performed. Motor neuron cultures were 
incubated with RV-G HIV-1 vectors between 5 and 60 minutes, fixed and double stained 
with anti-RV-G and endogenous Rab5/Rab7.  
The RV-G pseudotyped vector can be seen co-localising with Rab5 in motor neuron axons 
(Fig 5.4.A). These dual stained compartments were seen at 5 minutes post internalisation 
(Figure 5.4.C) which demonstrates that the RV-G HIV-1 vectors associated with early Rab5 
endosomes immediately after internalisation. In addition, this quantification showed this 
association peaks at 30 minutes after vector internalisation when almost 30% of the vectors 
were in Rab5 positive compartments. There is a decline in co-stained Rab5- RV-G vector 
structures and by 60 minutes post internalisation, only about 10% of the vectors co-localised 
with Rab5. 
Furthermore, just like the experimental results obtained in  NSC-34 cells, RV-G HIV-1 vectors 
can be seen co-localising with Rab7 (Figure 5.4.B). Quantitative analysis of the distribution 
of Rab7-RV-G vector dual stained compartments showed that the association at 5 minutes 
post vector internalisation. However, in contrast to the dual stained Rab5-vector 
compartments, there is a peak association at 60 minutes post vector internalisation (Figure 
5.4.C). These ratios are in good agreement with those observed in NSC-34 cells and suggest 
that Rab5 to Rab7 vesicular maturation is required for RV-G pseudotyped lentiviral vectors 
to progress along the classical axonal endosomal pathway. 
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Figure 5.4: Endosomal maturation during internalisation and axonal transport of RV-G 
pseudotyped HIV-1 vectors in motor neurons. Motor neurons were incubated with RV-G 
pseudotyped HIV-1 vectors at a MOI of 10 for 10 minutes at low temperature to allow 
binding before unbound vector was washed off and replaced with fresh media. The cells 
were moved to 37°C incubator and vectors allowed to internalise before being fixed at the 
indicated times and immunostained with anti-RV-G (A and B, red) and either anti-Rab5 (A, 
green) or anti-Rab7 (B, green). A and B show representative examples of co-localization 
(circles) after 10 minutes (A) or 40 minutes (B). Vector co-localization was then quantified 
and expressed as a percentage of total vectors associated with motor neuron axon (C, n = 3, 
15-20 vectors per time point.  ***p>0.001, two-way ANOVA).  Similar experiments were 
repeated with VSV-G pseudotyped HIV1 vectors, and visualised using anti VSV-G antibody 
and the data quantified (D).  
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5.3.5 Vector internalisation is temperature dependent 
To further determine the trafficking characteristics of lentiviral vectors in motor neurons we 
studied the internalisation of the tetracysteine tagged HIV-1 MA-C vector in live cells. This 
was to determine if these vectors internalised through endocytosis which is temperature 
sensitive.  In order to do this, FlAsH labelled, matrix tagged, RVG pseudotyped HIV-1 vectors 
were incubated with motor neurons on ice in order for the vectors to bind but not undergo 
endocytosis.  Unbound vectors in half the cultures were washed off and the cells fixed at 4 
°C, whereas the remaining cultures, had the media replaced and were incubated at 37°C for 
45 minutes before fixation.  Both cultures were then stained with an antibody against the 
RV-G without permeabilisation to specifically detect surface bound vectors. 
Imaging by confocal microscopy and subsequent quantification revealed approximately 75% 
of the vectors remained bound to the cell surface at 4°C, as indicated by co-localisation of 
the FlAsH and anti-RVG signals (Figure 5.5 A, B).  The cultures incubated at 37°C, showed a 
large decrease in the co-localized signal (less than 25% of total) suggesting these vectors 
were no longer on the surface. Under these conditions, the vectors are rapidly internalised 
by clathrin coated vesicles. Thus the entry of these vectors is temperature sensitive, which is 
indicative of uptake via endocytic vesicles. 
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Figure 5.5: Internalisation studies with FlAsH labelled RV-G HIV-1 vectors. A and B) Primary 
motor neurones (DIV 3) were incubated with FlAsH labelled RV-G pseudotyped HIV1 vectors 
(green) for 30 mins on ice (i-iii) before placing at 37oC for 45 mins (iv-vi), and fixing under 
non-permeablising conditions, and labelling with anti-RV-G (red).  Surface vectors are 
labelled with both markers and appear yellow in the merged images (iii and vi), whereas 
internal vectors are inaccessible to anti RV-G and appear green.  These data were quantified 
and expressed as a percentage of total vectors counted (B), n=3, 30 cells, 550 particles.   
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5.3.6 Live Cell Imaging Studies 
5.3.6.1 Trafficking Characteristics of Tetracysteine Tagged RV-G pseudotyped HIV-1 
vectors 
This part of the project attempted to determine whether retrograde trafficking of RV-G-HIV-
1 vectors also occurs in motor neurons and if so what are their trafficking characteristics. 
Time-lapse confocal microscopy was utilised for these studies. First and foremost, the 4°C , 
FlAsH labelled vectors were clearly visible within the axons of the motor neurons and the 
strength of the signal was high which distinguished them from any non-specific background 
fluorescence within the cells. As a control, motor neurons were incubated with untagged 
(wild type) vectors labelled with FlAsH. No vectors were visible during live cells imaging 
indicating the 4C tag labelled the vectors specifically. 
Vectors were observed that underwent significant displacement rapidly along the axon 
(Figure 5.6.A circles and kymograph B). There were also other vectors that were observed to 
be associated with the cells but were not mobile. It was difficult to determine whether these 
particles were non-productive viral vectors associated with the outside of the cell and 
unable to undergo endocytosis (perhaps poorly pseudotyped vectors) or internalised into 
endosomes that did not undergo significant displacement. As these vectors were not 
trafficking at all during imaging they were omitted from quantitative analysis of the moving 
vectors. 
Of the moving vectors, there was variation in both the distance travelled along the axon and 
their speed. Particle analysis of these vectors demonstrated that they were able to undergo  
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Figure 5.6: Trafficking of 4C tagged, FlAsH labelled RV-G-HIV-1 vectors in motor neurons. 
A-D) Motor Neurons (DIV 3) were incubated with FlAsH labelled RV-G pseudotyped HIV-1 
vectors for 30 mins (MOI 10) before time-lapse confocal imaging.  A) Representative image 
time series of trafficking vector particles from Movie 2 (Appendix B)  B) Kymograph of the 
extensive trafficking, often close to 100 µm during the acquisition process (Figure 5.6.C). 
Just like the observations in NSC-34 motor neuron like cells, the vectors trafficked in a same 
image series.  C) Individual track analysis and D) Speed distribution analysis of moving 
particles (>20m in one direction, 32 tracks, 518 individual events). 
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extensive trafficking, often close to 100µm during the acquisition process (Figure 5.6.C). Just 
like the observations in NSC-34 motor neuron like cells, the vectors trafficked in a  
retrograde direction from the axonal tip towards the soma. However, within certain tracks 
there were instances of start and stop movements with occurrences of temporary 
movement in anterograde direction which ultimately reversed towards the retrograde 
direction. This is characteristic of microtubule associated movement.  
Analysis of the speed of individual movement (speed between frames) suggested that the 
vectors moved at an average of three distinct distributions. Again, this is similar to that 
observed in the NSC-34 cell line. The majority of the movements (events) fell in the static to 
slow group (0.0-0.3 µm/sec). A second group of events falls into an intermediate speed 
category (0.5-0.7 µm/sec). A third group of events comprised the fast category (1.3-2.6 
µm/sec). This compares favourably with that previously described for myosin Va mediated 
retrograde microtubule transport (Salinas et al., 2009). A limitation of the mass culture of 
motor neurons is that, in some instances, axons tend to grow towards the cell bodies of 
other neurons, resulting in bundles of anti-parallel axons. In these instances one cannot 
always determine the direction of trafficking. However, the data obtained from motor 
neurons is in overall agreement to that observed in NSC-34 cells (Figure 4.8) and also the 
speeds recorded for other retrogradedly transported cargo (Deinhardt, Salinas, et al., 2006). 
A point of interest is that a greater number of pauses (marked by events with no speed 
during trafficking) were seen in NSC-34 cells than in motor neurons, an observation that is 
likely to reflect a more specialised or robust microtubule network present in motor neurons. 
In order to assess whether 4C tagging of the capsid affected its trafficking abilities, an 
identical study was performed utilizing RV-G-HIV-1 vectors which were labelled with a 
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lipophillic dye (Vybrant DiD) (Figure 5.7). Reinforcing what was observed with the 4C tagged, 
FlAsH labelled RV-G-HIV-1 vectors, DiD labelled vectors behaved in a similar manner to the 
4C vectors in motor neurons. A substantial proportion of the vector particles were 
stationary (Figure 5.7.A *). However, a significant number were able to undergo extensive 
trafficking (Figure 5.7.A, circles, and kymograph B) and some of the distance covered was 
over 100 µm. Analysis of the speed of individual movement movements suggested that the 
particles moved at an average of three distinct distribution (0.6 µm/sec, 1.8 µm/sec and 2.8 
µm/sec). This compares favourably with those observed for 4C tagged, FlAsH labelled RV-G-
HIV-1 vectors both in motor neurons and in NSC-34 cells. 
A comparison of particle speeds between DiD and FlasH labelled vectors (RV-G 
pseudotyped) vectors shows no overall differences (Figure 5.8A). If one looks at moving 
particles only, it would appear more movements occurred with DiD labelled vectors (Figure 
5.8.B). However, this is not very significant and maybe with the margin of error. 
Interestingly, comparison of the speed profile of RV-G trafficking in NSC-34 cells and motor 
neurons suggests that both the modal speed and the number of fast events (>2 µm/sec) is 
greater in motor neurons than in NSC-34 cells. Again, this may be a reflection of a 
specialised, better developed and robust microtubule network present in motor neurons. 
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Figure 5.7: Trafficking in primary motor neurons with lipophillic DiD labelled RV-G HIV-1  
vectors.(A-D) Motor neurons (DIV 3) were incubated with RV-G pseudotyped HIV-1 vectors 
(Vybrant DiD labelled) for 30 mins (MOI 10) before time-lapse confocal imaging.  A) 
Representative image series of trafficking vector particles from movie 3 (Appendix B).  B) 
Kymograph of the same image series.  C) Individual track analysis and D) speed distribution 
analysis of moving particles (>20 µm in one direction, 20 tracks, 458 individual events). 
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Figure 5.8: Comparison of retrograde speed distribution of DiD labelled and FlAsH labelled 
RV-G pseudotyped HIV-1 vectors in motor neurons. Single particle speed distribution was 
compared to see if there was a difference between the retrograde trafficking of 4C tagged, 
FlAsH labelled vectors and the envelope labelled vectors (lipid labelled with DiD). (A) 
Cumulative frequency profile of all movements during the lifetime of the track showing no 
difference. (B) The same tracks when comparing only the moving phases of the particles. 
More fast moving events were seen for the DiD labelled vectors. 
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5.3.6.2 RV-G pseudotying confers retrograde axonal trafficking in EIAV vectors 
Although it is clear that pseudotyping with RV-G can target HIV-1 vectors for retrograde 
transport, it is formally a possibility that this is just a reflection of the backbone of the vector 
it is in.  To test for this possibility, a 4C tag was inserted into the Matrix protein of the EIAV 
viral Gag gene (see Chapter 2- Materials and Methods and Chapter 3- Results).  Vectors 
were then produced and labelled with the biarsenical dye FlAsH as described (see Chapter 2-
Materials and Methods).  These vectors were then added to purified motor neurons grown 
in mass culture in the presence of labelled p75NTR. As with RV-G pseudotyped HIV-1 vectors, 
RV-G pseudotyped EIAV vectors were clearly observed trafficking along the axon and this 
was mostly within endosomal compartments also labelled with the p75NTR (Figure 5.9 A- 
time series, B-kymograph of same data showing motion and co-localisation of vector and 
p75NTR in same compartment). Also, as was observed with HIV-1 vectors, particle track 
analysis (Figure 5.6.C) showed that these vectors were able to undergo extensive long 
distance trafficking in motor neuron axons. In addition, analysis of the speed of individual 
movements suggest that the vector trafficking speeds fell into three distinct distributions 
(slow, intermediate and fast motion) which is very similar to the data obtained with the RV-
G pseudotyped HIV-1 capsid. 
Taken together, the results demonstrate that pseudotyping lentiviral particles with RV-G 
confers retrograde trafficking in motor neuron axons, irrespective of the backbone of the 
viral vector.  Furthermore, this process is mediated by interaction with p75NTR positive 
endosomal compartments which reinforces the immunostaining results of the RV-G vectors 
associating and internalising with their cognate receptors, as was discussed earlier in the 
chapter. In summary, these data explains (by demonstration of long range axonal 
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trafficking) how RV-G pseudotyped lentiviral vectors are able to transduce spinal motor 
neurons even after distal intramuscular application of vectors in vivo as had been reported 
before. (Mazarakis et al., 2001; Mentis et al., 2006).  
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Figure 5.9: Pseudotyping with RV-G targets EIAV vectors for retrograde endosomal 
transport in primary motor neuron cultures.  (A and B) Primary motor neurones were 
plated onto poly-l-ornithine and laminin coated Matek dishes at a density of 50,000 
cells/cm2.  48 hours post seeding, live cell imaging was performed.  Cells were incubated 
with FlAsH labelled RVG-EIAV vectors for 30 minutes with Alexa-647 labelled anti-P75LNGFR 
antibody.  Following incubation, cells were washed and fresh media added.  Dishes were 
then imaged within an environment chamber attached to a Leica SP5 II Confocal 
microscope.  A) Representative time series from movie 4 (Appendix B) showing retrograde 
trafficking of vector particle (red circles, cell body is on the right).  B) The same particle is 
represented in a kymograph (yellow spots).  C) Single vector track analysis showing the 
displacement from the origin of each moving particle (16 tracks).  D) Speed distribution 
analysis of individual particle movements (441 events). 
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5.3.6.3 Compartmentalised motor neuron cultures reveal extensive retrograde transport 
of RV-G pseudotyped HIV-1 vectors 
It is possible that the endocytic trafficking itinerary varies depending upon which part of the 
axon the vector internalizes (e.g. only axon tips allow retrograde transport).  To see if this is 
the case and to unambiguously demonstrate that RV-G pseudotyping does allow retrograde 
trafficking we grew motor neurons in microfluidic chambers (MFC) (Restani et al., 2012).  
These silicone inserts allow culture of motor neurons so that they project axons though 
channels to a second chamber, allowing separation of the soma, axon and axon tip.  Motor 
neurons which projected axons into the axonal compartment were traced by the addition of 
labelled tetanus neurotoxin binding fragment (TeNT-Hc-555) to the axonal compartment 
(Figure 5.10). This probe was internalised at the axonal compartment and retrogradedly 
transported to the motor neuron cell body, where it accumulated, thus labelling the length 
of the cell which had extended axons into the axonal side of the micro fluidic chamber. 
Next, time lapse imaging was done using both RV-G pseudotyped HIV-1 vectors and labelled 
ant-p75NTR which were incubated together for 60 minutes at 37°C, 5% CO2  before imaging. 
The results showed clear, fast retrograde transport of RV-G pseudotyped HIV-1 vectors 
(Figure 5.11.A and B). As was seen in non-compartmentalised mass cultures, these were 
predominantly co-localised with p75NTR (80.25% SD +/- 10%). In addition, RV-G pseudotyped 
HIV-1 trafficking events were more common under these conditions compared with mass 
cultures of motor neurons and were easier to detect (82 particles in 36 channels). This 
would suggest that these trafficking events are not that rare under these conditions and the 
process is in fact quite efficient. Reasons behind such observations could be decreased  
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Figure 5.10: Cultured motor neurons can grow through microfluidics chamber. (A) primary 
motor neurons purified from rat embryonic spinal cord were plated (50,000 cells/chamber) 
and left to grow for 14 days. A large number of cells can be seen in the somatic 
compartment and a few have grown through to the axonal compartment. These can be 
visualised by the addition of TeNT-Hc-555 to the axonal compartment for 45 minutes (right 
panel). The can be seen extending into the microgrooves and labelled tetanus has trafficked 
retrogradedly to the somatic compartment, thereby labelling the cell(s). (B) Schematic 
representation of a of a microfluidic chamber. 
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background in the area of imaging or increased vector concentration at the axon tip. 
Fixed imaging studies involving motor neurons grown in microfluidic chambers were done. 
The RV-G pseudotyped vectors were added and incubated for two hours along with other 
components before fixation and this allowed a more extensive quantification of the 
endosomal pathway utilised for retrograde trafficking. The results show that approximately 
85% of the trafficked vectors co-localised with both the tetanus neurotoxin and the majority 
of these also co-localised with p75NTR (Figure 5.11 C and D). 
5.3.6.4 Retrograde transport of RV-G pseudotyped HIV-1 vectors occurs mostly in pH 
neutral endosomes in compartmentalised motor neuron cultures 
There have been previous demonstrations that tetanus neurotoxin, p75NTR and NCAM 
trafficking in pH neutral endosomes and as we have demonstrated that the RV-G 
pseudotyped lentiviral vectors undergo trafficking with these components, it may be 
hypothesised that this neutral environment prevents viral fusion and escape.  
In order to verify that the endosome pathway used by RV-G pseudotyped HIV-1 vectors is 
also pH neutral, motor neurons were incubated with the pH sensitive dye, lysotracker-DND, 
for two hours to label the acidic compartments, before addition of RV-G pseudotyped HIV-1 
vectors labelled with DiO for two hours. The results show that under these conditions only 
12% of all vector containing compartments were positive for lysotracker suggesting that 
only a small minority trafficked in acidic endosomes. Even when the analysis is restricted to 
vectors that co-localise with p75NTR (endosomal), only 20.74% of vectors can be found in 
acidic endosomes (Figure 3.11 E and F). This data reveal that the RV-G pseudotyped HIV-1 
vectors undergo trafficking using quite rare pH neutral endosomes and this is most likely 
223 
 
through the same pH neutral endosomal pathway previously described for tetanus 
neurotoxin and the p75NTR in motor neurons (Deinhardt, Salinas, et al., 2006). 
5.3.6.5 nAchR undergoes retrograde trafficking in the same pathway as TeNT and RV-G 
HIV-1 vectors in compartmentalised motor neuron cultures 
It has been shown that NCAM also undergoes retrograde transport in the same endosomal 
population as p75NTR (Wade et al., 2012). However, it is not known whether the nAChR also 
undergoes retrograde trafficking, although in fixed imaging studies reported earlier in this 
chapter, it was shown that RV-G pseudotyped HIV-1 vectors do associate and internalise 
with this receptor. Using microfluidic chamber cultures conditions, retrograde transport of 
the labelled antagonist α-Bungarotoxin was observed (Figure 5.12 A and B). Of the total 
endosomes imaged containing α-Bungarotoxin-647, over 50% were also positive for TeNT 
(Figure 5.12 C and D). In addition, 40% of the observed RV-G pseudotyped HIV-1 vectors 
were seen to co-localise with α-Bungarotixin-647. This data suggest that the three distinct 
receptors of RV-G are able to bind to and are able in part to undergo retrograde axonal 
transport, often in the same compartment. 
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Figure 5.11: Retrograde trafficking of RV-G pseudotyped lentiviral vectors in the 
compartmented primary motor neuron cultures. A and B) Primary Motor neurones plated 
in microfluidics chambers (DIV 7) were incubated with RV-G pseudotyped HIV-1 vectors 
(Vybrant DiO labelled) and anti-p75NTR-AF647 for 60 mins in the axonal chamber before 
time-lapse confocal imaging of a region of axon >200 µm from the axonal compartment.  A) 
Representative image series of trafficking vector particles from movie 5 (Appendix B), 
showing RVG pseudotyped HIV1 (i, green in merged image,iii) and p75NTR,(ii, magenta in 
merged image iii).  B) Kymographs of the same image series. (C-D) Motor neurons (DIV 7) 
grown in microfluidics chambers were incubated with DiO labelled RV-G pseudotyped HIV-1 
with TeNT-AF555 and anti-p75NTR-AF647 for 2 hours at 37oC before fixing and imaging by 
confocal microscopy.  Shown are representative maximum projections of Z-stack images (C), 
where white circles show examples of co-localization of vectors with both markers and 
yellow circles show examples of colocalisation with just TeNT-AF555. D) Shows 
quantification of colocalisation (n = 3, 172 particles RV-G pseudotyped DiO labelled vector).  
(E and F) Motor neurons (DIV7) were grown in microfluidics chambers and incubated with 
lysotracker-DND for 2 hours followed by DiO labelled RV-G-HIV-1 and anti-p75NTR-AF647 for 
2 hours at 37 oC before fixing and imaging by confocal microscopy.  Shown is a 
representative maximum projection of Z-stack images (E), where white circles show 
examples of vectors with p75NTR or alone and yellow circles show an example of co-
localization with lysotracker. (F) Shows quantification of co-localization of all vectors or of 
vectors within endosomes either p75NTR and/or lysotracker positive (n = 3, 127 particles, or 
78 particles respectively). Only a very small proportion of vectors are within endosomes of 
acidic pH.  
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Figure 5.12: nAChR undergo retrograde trafficking in the same pathway as TeNT. (A and B) 
Primary motor neurones plated in microfluidics chambers (DIV 7) were incubated with a-
Bungarotoxin-AF-647 (100 ng/l final concentration) for 60 mins in the axonal chamber 
before time-lapse confocal imaging of a region of axon >200 m from the axonal 
compartment.  (A) Image series of trafficking endosomes.  (B) Kymograph of the same image 
series.  (C-D) Motor neurons (DIV 7) grown in microfluidics chambers were incubated with 
DiO labelled RV-G psudotyped HIV-1, TeNT-AF555 and aBungarotoxin-AF-647 for 2 hours 
at 37oC before fixing and imaging by confocal microscopy.  Shown are representative 
maximum projections of Z-stack images (C), where white circles show examples of co-
localization of a-Bungarotoxin-AF-647 with both vector and TeNT-AF555 and red circles 
show examples of co-localization with just TeNT-AF555. (D) Shows quantification of co-
localization (n = 3, 323 a-Bungarotoxin-AF-647 endosomes, 64 RV-G psudotyped DiO 
labelled vectors). 
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5.3 Discussion 
Wide ranging studies in motor neurons have revealed an elegant process by which proteins 
within the extreme section of the axon can undergo trafficking to the soma, a  process first 
identified as a mechanism for allowing extracellular signals at the axon tip to be transmitted 
to the cell body through retrogradedly trafficked signalling endosomes (Ginty, 2002). This 
process has been well characterised for p75NTR and involves trafficking of the receptor 
through Rab5 positive endosomes and accumulation in Rab7 positive endosomes 
(Deinhardt, Salinas, et al., 2006). These endosomes then undergo microtubule mediated 
axonal transport towards the cell soma, in a process driven by microtubule motor myosin Va 
(Lalli, Gschmeissner, & Schiavo, 2003). In addition to p75NTR trafficking, this pathway has 
been shown to mediate the transport of a range of cell adhesion molecule (LgCAM, NCAM) 
(Wade et al., 2012) as well as a number of neurotoxins (i.e. botulinum and tetanus) (Restani 
et al., 2012) and canine adeno virus (CAV) and its receptor CAR (Salinas et al., 2009).The 
work done for this part of the project shows that this axonal trafficking pathway is 
responsible for the retrograde transport of RV-G pseudotyped lentiviral vectors in motor 
neurons. By extension it’s also likely to be applicable to the trafficking of wild type rabies 
virus. 
To infect cells, viruses must first bind to the cell surface and this requires interactions 
between host cell receptors and viral encoded envelope (for enveloped viruses). Binding to 
receptors on the plasma membrane is the first step in viral infection and is usually highly 
specific (Marsh & Helenius, 2006). As was discussed in the previous chapter, three different 
receptors are known to interact with the RV-G, namely p75NTR, NCAM and nAchR. For the 
first time, this project demonstrates the co-internalisation of RV-G pseudotyped lentiviral 
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vectors with its three specific receptors in motor neurons. The fact that following 
internalisation the levels of association remains more or less constant suggests that the 
interaction remains throughout the vectors journey along the axon. Also, as not all the 
internalised vectors are not co-localised 100% with a given receptor at a given time point 
may indicate that that each of these receptors is a co-receptor or that binding to any of 
these receptors puts the vectors in the same axonal pathway. In addition to primary 
receptors critical for virus attachment to cell surface, it is now becoming apparent that 
viruses use a wide variety of co-receptors e.g. chemokine receptors CXCR4 or CCR5 for HIV 
(Freed & Mouland, 2006). This is because, in many cases, the signals from activation of 
primary receptors are not sufficient to stimulate viral entry thus viruses recruit and activate 
co-receptors at the cell surface for internalisation. 
Furthermore, it is the interaction of the RV-G pseudotype with the relevant receptors that 
determines the transport of the lentiviral vector. In the previous chapter, it was shown that 
pseudotyping the HIV-1 vectors with VSV-G completely impaired the ability of the vectors to 
traffic along the axon (Figure 4.8 E and F). In this chapter, it was shown that there is little to 
no interaction between VSV-G pseudotyped vectors and the three cognate receptors of RV-
G (Figure(5.3.E). In addition, RV-G pseudotyped EIAV vectors undergo long distance 
trafficking in a similar manner to RV-G HIV-1 vectors (Figure 5.9). Taken together, this all 
suggests that it is the pseudotype i.e. RV-G that determines the trafficking fate of the vector 
rather than the vector capsid. 
Next, it was shown that uptake of the vectors by the motor neurons is temperature 
sensitive, occurring efficiently at 37°C, by active internalisation processes. This is likely to be 
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through clathrin coated endocytic vesicles which is the major cellular entry pathway for 
many viruses. 
In addition, as was seen in the NSC-34 cell line, the RV-G HIV-1 vectors follow a sequential 
Rab5 to Rab7 endosomal maturation which is further evidence of endocytic trafficking of 
the vectors along the axonal transport pathway.  This characteristic of endosomal 
maturation of Rab proteins is similar to that observed for the tetanus neurotoxin   
(Deinhardt, Salinas, et al., 2006). In addition, work by Klingen et al. show that the rabies 
virus particle is transported inside a vesicle, mediated by surface G protein. The group used 
neuroblastomas infected with double labelled virus particles comprising a red fluorescent 
envelope and a green fluorescent P protein (labelling nucleocapsid), and observations show 
complete enveloped rabies virus particles  transported as cargo inside vesicles by typical 
retrograde transport (Klingen, Conzelmann, & Finke, 2008b). As the G protein is located 
inside the vesicle, it would presumably be unable to interact with microtubules or the 
dynein motors. Therefore, it may require interaction with transmembrane receptor proteins 
which link the vesicle to the transport superhighway, although the precise nature of these 
intermediary molecules for rabies virus containing endosomes are yet unknown. However, 
in HeLa cells, Rab7 effectors RILP and ORP1L can mediate the recruitment of cytoplasmic 
dynein motors to endosomes (Johansson et al., 2007) and it may be the case that RV-G 
pseudotyped lentiviral vectors undergoing this endosome maturation to Rab7 positive 
compartments undergo efficient, long range axonal transport. 
A unique feature of these vector containing Rab7 positive endosomes is that they have a 
luminal pH very close to neutral which is in direct contrast to typical Rab7/late endosomes 
where the luminal pH is considerably more acidic (Bohnert & Schiavo, 2005). It was 
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previously reported by Overly and Hollenbeck that a restricted area of the distal axon (50 
µm-150µm from the growth cone) and axonal branch points are major sites of acidification 
in the progression from endosomes to lysosomes (Overly & Hollenbeck, 1996). Our results 
suggest that whereas endosomes are acidified by the time they reach the proximal section 
of the axon, RV-G pseudotyped lentiviral vector carriers are not. It is plausible that the 
neutral pH is instrumental in the transport of lentiviral vectors through the whole length of 
the axon, since an acidic environment is required for the conformational change in the RV-G 
that mediates fusion of the viral envelope with the endosome membrane allowing 
endosomal escape of the viral capsid (Gaudin, 1999). Therefore, the neutral environment 
prevents endosomal escape, allowing transport of the vector to the soma, where it can 
enter the nucleus and integrate with the genome.  
Like the results obtained in live cell imaging studies with NSC-34 cells, extensive retrograde 
transport of the RV-G pseudotyped lentiviral vectors (both HIV-1 and EIAV) was observed in 
mass motor neuron cultures and these observations were also seen when RV-G HIV-1 
vectors were used in compartmentalised motor neuron cultures. However, it must be noted 
that in mass motor neuron cultures retrograde transport appears to be less efficient in 
terms of particles trafficking and it is difficult to determine if this is a limiting factor in the 
ability of these vectors to transduce efficiently. RV-G pseudotyped vector trafficking events 
were relatively easier to detect in compartmentalised cultures suggesting RV-G 
pseudotyped HIV-1 transport is quite efficient under these experimental conditions. This 
may be due to decreased background of MFC or to the increased concentration of vectors at 
the axonal tip, something that is impossible to do experimentally in mass cultures.  
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 However, in compartmentalised cultures where vectors were added to the axonal segment 
and efficient trafficking was observed, no transduction of the neurons were detected. This is 
similar to data previously observed with the neurotropic VEEV-G pseudotyped HIV-1 vectors 
(Trabalza et al., 2012), which showed retrograde transport in culture but very little 
transduction in vivo. Interestingly, one observes transduction of motor neurons when the 
RV-G pseudotyped HIV-1 vectors are added to the somatic compartment of the 
compartmentalised motor neuron cultures, indicating the use of an alternative transport 
pathway to the nucleus possibly due to the short distance that needs to be traversed from 
periphery of the soma.  This would indicate that specific receptor binding and efficient 
axonal retrograde transport are not the only requirement for transduction of motor neurons 
and other post trafficking factors are important. These are likely to include the ability of the 
envelope to promote fusion when the endosome does reach the soma and the molecular 
processes that allow transport of the capsid to the nucleus. An important point is that the 
wild type rabies virus is able to efficiently escape the endosome and get transported to the 
nucleus. This is in part mediated by a direct interaction between the capsid and the motor 
protein dynein (Moseley et al., 2007; Rasalingam et al., 2005; Raux, Flamand, & Blondel, 
2000), but also suggests that the envelope glycoprotein may not be the only requirement 
for efficient endosomal escape.   
In summary, pseudotyping of both HIV-1 and EIAV lentiviral vectors with RV-G  targets these 
vectors for endocytosis via their three cognate receptors (p75NTR, NCAM and nAchR). It is 
this interaction between the RV-G and it’s receptors that determines whether the vector is 
transported in the axon. Axonal transport occurs through a pH neutral compartment which 
also undergoes Rab5 to Rab7 maturation. Further data in compartmentalised chambers 
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indicates that this process is both rapid and efficient. Therefore, the inefficiency in 
retrograde transduction may reflect post-endosomal transport mechanisms rather than 
ability to undergo transport. The data further demonstrate the importance of this pathway 
for neuronal homeostasis and how viruses and toxins have evolved to make use of this 
unique trafficking route.  
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Chapter 6: Magnetic Pull-down Studies in Motor Neurons 
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6.1 Introduction 
6.1.1 Magnetic Nano Particles and Magnetofection 
Magnetic nanoparticle (MNP) technology describes the utilisation of nanometre sized 
materials and is being incorporated into numerous areas of molecular science and 
biomedicine. As the true potential of gene therapy has been unrealised by low efficiencies 
of viral and non-viral vectors, e.g. specificity, low titres and transduction efficiencies, MNPs 
hold great potential for the field by facilitating targeted delivery of DNA into tissues and 
cells. Often referred to as magnetofection, the principle is based on associating nucleic acids 
or viral vectors with MNPs. These complexes are then concentrated and then transported 
into cells, facilitated by a magnetic field generated from a magnet (see Figure 6.1). As a 
result of their size, they are able to enter almost all areas of the body, including the 
circulatory system, cells and tissues (Kami et al., 2011). In particular, work by Arsianti et al. 
has shown that cells are able to endocytose MNPs and this is done through a clathrin 
mediated mechanism (Arsianti et al., 2010). Furthermore, configuration of the vector-MNP 
complex dictate the vectors intracellular target location and thus efficiency of transfection 
(Arsianti et al., 2010). 
 Slow vector accumulation and consequently low vector concentration at tissues being 
targeted are also major barriers. Gene therapy vectors accumulate in target tissues based 
on their host cell tropisms and on their biophysical properties. Considerable amount of work 
has gone into engineering surface proteins of viral vectors (Kasahara, Dozy, & Kan, 1994)  or 
coupling targeting ligands to viral vectors (Curiel, 1999) to improve tissue selectivity. In 
practise however, these strategies of targeting are often insufficient for rapid and specific 
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accumulation of vectors and therefore achieving the sustained gene expression levels 
required for gene therapy trials. 
 
Figure 6.1: Schematic representation of a magnetic nanoparticle and magnetofection 
procedure. (A) a typical design of a magnetic nanoparticle (adopted from (McBain, Yiu, & 
Dobson, 2008). (B) Magnetofection: MNPs are coupled to lentiviral vectors to form MNP-
vector complexes. Following this, the MNP-vector suspension is added to a monolayer of 
target cells in culture and a magnet is placed underneath the culture dish to generate a 
magnetic field in the vicinity which sediments the MNP-vector complexes. Following a 48-72 
hours incubation period, transduced GFP expressing cells are observed under the 
fluorescence microscope. 
 
A
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Magnetic targeting exploits MNPs as carriers of vectors or drugs and guides their 
accumulation in target tissues with a strong local magnetic field. There are many magnetic 
materials available which have a wide range of magnetic properties. However, many of 
these materials, such as cobalt and chromium are highly toxic to cells and unlikely to be 
used in a biomedical setting without a non-toxic protective coating which has a high 
mechanical strength. On the other hand, iron oxide based materials such as magnetite and 
maghemite are relatively safe and are currently in wide use in the clinic as magnetic 
resonance imaging (MRI) contrast agents. Iron (III) ions are widely found in the human body 
so leaching of metal should not cause significant side effects and as a result iron oxide based 
MNPs are popular. 
The coating of MNPs with natural polymers such as carbohydrates and proteins is common ( 
(McDonald & Watkin, 2006; Nitin et al., 2004) and is necessary for biocompatibility. Many 
natural polymers are biocompatible and hence suitable for coating MNPs for biomedical 
use. As a result of their biocompatibility, carbohydrates are widely used as a coating 
material. In particular, dextran coated MNPs have been used in many biomedical 
applications such as cancer treatment and MRI. The surface coating of the MNPs also 
prevents nano particle agglomeration. MNPs agglomerate readily in aqueous solutions  
around pH7 (Williams et al., 2006), and it is very difficult to fathom the properties and 
amounts of agglomerated MNPs.  
There is also a requirement for surface modification in order for biomolecules to bind to 
MNPs. Even if they bind without surface modification, the interaction between 
biomolecules and the surface of MNPs is likely to be weak which would result in the instant 
release of these molecules during delivery with very little control. Surface modification of 
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MNPs creates strong interactions which enhances the binding process of biomolecules and 
also allows control over the release mechanism. The most common form of surface 
modification is through organic linkers which include amines, aldehydes, thiols and 
carboxylic acid. These linkers provide a wide range of surface properties to suit various 
biomolecules in many conditions. 
There have been a number of studies showing the usefulness of magnetofection. Orlando et 
al. demonstrated magnetofection using lentiviral vector-MNP complexes can facilitate 
efficient vector mediated transduction of airway epithelial cells by lowering the vector 
dosage and incubation time needed to achieve efficient transduction (Orlando et al., 2010). 
In another study, Hoffman et al. showed an enhanced transduction efficiency of endothelial 
cells with lentiviral vectors coupled to MNPs (Hofmann & Wenzel, 2009). Additionally, they 
demonstrated the ability to position these transduced cells, in vivo, at the intima of blood 
vessels under physiological conditions utilizing an external magnet. 
So, what is the mechanism of magnetofection and how are improved transduction 
efficiencies achieved? A study by Huth et. al has indicated that there are probably no 
fundamental mechanistic differences between magnetofection and gene delivery with non-
magnetic vectors (Huth et al., 2004). In this study, the researchers used magnetic and non-
magnetic complexes of plasmid DNA with the transfection reagent poly(ethylene imine) 
(PEI). The conclusion from this study was that the uptake mechanism of magnetic PEI-DNA is 
virtually the same as for standard PEI-DNA. Based on this and other published literature, 
one can conclude that attachment of MNPs to vectors in itself do not facilitate the 
endocytosis of these complexes. Rather, the diffusion barrier which exists for vector 
particles which maybe too small to sediment efficiently by gravitational force is overcome 
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and this leads to an accelerated sedimentation of vector-MNP complexes at the cell surface. 
An increased vector dose at the cell surface results in an increased internalised dose within 
a given period of time, unless the uptake process becomes saturated. This alone can lead to 
improved functional nucleic acid delivery into cells (Plank, Zelphati, & Mykhaylyk, 2011) and 
helps to explain improvements in transfection/transduction efficiencies. 
6.1.2 Magnetic purification of compartments associated with retrograde 
transport 
MNPs have also been utilized to isolate and purify axonal retrograde transport 
compartments (Deinhardt, Salinas, et al., 2006). This group had demonstrated that a 
fragment of tetanus toxin binds to motor neurons with high affinity and is endocytosed by a 
clathrin dependent pathway and is retrogradedly trafficked to the CNS (Deinhardt, 
Berninghausen, et al., 2006). The group successfully pulled down trafficking compartments 
containing MNPs coupled to tetanus toxin and performed proteomics analysis. This 
approach enabled the identification, among other factors, the small GTPase Rab7 as a 
functional marker of a specific pool of axonal retrograde carriers which transport 
neurotrophins and their receptors (Deinhardt, Salinas, et al., 2006). Furthermore, Rab5 is 
essential for an early step in the sorting of tetanus toxin  containing endosomes. 
The rationale behind this part of the project was to utilize the properties of MNPs in order 
to isolate (pull-down) vesicles (whole endosomes) that contain and transport the RV-G 
pseudotyped lentiviral vectors so that the structures and molecules associated with it during 
neuronal trafficking can be identified and characterised by proteomics. This approach 
should enable re-confirmation of some of the findings presented in the previous chapters of 
the project such as co-transport with specific rabies receptors and Rab5 and Rab7 
240 
 
association with vector transporting endosomes. In addition, characterisation of other 
factors identified using magnetic isolation strategy will enable the uncovering of more 
players in the network of interactions linking viral axonal transport and the endocytic 
machinery. This knowledge may enable us to design vectors which are better able to 
overcome barriers to efficient transduction.  In addition, RVG-pseudotyped MNP conjugated 
vectors will also be assessed in terms of whether they give better transduction efficiency in 
motor neurons compared with vectors which are not attached to MNPs, thus opening up 
options for their future use in gene therapy clinical trials.  
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6.2 Results 
6.2.1 Optimisation of magnetofection method 
The initial plan for the project was for paramagnetic beads to be chemically coupled to 
concentrated and purified RV-G pseudotyped HIV-1 vectors.  These vectors will be used to 
“infect” motor neurone cells (NSC-34 cell line and/or primary rat motor neurons).  These 
cells will be disrupted or ‘cracked’, releasing the cytoplasmic vesicles and organelles.  Vector 
associated structures will be pulled down using a powerful magnet.  The resulting samples 
will be analysed by proteomic analysis and compared to similar samples produced from 
beads conjugated to a mutated Sindbis (SinMu) pseudotyped vectors (no affinity to motor 
neurons Eleftheriadou et al submitted). 
We initially optimised the pull-down protocol using MNP (ViroMag R/L) supplied by Oz 
Bioscience, France, which have been optimised to bind to lentiviral vectors and increase 
transduction efficiencies. However, one drawback of using these MNPs was that the 
company declined to disclose the physical and binding properties of these nano particles, so 
we were unable to determine how well the beads bound to the vectors and whether this 
attachment existed once the MNP-vector complex had internalised. Nevertheless, several 
experiments were undertaken to determine their suitability for use in the actual pull-down 
experiment. 
Initially, we attempted to transduce differentiated NSC-34 cells with MNP—RV-G 
pseudotyped HIV-1 vectors. However, we could not get beyond 30% of total cells being 
transduced, as measured by the expression of GFP reporter gene 48 hours post 
transduction. A figure below 50% was unacceptable to us as it meant there was a risk that 
we would end up studying an aberrant trafficking pathway. This figure could not be 
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improved, even when a MOI of 200 was tried. We also carried out some experiments to 
transduce undifferentiated NSC-34 cells but again the transduction efficiencies were 
relatively low. 
 As a result we decided to optimise some of the parameters of transduction in HEK 293T 
cells, which had been relatively easy to transduce before in our hands. Initially we optimised 
the volume of Viromag R/L MNP needed to get optimised binding with a constant MOI of 
10. As Figure 6.2 A and B shows, there was an increase in transduction efficiencies with 
increasing volumes of MNPs. Regardless of the volume of MNPs attached, there was an 
increase compared with no MNPs coupled to lentiviral vectors.  With 8ul of MNPs we were 
able to get past the 50% transduction efficiency which we had set as our threshold figure. 
When varying the MOI in the ranges of 10-50, no significant improvements in the figure of 
transduction was observed (Figure 6.2.C), suggesting the volume of MNPs used was 
insufficient to efficiently form complexes with all the vectors and therefore its effect on 
transduction efficiencies was limited. 
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

Figure 6.2: Transduction efficiencies with variable MNPs9LUR0DJ5/EHDGVRIYDULDEOH
amounts were incubated (30 minutes) with a constant number of RV-G pseudotyped HIV-1 
vectors (MOI) to form MNP-vector complex. The MNP-vector mixture was added to HEK 
293T cells and allowed to incubate for 1 hour at 37°C, 5% CO2 on top of a magnetic plate. 
The magnetic field was then removed and cells incubated for a further 72 hours. (A) 
Fluorescence microscope images (x20 magnification) showing transduction (GFP expression) 
with RV-G pseudotyped HIV-1 vectors. The levels of transduction was quantified by counting 
GFP positive cells in 5 fields of view(B). Transduction using variable MOI and constant MNP 
volume (5 μl) was also quantified (C). 
A
B C
B C 
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6.2.2 Transduction of primary motor neurons with MNP-Vector complexes 
In the next stage, transduction studies were done on primary motor neuron cultures based 
on optimisation studies that were done on HEK 293T cells. This time round RV-G GFP and 
control vector SINmu-GFP (mutated sindbis envelope pseudotyped) attached to MNPs were 
utilized. When DIV2 motor neuron cultures were transduced, transduction efficiencies of up 
to 90% were obtained with vectors coupled to MNPs. The cells were also immunostained 
with anti-NeuN antibody, a reported marker of motor neurons. We see overlap of NeuN 
stain with that of GFP, suggesting that neuronal cells were being transduced with RV-G 
pseudotyped vectors  (Figure 6.3). 
The suitability of SINmu pseudotyped HIV-1 vectors as suitable negative control for 
magnetic pull down experiments was also assessed (Figure 6.4). This was done in terms of 
assessing its tropism and transduction of motor neurons. In these studies primary rat motor 
neurons were transduced with SINmu vectors attached to MNPs. Forty eight hours post 
transduction, these cells were fixed and probed with anti-ChAT antibody. This antibody 
recognises choline acetyl transferase found in cholinergic neurons of the brain and spinal 
cord and therefore regarded as a neuronal marker. This immunostain allowed the 
distinction of neurons from glial cells present in culture. As can be seen from Figure 6.4, 
SINmu pseudotyped HIV-1 vectors are not tranducing motor neurons, characterised by the 
absence of any GFP signal from the ChAT positive motor neurons. The odd transduced, GFP 
positive cell that can be seen in the image are glial cells which had been transduced by 
SINmu GFP vectors and are ChAT negative.  
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 Figure 6.3: Transduction of primary motor neurons with RV-G pseudotyped HIV-1 vectors. 
(A) DIV2 motor neuron cultures were transduced with RV-G pseudotyped HIV-1 vectors 
carrying the GFP genome. The vectors were either attached to Viromag R/L MNP or used 
without any MNPs. 72 hours post transduction, cells were fixed and immunostained O/N 
with mouse anti-NeuN (Milipore). (B)Levels of transduction for both MNP coupled and 
without any MNPs were quantified and expressed as % of cells expressing GFP. 
Magnification of objective x20.   
A
B
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Figure 6.4: Mutant SINmu structure and transduction with SINmu pseudotyped HIV-1 
vectors. (A) The class II fusion protein SINmu was derived from SIN. SIN contains two 
membrane glycoproteins (E1 and E2) and signal peptide E3: E1 for mediating fusion, E2 for 
receptor binding and E3 as a signal sequence for processing of E2 glycoprotein. A 10 residue 
tag sequence (MYPYDVPDYA) was inserted between amino acids 71 and 74 of the E2 
glycoprotein. A series of alterations (a4:deletion of amino acids 61-64 of E3; a5: mutations 
of 68SLKQ71 into 68AAAA71; a6: mutations of 157KE158 into 157AA158) was introduced to 
yield the binding defective and fusion competent SINmu (Yang, Bailey, Baltimore, & Wang, 
2006). (B) Panel of images showing levels of transduction (green) of motor neuron cultures 
with SINmu-HIV-1-GFP vectors 72 hours after vector addition. The cells were 
immunostained with anti-ChAT to label motor neurons (red). Scale bar= 100 μm.  
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6.2.3 Magnetic isolation of axonal retrograde carriers using Viromag R/L 
MNPs 
Once the MNP binding and transduction parameters were optimised, we attempted to pull- 
down carriers of the vectors in primary rat motor neurons. After transducing motor neuron 
cultures with either RV-G or SINmu pseudotyped lentiviral vectors, the cells were disrupted 
using a mechanical cell cracker and the post nuclear supernatant passed through a magnetic 
column under a magnetic field. MNP-Vector containing carriers which bound to the columns 
under a magnetic field were then eluted and analysed through SDS gel electrophoresis and 
colloidal comassie staining as well as Western Blotting. Unfortunately, no significant bands 
were seen in the colloidal commassie stained gel (data not supplied) nor could one see any 
bands on Western Blots probed with Rab5 and Rab7 antibodies (early and late endosomal 
markers which our fixed cell immunostaining studies have shown to be associated with RV-G 
pseudotyped lentiviral vectors). Initially it was assumed that the number of cells that was 
used for the pull down experiment was too low to give significant results. However, 
repeating the experiment with increased number of cells also yielded no significant results. 
It was speculated that one of the main reasons for not pulling down any vector associated 
carriers is the weak coupling of magnetic nanoparticles with vectors which most likely 
dissociates from the complex once the vector is internalised. For this reason, one sees 
increased transduction of primary motor neurons with MNP associated vectors but no 
detectable levels of carriers pulled down. Therefore, alternative ways generating MNP-
vector where the coupling is of a greater magnitude was investigated. One promising 
alternative is described by Weber et al. (Weber et al., 2009). This system uses streptavidin 
which is expressed on the envelope of the lentiviral vector and forms a strong bond with 
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biotin coated MNPs (available commercially). With a view to utilizing this system, many of 
the reagents needed to utilize this systems including the streptavidin expressing plasmids 
was sourced from the Fussenegger group in Switzerland with a view to producing 
streptavidin displaying RV-G pseudotyped vectors and subsequently characterising and 
utilizing them for magnetic pull down study. 
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6.2.4 Production and characterisation of streptavidin displaying lentiviral 
vectors 
Efficient display of streptavidin on lentiviral surface requires two independent vectors 
whose expression units are under the control of the constitutive human elongation factor 
1α promoter (PhEF1α) and terminated by a polyadenylation signal (pA) (Weber et al., 2009) 
The plasmid pWW1051 encodes multi-domain protein consisting of a membrane anchoring 
transmembrane domain (TD) derived from the platelet-derived growth factor receptor 
transmembrane domain (PDGFRTD) as well as a myc-tag which may be used for 
immunodetection, streptavidin (SA) and the signal sequence derived from the murine Igk-
chain V-12-C region (SSIgK) (Weber et al., 2009) (See Figure 6.5). 
pWW1058 encodes a multi domain protein consisting of a HA tag for immunodetection, SA 
and SSIgK . HA, SA and SSIgK is secreted by transfected cells and can homo-multimerise with 
surface displayed SA (See Figure 6.5).   
SA expressing rabies pseudotyped and SINmu vectors were produced using the Olsen 
modified calcium phosphate protocol (see materials and methods). The modification to the 
original protocol was the addition of the two streptavidin plasmids to the mix. Initially, 
vectors were made using plasmid ratios of 1 gag-pol: 2 GFP genome: 1 Rev: 1 RV-G 
envelope: 1 pWW1051: 1 pWW1058.  
The harvested vector particles were concentrated on 20% sucrose cushion. Following this 
lentiviral surface expression of streptavidin was examined on Western blots. Vectors were 
probed with both anti-HA and anti-Myc antibodies to detect the respective tags in the 
expressed streptavidin. However, extremely faint bands for HA and Myc were detected 
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suggesting that surface display of streptavidin was not significant. In order to improve 
surface display, vectors were produced by varying the ratios of streptavidin plasmids in 
relation to gag-pol and then equal p24 amounts of vector blotted on a Western blot (Figure 
6.5.C). 
Differences in band intensity on the Western blot suggested that varying the ratios of the 
streptavidin plasmids does have an effect on the surface display of streptavidin on the 
lentiviral vectors. It was shown that 1 gag-pol to 3 streptavidin plasmids gave the best 
surface display and subsequent productions of the vectors were made using this ratio 
(Figure 6.5 C). 
The next step in the characterisation of these vectors was to show that the surface 
displayed streptavidin is functional i.e. they have the ability to bind biotin coated MNPs and 
internalise into cells. To qualify this RV-G-Streptavidin vectors were mixed with biotin 
coated MNPs at a ratio of 1 transduction unit to 100 femtogram of beads. This mixture was 
incubated at room temperature for 5 minutes and then washed 2x with PBS by 
centrifugation at 13,000 x g to remove unbound vectors. The vector-MNP pellet is then 
resuspended in cell media and was added to differentiated NSC-34 cells and incubated 
under a magnetic field for 30 minutes at 37°C. Following this the cells were washed to 
remove unbound vectors and fixed and stained with anti-gag and anti-biotin (texas red 
conjugated). As the panel of images in Figure 6.6.A shows, the anti-gag and anti-biotin 
signals co-localise within the NSC-34 cells. This suggests that the biotin displayed on the 
surface of the lentiviral vector is functional and is able to bind the MNPs and internalise into 
cells. A point to note is that, the binding to vector was done without optimising the binding 
ratio/protocol and this was done in the next stage.   
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Figure 6.5: Streptavidin expressing RV-G pseudotyped lentiviral vectors. (A) Schematic 
representation of biotin coated magnetic nanoparticle and their binding to  streptavidin 
displaying lentiviral particle. (B) Plasmid map of pWW1051 encoding membrane anchoring 
domain streptavidin and pWW1058 encoding unbound streptavidin. Adopted from (Weber 
et al., 2009). (C) Surface expression of streptavidin on RV-G pseudotyped HIV-1 vectors was 
confirmed by Western Blot. RV-G pseudotyped HIV-1 vectors were produced using a calcium 
phosphate transfection protocol using variable ratios of the streptavidin plasmids to gag. 
Equal p24 amounts of concentrated vectors were put in each lane and blotted with Anti-HA 
antibody. A control was set up by transfecting HEK293 T cells with pWW1058 plasmid and 
Western blotting with Anti-HA antibody.  
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The next stage of characterisation involved optimising and quantifying lentiviral vector 
association with MNPs. This was done using a sedimentation assay. This involved mixing RV-
G pseudotyped streptavidin lentivectors with MNPs in an eppendorf tube in a final volume 
of 300ul. Various ratios of lentiviral vector to MNP was tried including  0, 500, 5000, 10000 
fg of MNP for 1 TU of vector and complexes were allowed to form for 30 minutes at room 
temperature. The sample was loaded onto a 96 well plate and allowed to sediment for 30 
minutes by putting on a magnetic plate. Then, very carefully, 100ul of the supernatant was 
removed from each well and a measurement of viral nucleic acid was done using the 
QuickTiter Lentivirus Quantitation Kit (Cell Biolabs #VPK-112). This, in theory, should give a 
measurement of unbound vectors and thus allow us to determine the best Vector to MNP 
ratio for efficient binding. As can be seen from the graph in figure 6.6.B, vector alone 
without beads yielded 6000 ng of lentiviral RNA. Then with 100 fg of beads there was a 
significant reduction in free viral RNA, suggesting that vectors had bound the biotin coated 
MNP and had been sedimented. However, with increased concentration MNP (1,000 and 
10,000 fg), there were no significant improvements in vector binding compared with the no 
MNP control. This is probably due to a saturation of MNP’s in binding suspension whereby 
they aggregated and lost their ability to bind efficiently.  
In order to determine if the streptavidin-lentiviral vector-MNP complexes are capable for 
transducing primary motor neuron cells, a transduction experiment was carried out. Again, 
vector concentration was kept constant and was bound with variable amounts of MNP’s. 
The vector-MNP complex was then placed on primary motor neurons grown in a chambered 
slide which was in turn put under a magnetic field. The vectors were allowed to internalise 
for 1 hour followed by 2X PBS washes and replacement with complete media. Transduction 
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was allowed to proceed for 48 hours followed by fixation and immunostaining with the 
neuronal marker ChAT and mounting in DAPI containing Mowiol. Images of cells were 
captured on a confocal microscope. It can be seen from figure 6.7.A that cells transduced 
with the vectors also express ChAT indicating the transduction of motor neurons. Cells 
expressing GFP were counted in 10 fields of view and its proportion in relation to total cells 
worked out (Figure 6.7.B). It can be seen from the graph that vectors without coupling to 
beads, approximately 15% of the cells express visible GFP and this rises to 25% when 
coupled with MNP (MOI 5). With increases in MOI, there is a corresponding increase in 
levels of transduction. MNP coupled vectors always yielded a higher levels of transduction 
with 50% transduction level reached with a MOI of 25 and it was decided this figure would 
be used in the pull-down experiments. 
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Figure 6.6: RV-G pseudotyped streptavidin vectors display functional streptavidin with 
ability to bind biotin. (A) RV-G vectors were coupled with biotin coated MNPs and the 
complexes incubated with differentiated NSC-34 motor neuron like cells in order for them to 
internalise. Unbound vectors were washed off and the cells fixed and dual stained with anti-
biotin and anti-gag. Image is representative and shows the co-localisation of vector and 
MNP stain within cells. (B) Sedimentation assay results demonstrating the association of RV-
G streptavidin vectors with MNPs (n=1).  
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Figure 6.7: Transduction of primary motor neurons with streptavidin displaying RV-G 
pseudotyped HIV-1-GFP vectors bound to biotin coated MNPs. (A) DIV 2 motor neurons 
were incubated with vector-MNP complex for 1 hour at 37°C above a magnetic plate. 
Following this, unbound vectors were washed off and cells incubated for 2 days. After this, 
cells were fixed with 4% PFA, stained with the neuronal marker ChAT at an antibody dilution 
of 1:250 for 1 hour at 37 °C and secondary antibody Alexa 594 at a dilution of 1:1000.(B) 
Quantification of transduction at different MOIs expressed as a percentage of total cells 
along with tabulation of data. Identical experiments were set up for both vectors bound to 
MNPs and vectors not coupled to MNPs. 
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6.2.5 Isolation of axonal carriers by magnetic pull-down of streptavidin 
displaying RV-G-HIV-1 conjugated to MNPs 
To further characterise the axonal carriers of RV-G pseudotyped lentiviral vectors 
proteomically, a purification protocol was used which was based on streptavidin displaying 
RV-G pseudotyped HIV-1 vectors coupled to biotin coated MNPs. Spinal cord motor neuron 
cultures (2 days in vitro-Div2) which were originally seeded at a density of 1.2 x 107 
cells/10cm tissue culture dish, were incubated with strepavidin-RV-G-vector-MNP or 
streptavidin-SINmu-vector-MNP complexes. Following incubation, the cells were 
mechanically disrupted in detergent free medium and the resulting extracts passed through 
a magnetised column in a magnetic field device (SuperMACS II, Miltenyi Bioscience, France). 
The proteins recovered with either of the two vector complexes were TCA precipitated and 
then analysed by SDS-PAGE and Western Blot.  
When the two colloidal commassie stained gels were compared, one could identify 10 
specific bands on the pull-down gel for streptavidin-RV-G-vector-MNP (See Figure 6.7.A). 
There was only 1 significant band visible in the streptavidin-SINmu-vector-MNP gel around 
the 60kDa molecular weight which was also present in the streptavidin-RV-G-MNP gel and 
was most likely to be background protein (see Figure 6.8 A and B). The other bands visible 
on the RV-G gel appears to be unique as they were absent in the SINmu gel. The lane 
containing the bands (endosomal elute) was cut out in equal segments (as there was a risk 
that one would miss relatively lower abundance proteins not detected by commassie if only 
visible bands were cut). The segments were then peptide mass finger printed by MALDI TOF-
TOF which enabled the identification of 16 unique protein sequences enabling identification 
of proteins from SwissProt database (Table 6.1). These proteins were absent from the 
258 
 
control gel of SINmu vectors which only yielded some background proteins such as keratins 
(61 kDA). The proteins identified by this approach maybe classified into three functional 
classes: (1) vesicular transport/cytoskeleton (2) signalling (3) chaperone/translocation. 
Although there are reports that many of the proteins pulled down with the RV-G vectors  
play a role in cellular traffic in non-neuronal cells, they are also likely to play a role in axonal 
transport by virtue of their functions in other systems. 
In addition, an attempt was made to verify some of the peptide mass fingerprinting 
candidates by Western Blotting. However, although one could detect the lentiviral vectors in 
the purified vector-MNP (data not presented) we were unable to detect proteins such as 
Rab5 and Rab7 by this method. 
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Figure 6.8: Proteins associated with vector-MNP carriers purified by magnetic pull-down.  
MNPs coupled with (A) streptavidin-RV-G pseudotyped HIV-1 vectors or (B) streptavidin-RV-
G-SINmu vectors (MOI 25) were incubated with 1.2x107 motor neurons (DIV 5) isolated from 
12 rat embryos. Detergent free MN extracts were used for the magnetic pull-down and 
precipitated proteins were separated by gradient SDS-NuPAGE (4%-12%; Invitrogen). 
Proteins were stained with colloidal commassie and bands cut out as indicated. Protein 
bands were analysed by mass peptide fingerprint using a MALDI TOF-TOF analyser. 
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Classical Function Name Gel Segment Reported Roles 
in Cellular 
Trafficking 
Vesicle 
transport/Cytoskeleton  
Actin RVG5  
Tubulin RVG5  
Chaperone/ 
Translocation 
Heat Shock Protein 
(HSP 90 alpha) 
RVG3 (Zheng et al., 2010) 
Heat Shock Protein 
(HSP 90 beta) 
RVG3 (Zheng et al., 2010) 
Heat Shock Cognate 
(HSP 70) 
RVG7  
Signalling/Regulation E3 ubiquitin protein 
ligase RNF181 
RVG4 (d’Azzo, 
Bongiovanni, & 
Nastasi, 2005) 
RNA Binding Protein 
44 
RVG4 (Blackham & 
McGarvey, 2013) 
14-3-3 Protein 
Epsilon 
RVG6 (S. Sun, Wong, Li, 
Lee, & Cheng, 2009) 
14-3-3 Protein Zeta RVG6 (S. Sun et al., 2009) 
GAPDH 
glyceraldehyde-3-
phosphate 
dehydrogenase 
RVG6 (Tisdale, Kelly, & 
Artalejo, 2004) 
ADP ribosylation RVG8 (Memon, 2004) 
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factor 1 (Arf1) 
Multitasking/ Non-
specific 
  
Heterogeneous 
Nuclear Riboprotein 
A 
RVG6 (He, Brown, 
Rothnagel, 
Saunders, & Smith, 
2005) 
Malate  
dehydrogenase, 
mitochondrial 
RVG6  
Dihydropyrimidinase 
related protein 2 
RVG7  
Peptidyl-prolyl cis-
trans isomerase A 
RVG8  
Histone H2A type 1C RVG8  
 
Table 6.1: Proteomic analysis of  streptavidin RV-G-HIV-1 carriers purified by magnetic 
pull-down. Summary of results after magnetic pull-down of carriers followed and 
subsequent gel segment analysis by MALDI TOF-TOF. The control SINmu gel, handled and 
analysed in an identical way, yielded no significant proteins (with the exception of some 
background keratin proteins).   
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6.3 Discussion 
There have been few reported attempts to purify axonal retrograde transport 
compartments. Using a novel methodology, this study demonstrates the advantages of 
using MNP technology for enhancing viral vector internalisation and transduction as well as 
enabling the isolation of transport compartments using the pull down approach. 
There have been a number of studies which have shown the multiple uses of MNP 
technology in biomedical research. In particular, Fukushima et al. demonstrated the ability 
to enhance transfection by binding plasmids with MNPs (Fukushima et al., 2007), while 
others have used magnetism to grow multiple layers of cell sheets by magnetic cell 
accumulation (Akiyama et al., 2010) as well as to capture and transduce target cells by the 
method of magselectofection (Sanchez-Antequera et al., 2011). There have also been 
attempts to improve the transduction efficiency of non-dividing cells, such as airway 
epithelium, with lentiviral vectors attached to MNPs (Orlando et al., 2010). This study 
demonstrated improved transduction efficiency of up to 3.9 fold with a MOI of 50, levels 
that are seen for lentiviral vector only when an MOI of 200 is used (Orlando et al., 2010) and 
crucially there was an absence of cell toxicity. Our results have confirmed this improvement 
in transduction efficiency both in HEK293T cells (Figure 6.2) and in primary motor neurons 
(Figure 6.7) with two different types of MNPs. In addition we did not observe any outward 
signs of cellular toxicity such as increased cell death, therefore further validating the 
usefulness of this technology. 
The efficiency of transduction of cell cultures achieved with lentiviral vectors is primarily 
limited by diffusion dependent cell attachment of the vector (Haim, Steiner, & Panet, 2005). 
A major boundary in gene transfer is the distance between the viral particle in suspension 
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and the target cell (Chuck, Clarke, & Palsson, 1996) since the subsequent binding to the cell 
surface is essential for viral infection. Attaching viral vectors to MNPs provides a route to 
overcoming the diffusion barrier so that the adsorption step is enhanced by the magnetic 
pull so as to improve gene delivery (Scherer et al., 2002; Kadota et al., 2005; Krötz et al., 
2003).   
The aim of the project was not only to show better transduction efficiencies through the use 
of lentiviral vector-MNP but also to use this system to purify the vesicles containing  these 
complexes during axonal trafficking with the aid of magnetic columns. Previously, Deinhardt 
et al. had used a similar method to characterise the axonal retrograde transport of tetanus 
neurotoxin (TeNT) by binding the protein to MNPs (Deinhardt, Salinas, et al., 2006). We 
aimed to adopt this protocol for RV-G pseudotyped lentiviral vectors. However, it was 
realised that the MNPs they were using and the preparation to bind protein (including 
ultracentrifugation at 265,000 x g) would be unsuitable for lentiviral vectors and risked 
damaging them. With this in mind, we sourced an alternative MNP system called ViroMag 
R/L (Oz Biosciences, France). According to the manufacturer’s instruction, the vector and 
MNP formed a complex just by mixing them and it yielded improved transduction 
efficiencies in our hands. However, when the actual pull down experiment was performed 
and the pull down elute was analysed by SDS PAGE and Western blotting, no proteins were 
detected. We speculated that there was inefficient coupling of the MNPs to the viral 
vectors. This would explain the increased transduction efficiency as vectors were better 
internalised, but within the cell the complex uncoupled and therefore the vectors associated 
with transport could not be isolated by magnetism. This issue could have been dealt with by 
quantifying the best ratio of viral vector to MNP in order to optimise complex formation, for 
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example using a sedimentation assay (Sanchez-Antequera et al., 2011). However, the 
company supplying the reagent wasn’t forthcoming with basic particle information such as 
its mass as they said it was a ‘commercial secret’. It was also speculated that the oxidation 
of the MNPs could be a limitation when incubating them with the viral vectors, since 
oxidation status influences the interaction of the iron MNPs and could cause their 
aggregation.  
In order to overcome these barriers, we set about looking for an alternative MNP system. A 
novel approach used by Weber et al. involved expressing streptavidin on the surface of 
lentiviral vectors and these were used to bind biotin coated MNPs. This type of system 
would overcome the weak interactions between vector and MNP as the conjugation 
between streptavidin and biotin is one of the strongest in nature.  
Once the streptavidin displaying RV-G HIV-1 vectors were produced by the calcium 
phosphate co-transfection method, we set about characterising and optimising its 
interactions with MNPs. This time, the MNPs were biotin coated and sourced from a 
different company (Kisker, Germany) who were willing to divulge the specific details 
regarding the beads. This helped great deal in optimising vector binding conditions in 
relation to MNPs. 
First of all, surface expression of streptavidin on RV-G pseudotyped HIV-1 vectors was 
confirmed by Western blot which showed that a 1 gag to 3 streptavidin plasmid ratio 
produced the best expression of streptavidin on the surface. Next, we assessed the ability of 
this surface streptavidin to bind biotin coated MNPs by sedimentation assay (Figure 6.6B) 
which demonstrated that a ratio of 100 fg of MNPs per transducing unit of lentiviral vector 
produced the best association among the ratios tried. It is important to establish a specific 
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MNP: virus ratio since a major limitation of magnetofection is the residual presence of small 
amounts of MNPs following infection (Sacha & Watkins, 2010). This excess MNPs might 
interfere with cell viability by interacting with unspecific sites of the cell surface and 
blocking receptors that vectors need to attach to enter the cell. Of course, at the other 
extreme not enough MNPs may reduce the chances of all the vectors being magnetised, 
thereby reducing the potential of magnetofection. 
Once we confirmed that the streptavidin displaying vectors expressed functional 
streptavidin with the ability to bind biotin coated MNPs, we demonstrated the enhanced 
ability of this system to transduce primary motor neurons (Figure 6.7). It was important to 
determine the lowest MOI which produced at least 50 % transduction efficiency as lower 
levels of transduction may suggest we were following an aberrant trafficking pathway. 
Furthermore, depending on the amount of virus used, magnetofection could result in super-
physiological amounts of virus entering target cells thereby severely disrupting cell 
physiology. Dienhardt et al. had shown that TeNT-MNP beads were transported in a 
retrograde fashion along the axon, indicating that TeNT-MNP are targeted to tubulo-
vesicular organelles in the  spinal cord MNs (Deinhardt, Salinas, et al., 2006). Although we 
are using a neurotropic vector in our studies and not a toxin, the increased transduction 
efficiency we see is also suggestive that the RV-G-MNP vector complexes are also targeted 
to the tubuo-vesicular organelles for retrograde transport leading  to  transduction.  
Once, the vector-MNP complex formation and transduction was optimised, they were 
utilized in pull down studies. Briefly, we incubated primary motor neurons with either 
streptavidin-RV-G-HIV-1 or streptavidin-SINmu-HIV-1 vectors under a magnetic field before 
‘cracking’ the cells and purifying the endosomal elute in a magnetic column. We 
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endeavoured to use as many motor neurons as was physically possible to isolate in our 
laboratory as our collaborators in the Schiavo group (CRUK), who have vast experience of 
isolating tetanus toxin transporting compartments,  had informed us that a figure less than 
1.2 x 107 cells resulted in undetectable pull-down proteins. We used this figure for our pull 
down. In our studies, the vectors were allowed to traffic for 45 minutes after binding, a 
figure which is based on our Rab to Rab7 maturation data and at a time point when the 
significant number of vectors should be in the long range axonal pathway (as Rab7 
association peaks around this time). Our collaborators in the Schiavo group (CRUK), incubate 
their magnetised tetanus toxin for 60 minutes with MNs, which is the time point where they 
see most Tetanus-Rab7 association (28% of double positive structure) (Deinhardt, Salinas, et 
al., 2006).  
Following the pull-down we SDS PAGE separated the endosomal elute and visualised the 
proteins with colloidal commassie stain. Encouragingly, a number of protein bands were 
detected on the RV-G pseudotyped HIV-1 vector gel which were absent in the control SINmu 
pull-down gel (Figure 6.8). Segments of the RV-G gel and the corresponding SINmu 
segments were excised from the gel and sent for analysis by peptide mass fingerprinting. 
Looking at the proteins pulled down with the vectors presented in Table 6.1, one could see a 
range of proteins which were not detected in the control SINmu extracted samples 
suggesting the magnetic pull-down had worked and the proteins are likely to have been 
associated with the compartment enclosing the streptavidin-RV-G pseudotyped HIV-1 
vector. Peptide mass fingerprinting analysis of gel segments from the SINmu gel only yielded 
keratins which are likely to be background proteins. 
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Analysing the 16 pull-down proteins further, one is broadly able to group them into three 
main groups based on their reported classical functions: (1) vesicle transport/cytoskeleton, 
(2) chaperone/translocation and (3) signalling as well as proteins with other functions. Actin 
and Tubulin were identified which form the cytoskeleton and therefore not surprising that 
they associated with trafficking endosomes.  
In addition, we also pulled down Heat shock protein (HSP) 90 and heat shock cognate 71 
kDa protein, both members of the heat shock family of proteins which classically functions 
as molecular chaperones that controls the activity, turnover and trafficking of many 
proteins. However, a recent publication has highlighted a role for HSP 90 in hepatitis E virus 
(HEV) capsid trafficking (Zheng et al., 2010). In this study, geldanamycin (GA), a HSP 90 
specific inhibitor, blocked intracellular transportation of HEV but had no effect its binding 
and cellular entry suggesting that HSP 90 is important for HEV capsid intracellular transport. 
Other proteins of interest pulled down include GAPDH which has been reported to interact 
with Rab2 for membrane transport between endoplasmic reticulum and the Golgi complex 
(Tisdale et al., 2004). In addition, E3 ubiquitin ligase has been reported to be a regulator of 
membrane protein degradation and trafficking (d’Azzo et al., 2005).  
In a similar study with TeNT-MNP Deinhardt et al had magnetically isolated and identified a 
number of proteins involved in vesicular transport including the specific recruitment of Rab7 
to TeNT-MNP carriers. In addition, p75NTR and endogenous TrkB were also  associated with 
the carriers, confirming the notion that TeNT enters the neurotrophin receptor route 
(Deinhardt, Salinas, et al., 2006). This further backs up the data we obtained from trafficking 
of RV-G pseudotyped vectors in MNs (Chapter 5) where we see trafficking of these vectors 
with p75NTR and is indicative of the vectors sharing the neurotrophin receptor trafficking 
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route.  In another similar study using TeNT-MNP particles, Wade et al. have isolated and 
purified NCAM, leukocyte cell adhesion molecule (LCAM) as well as CAR and junction 
plakoglobin associated in the same carrier as the toxin (Wade et al., 2012). 
However, in this pull-down study we were unable to detect some of the proteins we have 
identified as trafficking partners of RV-G pseudotyped vectors, such as Rab5 and Rab7. We 
speculate that this was due to low levels of protein samples being loaded for purification on 
the magnetic column and therefore they didn’t reach detection level by colloidal commassie 
stain or peptide mass fingerprinting. A major handicap has been the total number of motor 
neurons we can isolate in the laboratory on a given day. Use of a larger number of motor 
neurons in the pull down would enable more material to be put through the column and 
therefore better chance of detection. With this in mind the laboratory is now moving 
towards using embryonic stem (ES) cells to generate a far greater number of ES cell derived 
motor neurons for future pull down studies.  
In conclusion, this study has characterised and optimised the use of magnetofection to 
magnetise lentiviral vectors. In particular, streptavidin displaying, RV-G pseudotyped HIV-1 
vectors were produced and assessed for coupling to MNPs and increasing transduction 
efficiencies in primary motor neurons. We have undertaken pull-down experiments with 
such MNP-vector complex from which proteomics analysis has identified a number of 
proteins which potentially traffics with RV-G pseudotyped HIV-1 vectors. 
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7.1 General Discussion 
The delivery of therapeutics and genes to the central nervous system to treat motor neuron 
diseases poses a major challenge mainly due to the presence of the blood brain barrier 
which restricts the penetration of conventional drugs to the desired target cells. Gene 
therapy continues to be an attractive option for the treatment of MNDs such as ALS and 
SMA, which are as yet, incurable. In particular, gene therapy approaches using lentiviral 
vectors offer a strategy to deliver therapeutic genes to enhance motor neuron survival. 
Long term stable expression of therapeutic gene is essential for successful gene therapy. 
Gene expression after transduction with lentiviral vectors have been reported for up to 16 
months (Kordower et al., 2000; Waddington et al., 2003) and animals made transgenic with 
lentiviral vectors, maintain expression without silencing (Lois, Hong, Pease, Brown, & 
Baltimore, 2002; Whitelaw et al., 2004). Many types of therapeutic genes are being 
evaluated including trophic factors and enzymes, as well as intrabodies and siRNA targeted 
to defective intracellular proteins and genes.  
The versatility of lentiviral vectors can be further increased by pseudotyping these vectors 
with specific viral glycoproteins which allows their targeting to specific cell populations 
(James Cronin, Xian-Yang Zhang, 2005; L.-F. Wong et al., 2006). In particular, pseudotying 
vectors with the glycoprotein from rabies virus generates vectors that are more neurotropic 
and allows them to transduce neurons even when delivered to sites distal to the cell body 
(retrograde transduction). This development makes RV-G pseudotyped vectors an attractive 
vector for use in the gene therapy of motor neuron diseases, since vectors can be delivered 
to motor neurons simply by intramuscular injection, without the requirement for invasive 
intraspinal injections (Mazarakis et al., 2001). 
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However, despite these successes, experiments thus far with rabies-G pseudotyped vectors 
in non-human primates have failed to give the necessary efficiency of transduction of motor 
neurons so as to be able to proceed to the clinic for the treatment of motor neuron 
diseases. Currently, the molecular pathway of retrograde transport of the rabies-G 
pseudotyped lentiviral vectors remain uncharacterised. Therefore, this project aimed to 
investigate the mechanism of retrograde transport, including barriers to efficient 
transduction, with the view to further improve the transduction efficiency of these vectors. 
The first stage of the project was to generate biologically active tagged/labelled lentiviral 
vectors. Previous reports had indicated that the insertion of relatively large tags such as 
eGFP (27 kDa) into the viral capsid has resulted in significantly reduced vector production 
(Müller et al., 2004). Therefore, a new strategy needed to be devised to visualise viral 
vectors in live cells. This project utilised a number of labelling techniques to visualise vector 
trafficking.   Labelling of the vector envelope with lipophilic dye allowed highly efficient 
labelling of viral vectors with comparable biological titres to unlabelled vectors. In addition, 
components of the viral capsid itself were also tagged using the small tetracysteine tag and 
labelling the tagged component during vector production with the biarsenical dye FlAsH.  
The relatively small size of the tetracysteine tag was predicted to have minimal disruptive 
effects on protein function therefore no or minimal impact on the biological activity of the 
vector. Tetracysteine tag insertion sites were carefully selected on the structural proteins 
encoded by the gag gene.  However, even with this relatively small addition, the tagging of 
the capsid led to hugely reduced  biological titre except with the tag in the matrix protein.  
This would suggest that the stability of the highly ordered capsid lattice might be 
compromised by the TC tag.  
272 
 
Insertion of the tag to the matrix protein in both HIV-1 and EIAV particles and subsequent 
labelling with FlAsH during vector production gave similar biological titres to that seen with 
wild type (untagged) vectors. This is very crucial as one of the concerns when performing  
trafficking studies with tagged vectors by live cell fluorescence microscopy is whether the 
particle being tracked is infectious and whether the intracellular trafficking observed is 
representative of the transduction pathway. Therefore, by generating and using labelled 
vectors of similar titre to the wild type, the project was able to address these concerns. It 
was found that labelling with biarsenical dye must be done during production, most likely 
because the label is incorporated after the protein is translated and then the labelled 
protein is incorporated into biologically active particles during virus assembly. 
 Furthermore, by labelling the vectors during production the requirement for high 
concentrations of reducing agents during labelling was avoided. In addition, by 
ultracentrifuging the vectors through a sucrose cushion, it was found that non-specifically 
labelled cellular debris and excess dye was efficiently removed leading to substantial 
reduction in background fluorescence.   
There have been extensive studies in motor neurons has revealed an elegant process by 
which proteins within the extreme distal portion of the axon can undergo retrograde 
trafficking to the soma, a process first identified as a mechanism for allowing extracellular 
signals at the axon tip to be transmitted to the cell body through these retrogradely 
trafficked signalling endosomes (Ginty, 2002). Axonal transport has been described for a 
small number of viruses including, rabies, herpes simplex virus 1 (HSV-1) and polio virus. 
Different mechanisms of axonal transport have been described, most notably direct 
interaction of with molecular motors for HSV-1 (Smith et al. 2004) versus endosomal 
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trafficking of polio virus (Mueller, Wimmer, & Cello, 2005). In addition trafficking 
mechanisms have been well characterised for the p75NTR and as with many endosomal 
processes involves the trafficking of the receptor through Rab5 positive endosomes and 
accumulation in Rab7 positive endosomes (Deinhardt, Salinas, et al., 2006).  The nature of 
this clathrin mediated endosomal transport is retrograde and relies on the  microtubule 
network in process driven by the microtubule motor myosin Va (Lalli et al., 2003).  This 
pathway has been shown to mediate the transport of numerous cell adhesion molecules 
(LgCAM, NCAM) (Wade et al., 2012), as well as a number of neurotoxins (i.e. botulinum, 
tetanus) (Restani et al., 2012), and the Canine Adeno Virus (CAV) and its receptor Canine 
Adenovirus Receptor (CAR) (Salinas et al., 2009). This project has demonstrated that this 
axonal trafficking pathway is responsible for the retrograde transport of RV-G pseudotyped 
lentiviral vectors. 
This project has demonstrated, for the first time, co-internalisation of RV-G pseudotyped 
lentiviral vectors with three specific receptor, namely  p75NTR, NCAM and nActhR, both in 
NSC-34 cell line and primary motor neurons and the level of association remains steady 
suggesting that the interaction remains throughout axonal trafficking of the vector.  
Conversion from early to late endosome (Rab5 to Rab7) is emerging as an important 
mechanism for cargo progression. Two models have been proposed whereby Rab7 is 
targeted to endosomal structures during endocytic maturation either in presence of Rab5 
(Vonderheit & Helenius, 2005) or when Rab5 dissociates from these compartments (Rink et 
al., 2005). Whether the recruitment of Rab7 is part of an automatic process of early 
endosome maturation or whether it depends on the presence of specific cargo remains to 
be determined. Interestingly, the project has shown that when the same lentiviral vector is 
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pseudotyped with VSV-G, there is considerably less Rab5 and Rab7 association, with the 
latter being almost at background level. First of all, this shows that it is the viral glycoprotein 
and not the capsid which determines whether the vector is sorted into a long range 
trafficking compartment and by virtue Rab5 to Rab7 maturation. In contrast, the VSV-G 
pseudotype sorts the vectors into a different compartment, unable to undergo long distance 
retrograde transport which explains their inability to transduce neurons in vivo (Mazarakis 
et al., 2001). It has also been reported that wildtype VSV traffics only through the early 
(Rab5 positive) endosome (Sieczkarski & Whittaker, 2003), which again suggests that it uses 
an alternative pathway and is perhaps evidence that the particle can fuse out of the 
endocytic pathway at an early stage. However, in the case of neurons, this is likely to be 
detrimental in the vectors effort to travel to the soma. 
In contrast to the classical clathrin mediated endocytosis pathway where there is a shift in 
luminal pH to form neutral to acidic pH in the Rab7 positive/late endosomes, the project has 
shown that the vector carrying endosomes are pH neutral. In fact acidic pH triggers a 
conformational change of RV-G that mediates fusion of the viral envelope with the 
endosome membrane allowing endosomal escape of the viral capsid (Gaudin, 1999). The 
lack of acidification of the fast retrograde transport carriers contributes to the low 
degradative capability of this compartment and ensures that the vector reaches the soma of 
the neuron. Several pathogens and toxins have been shown to either transit or accumulate 
in non-acidic cellular compartments including tetanus toxin (Bohnert & Schiavo, 2005) and 
canine adenovirus serotype 2 (CAV2) (Salinas et al., 2009). In addition, Bohnert et al. 
reported stationary tetanus toxin carrying compartments which are distributed in the soma 
and neurites have a much broader pH range spanning from pH 5.0- 7.5 (Bohnert & Schiavo, 
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2005). This would indicate that the machinery determining intraluminal pH of these axonal 
compartments is strictly regulated and co-ordinated to the activity of motor complexes 
responsible for their retrograde movement (Gunawardena & Goldstein, 2004). The 
mechanistic basis of this lack of acidification has been suggested to be due to the absence of 
(H+) vATPase from the retrograde carriers and not to an altered proton permeability of their 
membrane bilayer (Bohnert & Schiavo, 2005). 
Live cell studies in this project has shown that both HIV-1 and EIAV vectors pseudotyped 
with RV-G has the ability to undergo fast axonal transport with retrograde speeds of over 1 
µm/s. The regulation of this fast transport is still poorly understood in terms of how 
vesicular cargo co-ordinates the recruitment of microtubule dependent molecular motors 
such as cytoplasmic dynein. It may be envisaged that the internalised cargo, via its 
interaction with specific integral membrane proteins, dictates the directionality of transport 
(Salinas et al., 2009). There may exist discrete sorting steps during internalisation or en 
route to endosome maturation, which alter the ability of transported endosomes to recruit 
or activate  retrograde and/or anterograde motor complexes. A way to achieve this maybe 
through the recruitment of specific adapter proteins able to co-ordinate motor complex 
activity, as was shown in the case of huntingtin, which controls the directionality of vesicular 
carriers in cortical neurons via an Akt-dependent phosphorylation switch (Colin et al., 2008). 
In this regards, RV-G vector containing endosomes could represent an ideal tool to address 
this issue. 
Although, RV-G pseudotyped lentiviral vectors undergo long range axonal transport in both 
mass and compartmentalised cultures, it was difficult to transduce motor neurons under 
these conditions. This indicates that targeting for efficient retrograde transport which 
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enables the vector to reach the soma is not the only requirement for transduction of motor 
neurons and other post trafficking factors are important. Although, the pH neutral 
compartment enabled the vector to reach the soma, being in it at this stage has hampered 
the ability of RV-G envelope to promote fusion. In addition, there may be other barriers in 
the molecular process that allow the transport of the escaped capsid to the nucleus. A 
tantalising question is why is the wild type rabies virus able to efficiently escape the 
endosome and get transported to the nucleus? First of all, the wildtype rabies virus has 
been reported to bind the nicotinic acetyl choline receptor in the post synaptic membrane 
at the neuromuscular junction which concentrates the virus at the NMJ (Lentz et al., 1983; 
Schnell et al., 2010) and through replication  probably results in a much higher 
concentration (MOI) internalising through neurons which in turn means more particles 
traffic and reach the soma and escape so that a more efficient infection can occur. Secondly, 
the wild type rabies escape from the endosome is partly mediated by a direct interaction 
between the capsid and the motor protein dynein (Moseley et al., 2007; Rasalingam et al., 
2005) but also suggests that the envelope glycoprotein may not be the only requirement for 
efficient endosomal escape and other fusogenic factors may be present in the wildtype 
envelope which facilitates the capsid escape.  
7.2 Summary of conclusions 
The studies presented in this thesis have demonstrated that the RV-G pseudotyped vectors 
bind and internalise through the three cognate rabies recptors. Pseudotyping of both EIAV 
and HIV-1 lentiviral vectors with the rabies virus glycoprotein targets these vectors for 
endocytosis and axonal transport through a p75NTR positive endosomal compartment which 
undergoes Rab5 to Rab7 maturation but maintains a neutral luminal pH. Furthermore, in 
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compartmentalised primary motor neuron cultures, this process is both rapid and efficient 
which indicates that the barrier to efficient retrograde transduction may lie in post 
endosomal transport mechanism, such as endosomal escape. In addition, a magnetic pull-
down protocol was optimised and gave some preliminary results regarding some of the 
proteins associated with this trafficking compartment. The project has further 
demonstrated the importance of this trafficking pathway for neuronal homeostasis and how 
viruses and toxins have evolved to make use of its unique properties. 
7.3 Future studies 
The data presented in this thesis suggest that the barrier to retrograde transduction of 
motor neurons is in the ability of the RV-G pseudotyped vector to escape the endosome 
once it has reached the soma and characterising this barrier and overcoming it will be an 
interesting area of study in the goal of improving the efficacy of gene therapy vectors. A 
possible strategy maybe utilizing fusogenic peptides to destabilize the endosomal 
membrane. Several viral, bacterial, plant and synthetic proteins have been identified that 
have the ability to enhance endosomal escape (Varkouhi, Scholte, Storm, & Haisma, 2011). 
It may be  feasible to engineer some of these fusogenic agents onto the vector envelope, 
thereby aiding its escape into the soma. 
Proteins which are to be imported into the nucleus contain amino acid sequences called 
nuclear localisation signals (NLS). It has been reported that viruses such as SV40 contain 
such signal which are displayed following capsid uncoating during endosomal escape and 
facilitates the transport of viral geneome to the nucleus. Therefore, it remains to be 
determined what the NLS status of the vectors are and whether a more specific signal needs 
to be incorporated. For example Gregory et al. have used an EIAV vector (SMART3 NZ) 
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which has a NLS and reported effective transduction ability of skeletal muscle (Gregory et 
al., 2004).  
Another interesting aspect is the ability of the RV-G protein to induce the apoptotic 
pathway. The amount of RV-G present is a key factor in triggering apoptosis (Lafon, 2005; 
Schnell et al., 2010). The less G protein present, the less apoptosis would occur, however 
the precise mechanisms are unknown. The wildtype rabies virus is likely to promote cell 
survival by controlling RV-G expression. Therefore, there perhaps is a need to investigate 
further the level of RV-G expression on RV-G pseudotyped vectors. 
Other experiments can be performed to build on the data obtained from the studies in this 
project. Firstly, although the project has shown that it is the RV-G which determines the fate 
of the vector in terms of axonal transport, experiments can be done to determine which of 
the three reported rabies virus receptors or their combination plays a role in determining 
the fate of the internalised vector. It could be that only binding to one of the receptor puts 
the vector on the fast axonal pathway. This can be through a strategy which uses small 
interfering RNA  (siRNA) to knock-down (stopping translation) of one of the three cognate 
rabies virus receptors in vitro and then determining whether the vectors undergo fast 
axonal transport. This method has already been used to knock-down p75NTR (Firouzi et al., 
2011), NCAM (Hansen et al., 2007) and nicotinic acetylcholine receptor (G. Zhang et al., 
2011). 
In addition, to address the functional relationship between RV-G pseudotyped lentiviral 
vector transport and Rab5 and Rab7 activity, studies can be done where motor neurons are 
transfected with plasmids expressing GFP tagged fusion proteins of either wild type Rab or 
with its dominant negative mutant. This can be followed by an assessment of axonal 
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transport of the vectors using live cell imaging. Trafficking studies using dominant-negative 
mutant forms of the proteins had been previously reported for Rab5 (Deinhardt et al., 2006) 
and Rab7 (Deinhardt et al., 2006; Salinas et al., 2009). These studies showed overexpression 
of the dominant-negative mutant GFP-Rab5 in motor neurons completely abolished 
retrograde trafficking of tetanus toxin (Deinhardt et al., 2006). Similarly, when a GFP fused 
dominant negative mutant of Rab7 was overexpressed and axonal trafficking of Canine 
Adenovirus 2 (CAV-2) studied, there was a strong impairment in the movement of the virus 
(Salinas et al., 2009). 
Furthermore, the magnetic pull-down endosomal isolation strategy can be repeated at a 
larger scale to uncover more players in the network of interactions linking axonal transport 
of lentiviral vectors  to the endocytic machinery.  
Taken together, these studies are further likely to facilitate improvements in transduction 
efficiency, thereby leading to greater uses as a gene therapy tool in the clinic. 
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Appendix A: Plasmid Maps 
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Appendix B: Representative live cell trafficking movies (contained on attached disc) from 
which time series images were made. 
 
Figure 4.8; Movie 1: Trafficking of 4C tagged FlAsH labelled RV-G pseudotyped HIV-1 
particles in NSC-34 cells 
Figure 5.6; Movies 2: Trafficking of 4C tagged, FlAsH labelled RV-G-HIV-1 vectors in motor 
neurons 
Figure 5.7; Movie 3: Trafficking of DiD labelled RV-G-HIV-1 vectors in motor neurons 
Figure 5.9; Movie 4: Trafficking of 4C tagged, FlAsH labelled RV-G-EIAV vectors in motor 
neurons 
Figure 5.11; Movie 5: RV-G HIV-1 (DiD labelled) trafficks with p75NTR  
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Appendix C: Average biological titres of vectors produced and used 
 
Vector Biological Titre - Mean Biological Titre - SEM 
RV-G-HIV1 3.59 x 107 Lfu/ml 0.97 x 107 Lfu/ml 
RV-G-HIV1-DiD 7.4 x 107 Lfu/ml 1.87 x 107 Lfu/ml 
RV-G-HIV1 (FlAsH) 2.29 x 107 Lfu/ml 0.91 x 107 Lfu/ml 
RV-G-HIV1-4C-MAC (FlAsH) 1.72 x 107 Lfu/ml 0.38 x 107 Lfu/ml 
RV-G-EIAV-4C-MAC (FlAsH) 9.47 x 106 Lfu/ml 0.13 x 106 Lfu/ml 
VSV-G-HIV1 8.59 x 107 Lfu/ml 3.4 x 107 Lfu/ml 
 
 
